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SUMMARY 
Arenaviruses are enveloped negative-strand RNA viruses that contain a bi-segmented 
genome. They are rodent-borne pathogens endemic to the Americas and Africa, with the exception 
of lymphocytic choriomeningitis virus (LCMV) that is world-wide distributed. The arenaviruses 
include numerous important human pathogens including the Old World arenavirus Lassa virus 
(LASV), the causative agent of a severe viral hemorrhagic fever in humans with several hundred 
thousand infections per year in Africa and thousands of deaths. Viruses are obligatory intracellular 
parasites, strictly depending on cellular processes and factors to complete their replication cycle. 
The binding of a virus to target cells is the first step of every viral infection, and is mainly mediated 
by viral proteins that can directly engage cellular receptors, providing a key determinant for viral 
tropism. This early step of infection represents a promising target to block the pathogen before it 
can take control over the host cell. Old World arenaviruses, such as LASV and LCMV, bind to host 
cells via attachment to their main receptor, dystroglycan (DG), an ubiquitous receptor for 
extracellular matrix proteins. The engagement of DG by LASV results in a fast internalization and 
transfer the virus to late endosomal compartment suggesting that the virus binding to DG causes 
marked changes in the dynamics of the receptor. These events could result in the clustering of the 
receptor and subsequent induction of signaling that could be modulated by the virus. Recently, 
numerous findings also suggest the presence of alternative receptor(s) for LASV in absence of the 
main DG receptor. 
In my first project, I was interested to investigate the effects of virus-receptor binding on 
the tyrosine phosphorylation of the cytoplasmic domain of DG and to test if this post-translational 
modification was crucial for the internalization of the LASV-receptor complex. We found that 
engagement of cellular DG by a recombinant LCMV expressing the envelope GP of LASV in 
human epithelial cells induced tyrosine phosphorylation of the cytoplasmic domain of DG. LASV 
GP binding to DG further resulted in dissociation of the adapter protein utrophin from virus-bound 
DG. Virus-induced dissociation of utrophin and consequent virus internalization were affected by 
the broadly specific tyrosine kinase inhibitor genistein. We speculate that the detachment of virus-
bound DG from the actin-based cytoskeleton following DG phosphorylation may facilitate 
subsequent endocytosis of the virus-receptor complex. 
In the second project, I was interested to characterize the newly indentified LASV alternative 
receptor Axl in the context of productive arenavirus infection. In a first step, we demonstrated that Axl 
supports productive infection by rLCMV-LASVGP in a DG-independent manner. In line with 
previous studies, cell entry of rLCMV-LASVGP via Axl was less efficient when compared to 
functional DG. Interestingly, Axl-mediated infection showed rapid kinetics similar to DG-dependent 
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entry. Using a panel of inhibitors, we found that Axl-mediated cell entry of rLCMV-LASVGP 
involved a clathrin-independent pathway that critically depended on actin and dynamin and was 
sensitive to EIPA but not to PAK inhibitors, compatible with a macropinocytosis-like mechanism of 
entry. In a next step, we aimed to investigate the molecular mechanism by which rLCMV-LASVGP 
recognizes Axl. Phosphatidylserine (PS) is the natural ligand of Axl via the adaptor protein Gas6. We 
detected the presence of PS in the envelope of Old World arenaviruses, suggesting that PS could 
mediate Axl-virus binding, in a mechanism of apoptotic mimicry already described for other viruses. 
Whether envelope PS and/or the GP of LASV plays any role in virus entry via Axl is still an open 
question. 
The molecular mechanisms underlying host cell-virus interaction are of particular interest to 
answer basic scientific questions as well as to apply key findings to translational research. 
Understanding pathogen induced-signaling and its link to invasion of the host cell is of great 
importance to develop drugs for therapeutic intervention against highly pathogenic viruses like LASV. 
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RÉSUMÉ 
Les Arénavirus sont des virus enveloppés à ARN négatifs organisés sous forme de génome 
bisegmenté. Ils sont véhiculés par les rongeurs et se retrouvent de manière endémique aux 
Amériques et en Afrique avec l’exception du virus de la chorioméningite lymphocytaire (LCMV) 
qui lui est distribué mondialement. De nombreux pathogènes humains font parti de la famille des 
Arénavirus dont le virus de l’Ancien Monde Lassa (LASV), un agent responsable de fièvres 
hémorragiques sévères chez les humains. Le virus de Lassa cause plusieurs centaines de milliers 
d’infections par année en Afrique ainsi que des milliers de morts. De manière générale, les virus 
sont des parasites intracellulaires obligatoires qui dépendent strictement de processus et facteurs 
cellulaires pour clore leur cycle de réplication. L’attachement d’un virus à sa cellule cible 
représente la première étape de chaque infection virale et est principalement dirigée par des 
protéines virales qui interagissent directement avec leur récepteurs cellulaires respectifs fournissant 
ainsi un indicateur déterminant pour le tropisme d’un virus. Cette première étape de l’infection 
représente aussi une cible prometteuse pour bloquer le pathogène avant qu’il ne puisse prendre le 
contrôle de la cellule. Les Arénavirus de l’Ancien Monde comme LASV et LCMV s’attachent à la 
cellule hôte en se liant à leur récepteur principal, le dystroglycan (DG), un récepteur ubiquitaire 
pour les protéines de la matrice extracellulaire. La liaison du DG par LASV résulte en une rapide 
internalisation transférant le virus aux endosomes tardifs suggérant ainsi que l’attachement du virus 
au DG peut provoquer des changements marqués dans la dynamique moléculaire du récepteur. Ces 
événements sont susceptibles d’induire un regroupement du récepteur à la surface cellulaire, ainsi 
qu’une induction subséquente qui pourrait être, par la suite, modulée par le virus. Récemment, 
plusieurs découvertes suggèrent aussi la présence d’un récepteur alternatif pour LASV en l’absence 
du récepteur principal, le DG. 
Concernant mon premier projet, j’étais intéressée à étudier les effets de la liaison virus-
récepteur sur la phosphorylation des acides aminés tyrosines se trouvant dans la partie 
cytoplasmique du DG, le but étant de tester si cette modification post-translationnelle était cruciale 
pour l’internalisation du complexe LASV-DG récepteur. Nous avons découvert que l’engagement 
du récepteur DG par le virus recombinant LCMV, exprimant la glycoprotéine de LASV, dans des 
cellules épithéliales humaines induit une phosphorylation de résidu(s) tyrosine se situant dans le 
domaine cytoplasmique du DG. La liaison de la glycoprotéine de LASV au DG induit par la suite la 
dissociation de la protéine adaptatrice utrophine du complexe virus-DG récepteur. Nous avons 
observé que cette dissociation de l’utrophine, induite par le virus, ainsi que son internalisation, sont 
affectées par l’inhibiteur à large spectre des tyrosines kinases, la génistéine. Nous avons donc 
supposé que le détachement du virus, lié au récepteur DG, du cytosquelette d’actine suite à la 
phosphorylation du DG faciliterait l’endocytose subséquente du complexe virus-récepteur. 
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Dans le second projet, j’étais intéressée à caractériser le récepteur alternatif Axl qui a été 
récemment identifié dans le contexte de l’infection productive des Arénavirus. Dans un premier 
temps, nous avons démontré que le récepteur alternatif Axl permet l’infection des cellules par le 
virus LCMV recombinant LASV indépendamment du récepteur DG. Conformément aux études 
publiées précédemment, nous avons pu observer que l’entrée du virus recombinant LASV via Axl 
est moins efficace que via le récepteur principal DG. De façon intéressante, nous avons aussi 
remarqué que l’infection autorisée par Axl manifeste une cinétique virale d’entrée similaire à celle 
observée avec le récepteur DG. Utilisant un éventail de différents inhibiteurs, nous avons trouvé 
que l’entrée du virus recombinant rLCMV-LASVGP via Axl implique une voie d’entrée 
indépendante de la clathrine et dépendant de manière critique de l’actine et de la dynamine. Cette 
nouvelle voie d’entrée est aussi sensible à l’EIPA contrairement aux inhibiteurs PAK indiquant un 
mécanisme d’entrée compatible avec un mécanisme de macropinocytose. L’étape suivante du projet 
a été d’investiguer le mécanisme moléculaire par lequel le virus recombinant rLCMV-LASVGP 
reconnaît le récepteur alternatif Axl. La phosphatidylsérine (PS) se trouve être un ligand naturel 
pour Axl via la protéine adaptatrice Gas6. Nous avons détecté la présence de PS dans l’enveloppe 
des Arénavirus du Vieux Monde suggérant que la PS pourrait médier la liaison du virus à Axl dans 
un mécanisme de mimétisme apoptotique déjà observé et décrit pour d’autres virus. Cependant, il 
reste encore à déterminer qui de la PS ou de la glycoprotéine de l’enveloppe virale intervient dans 
le processus d’entrée de LASV via le récepteur alternatif Axl. 
Les mécanismes moléculaires à la base de l’interaction entre virus et cellule hôte sont 
d’intérêts particuliers pour répondre aux questions scientifiques de base ainsi que dans l’application 
de découvertes clés pour la recherche translationnelle. La compréhension de la signalisation induite 
par les pathogènes ainsi que son lien à l’invasion de la cellule hôte est d’une importance 
considérable pour le développement de drogues pour l’intervention thérapeutique contre les virus 
hautement pathogènes comme LASV. 
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The Arenaviridae family 
Viruses are studied for the diseases they cause and can also serve as molecular probes to 
dissect fundamental biological mechanisms. The Arenaviridae family contains a number of viruses 
including Lassa virus (LASV), Junin (JUNV), Machupo (MACV), Guanarito (GTOV), and Sabia 
virus (SABV) that are important human pathogens causing hemorrhagic fevers with significant 
morbidity and high mortality (Botten et al., 2007; Geisbert and Jahrling, 2004). The family comprises 
more than 20 viral species initially subdivided into two major groups, the Old World (OW) and the 
New World (NW) arenaviruses, based on geographic relationships, serologic typing, and phylogenetic 
evidence (Charrel, de Lamballerie, and Emonet, 2008; Emonet et al., 2009) (Fig. 1). The NW 
arenaviruses, found in the Americas, include Tacaribe virus (TACV), Pichinde virus, JUNV, MACV, 
SABV and GTOV. The OW arenaviruses, found in Europe and Africa, include LASV, Mopeia, 
Mobala, Ippy. The prototypic member of the family, lymphocytic choriomeningitis virus (LCMV) has 
a world-wide distribution. 
 
Figure 1. Phylogeny of arenaviruses. Arenaviruses are classified in two main complexes established according 
to their serologic, genetic and geographic characteristics: The Lassa/LCMV virus complex, called the Old-World 
arenaviruses, mainly localized in Africa and the Tacaribe virus complex, called the New-World arenaviruses, 
mainly localized in America. 
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Apart from being an important human pathogen in its own right, LCMV is a powerful experimental 
model that had been instrumental in uncovering much of our current knowledge of viral persistence, 
viral pathogenesis, and several aspects of viral immunobiology (Buchmeier, 2007). LCMV is a 
neglected human pathogen of clinical significance, especially in pediatric medicine (Barton and Mets, 
1999; Barton, Mets, and Beauchamp, 2002) and represents a threat to immune-compromised 
individuals, as tragically illustrated by recent fatal cases of transplant-acquired LCMV infection 
(Fischer et al., 2006; Palacios et al., 2008). 
For most arenaviruses, the natural reservoirs are specific rodent species as e.g. Mastomys natalensis 
for LASV or Mus musculus and Mus domesticus for LCMV (Clegg, 2002). The possible exception is 
TACV, which has only been isolated from bat species. In rodents, arenaviruses are generally 
maintained via asymptomatic persistent infections, primarily transmitted by congenital and vertical 
routes. This occurs through transmission of the virus from infected mothers to the fetus maintaining 
the arenavirus population within their respective host species. This vertical transmission happens 
before positive and negative selection of the T cell and B cell repertoire. As a consequence, the virus is 
recognized as “self” by the host’s adaptive immunity allowing establishing the so called “carrier state” 
where host rodents are persistently infected showing high level of virus replication with the adaptive 
immune system being tolerant for the virus. Immune-competent adults, horizontally infected, manifest 
a self-limiting disease rapidly counteracted by the anti-viral adaptive immunity, predominantly the 
anti-viral T cell response (Barton, Mets, and Beauchamp, 2002; Oldstone, 2002). 
Arenavirus particle and genome organization 
Arenaviruses are enveloped viruses with a nonlytic life cycle confined to the cytoplasm. They contain 
as genome two negative bisegmented strand RNAs composed of a large L segment (ca 7.3 kb) and a 
small S one (ca 3.5 kb) (Fig. 2A) (Emonet et al., 2009). Both RNA segments are encoded in an 
ambisense strategy resulting in two open reading frames in opposite orientation separated by a 
noncoding intergenic region (IGR) predicted to fold in a stable hairpin structure (Fig. 2B). The S RNA 
segment encodes for the viral glycoprotein precursor (GPC) and the nucleoprotein (NP) (Fig. 2B). 
GPC is post-translationally processed by the cellular proprotein convertase subtilisin kexin isozyme-
1/site-1 protease (SKI-1/S1P) to yield the mature virion glycoproteins (GPs) GP1 and GP2.. Located at 
the top of mature GP spikes in the viral envelope (Fig. 2A), GP1 mediates attachment of the virus to 
the host cell, followed by membrane fusion mediated by the transmembrane GP2 that resembles class I 
viral fusion proteins. The L RNA segment encodes the viral RNA-dependent RNA polymerase (L) and 
the small RING finger protein Z, the main driving force for arenavirus budding (Perez, Craven, and de 
la Torre, 2003; Strecker et al., 2003). The L and NP viral proteins are responsible for the first steps of 
viral transcription and replication (Buchmeier, 2007). 
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Cell biology of arenaviruses 
Viral cell entry is the initial step for all viral infections and represents a target of choice for 
blocking viruses before they can exploit the cell for their proper needs. The cellular entry pathway of 
arenaviruses is dependent on virus receptor(s). The precise entry mechanisms are still not clearly 
understood, however, according to their different receptor use, OW and NW arenaviruses seem to use 
distinct entry pathways (Rojek and Kunz, 2008). 
 
Figure 2. Arenavirus particle and genome organization. (A) Schematic of an arenavirus particle. The viral RNA 
is packaged into ribonucleoparticles (RNPs) containing the viral NP. The RNA-dependent RNA polymerase (L) 
is associated with RNP and is required for the initial steps of viral transcription. The matrix protein, Z, associates 
with the inner leaflet of the viral membrane envelope and interacts with the C-terminal part of the 
transmembrane GP2 moiety of the mature GP1/GP2 complex covering the virion surface. The receptor-binding 
GP1 forms the top part of the GP virion spikes, whereas the transmembrane GP2 part contains the fusion 
machinery. In their mature form, arenavirus GPs are fully processed and presumably form trimers, similar to 
other fusion-active viral membrane proteins. (B) The ambisense coding strategy of arenaviruses. Each of the two 
ssRNA segments, L (ca 7.2 kb) and S (ca 3.5 kb), uses an ambisense coding strategy to direct the synthesis of 
two polypeptides in opposite orientations and is separated by an IGR predicted to have a stable hairpin structure. 
The 5’ ends of the genomic arenavirus RNA cannot serve as a template for translation and viral protein 
expression requires prior transcription, as in true negative-strand viruses. (GP: Glycoprotein; GPC: Glycoprotein 
precursor; IGR: Intergenic region; L: RNA-dependent RNA polymerase; NP: Nucleoprotein) (adapted from 
(Moraz and Kunz, 2011). 
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The hemorrhagic NW arenaviruses like JUNV, MACV, GTOV and SABV use the human transferrin 
receptor 1 (TfR1) (Radoshitzky et al., 2007). The TfR1 is ubiquitously expressed in a wide range of 
human cells and tissues and is responsible for cellular iron uptake. After viral binding to TfR1, the 
virus is targeted to the classical clathrin and dynamin-dependent entry pathway, with subsequent 
delivery to acidified endosomes, where fusion is initiated by low pH (Martinez, Cordo, and Candurra, 
2007). 
The cellular receptor for LASV, most isolates of LCMV, other OW arenaviruses, and Clade C 
NW arenaviruses is alpha-dystroglycan (α-DG), a highly conserved and ubiquitously expressed cell 
surface receptor for extracellular matrix (ECM) proteins (Cao et al., 1998; Kunz, 2009). DG is initially 
encoded as a single polypeptide cleaved into the extracellular α-DG and transmembrane β-DG (Barresi 
and Campbell, 2006). DG is expressed in most cells of adult and developing tissues and provides a 
molecular link between the ECM and the actin-based cytoskeleton (Fig. 5). After binding to the 
receptor, OW arenaviruses undergo endocytosis and are delivered to late endosomal compartments 
where low pH is required for the fusion between the viral and cellular membrane (Borrow and 
Oldstone, 1994). The optimal pH for LASV and LCMV fusion is remarkably low <5.0 indicating 
possible fusion in late endosomal compartment (Klewitz, Klenk, and ter Meulen, 2007). LASV and 
LCMV enter the cell mainly through an unusual endocytic pathway having some dependence on 
membrane cholesterol (Rojek, Perez, and Kunz, 2008), but that seems independent of clathrin, 
caveolin, dynamin and actin (Quirin et al., 2008; Rojek, Perez, and Kunz, 2008; Rojek et al., 2008). 
Electron microscopic studies of LCMV cell entry showed uptake of viral particles in smooth vesicles 
lacking clathrin coat (Borrow and Oldstone, 1994; Quirin et al., 2008). 
Based on available evidence, the following working model for cell entry of OW arenaviruses 
is proposed (Pasqual et al., 2011): (1) Virus-receptor binding induces receptor clustering at the cell 
surface, possibly followed by receptor-mediated signaling (Fig. 3). (2) After attachment, virus is 
internalized in smooth vesicles involving a clathrin- and caveolin-independent pathway. (3) Virus-
containing vesicles may be delivered either directly to multivesicular bodies (MVB) or passing 
through a yet unknown intracellular compartment. The MVB is a dynamic organelle giving raise to 
late endosomes. The delivery of virus-receptor complex within the MVB to late endosomes seems to 
depend on microtubular transport. (4) As found by Pasqual et al., at the level of the MVB, the virus-
receptor complex may undergo sorting into intraluminal vesicles (ILV) mediated by the endosomal 
sorting complex required for transport (ESCRT) (5), followed by delivery and fusion in late 
endosomes (6) (Fig. 3). 
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Figure 3. Working model for the cell entry of the OW arenaviruses LASV and LCMV. For details see 
text (adapted from (Pasqual et al., 2011). 
Arenaviruses as human pathogens 
The large and diverse family of arenaviruses includes several causative agents of severe viral 
hemorrhagic fevers (VHFs) that belong to the most devastating emerging human diseases and pose 
serious public health problems (Buchmeier, 2007; Geisbert and Jahrling, 2004). Arenaviruses 
responsible for VHFs are LASV, JUNV, MACV and SABV causing Lassa fever, Argentine, Bolivian, 
Venezuelan and Brazilian hemorrhagic fever, respectively (Rojek, Spiropoulou, and Kunz, 2006). The 
highest morbidity and mortality among these VHFs is associated with LASV responsible for 300’000 
to 500’000 infections per year in Western Africa (McCormick and Fisher-Hoch, 2002). Due to the 
lack of effective treatments of arenavirus infections, the mortality among hospitalized Lassa fever 
patients is 15-30% and can reach more than 50% in nosocomial outbreaks (Fisher-Hoch et al., 1995). 
Available data on the seroprevalence for some endemic regions revealed that 20-50% of the adult 
population have been infected with LASV (Richmond and Baglole, 2003), making LASV a crucial 
public health problem. The main routes of human transmission are contact with or inhalation of urine 
and feces from persistently infected rodents, living in close contact to humans. Human-to-human 
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transmission occurs mainly by close contact with contaminated blood, body fluids and aerosols 
making LASV a severe nosocomial pathogen (Fisher-Hoch et al., 1995; McCormick et al., 1987b). 
Clinical disease and pathogenesis of Lassa fever 
A wide spectrum of clinical manifestations is observed in acute Lassa fever ranging from 
asymptomatic infection to fatal hemorrhagic fever. The early flu-like symptoms render the diagnosis 
often difficult (McCormick et al., 1987a). Following an incubation period of 7-18 days, patients 
develop weakness, fever and general malaise. Most of the patients develop severe headache, sore 
throat and cough. Frequently, gastrointestinal symptoms such as nausea, vomiting and diarrhea 
manifest. Poor disease prognosis is indicated by signs of increased vascular permeability such as 
pleural effusions and facial edema that occur in a minority of patients. In severe cases, decline is rapid 
with progressive signs and symptoms of pulmonary edema, respiratory distress, shock, signs of 
encephalopathy followed by seizures, coma and bleeding from mucosa. Survivors usually recover 
during 2-3 weeks after the disease onset and are able to clear the virus from the blood. Sensorineural 
deafness is the most commonly encountered complication late in the disease or early in convalescence, 
making LASV a leading cause of deafness in Western Africa (Cummins et al., 1990). 
The extent of viremia is a highly predictive factor for the outcome of the LASV infection: 
Severe cases of Lassa fever are characterized by high viral load reflecting the inability of the immune 
system to limit viral replication. During LASV infection, immune function is perturbed by the virus at 
the level of both innate and adaptive response through different mechanisms. In contrast, survivors 
have lower initial viral load allowing and control the infection by the unfolding anti-viral immune 
response (Johnson et al., 1987). 
The inability of the patient’s immune system to contain and control the virus is a hallmark of 
human fatal LASV infection. Indeed, arenaviruses are able to subvert the mechanisms of innate 
pathogen recognition through escape of detection by innate immune receptors or by blocking related 
signaling pathways. The RNA genome of arenaviruses can be recognized by the cytoplasmic RNA 
helicases RIG-I and MDA5, leading once activated to the production of type I interferons (IFNs). The 
viral NP has been shown to mechanistically block signal transduction, by avoiding IFN transcription 
factor activation preventing IFNs production (Martinez-Sobrido et al., 2009; Martinez-Sobrido et al., 
2006). 
The marked suppression of the adaptive immune response, including cellular and humoral 
immunity, is likewise found in fatal Lassa fever. The ability of survivors to control the infection is 
primarily mediated by cellular immunity, especially the anti-viral CD8 T-cell response (Fisher-Hoch 
et al., 2000; ter Meulen et al., 2000). In contrast, the humoral response plays a limited role in the 
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control of acute LASV infection in which a neutralizing antibody response is not necessary for 
recovering (Johnson et al., 1987). In fatal disease, the development of an efficient adaptive immune 
response is blunted by the inhibition of viral antigen presentation by antigen presenting cells (APCs) 
such as dendritic cells (DCs) and macrophages (Fig. 3) (Moraz and Kunz, 2011). 
 
Figure 4. Model for LASV pathogenesis. Macrophages and DCs are early and preferred targets for LASV in 
human infection. However, instead to being recognized and presented as foreign antigen, LASV establishes 
productive infection that fails to activate the cells and perturbs their ability to stimulate T cells, contributing to 
immunosuppression. LASV infection in macrophages and in particular DCs does not result in excessive 
production of cytokines, but releases significant amount of infectious virus. Infection of the liver results in 
enhanced levels of transaminases and hepatocellular necrosis. While the histopathology in the liver is too weak 
to account for liver failure, infection of hepatocytes may alter the production of serum proteins, possibly 
affecting hemostasis. Extensive viral replication in the adrenal cortex, where high viral loads are detected, may 
affect the production of mineralcorticoids leading to fluid imbalance. LASV can productively infect vascular 
endothelial cells without causing overt cytopathology and vascular lesions are mild in fatal Lassa fever. The 
mechanisms underlying the alterations in endothelial cell functions that precede shock and death in fatal Lassa 
fever are largely unknown and may involve direct effect of virus infection as well as effects mediated by as yet 
undefined soluble factors released by other cells (adapted from (Moraz and Kunz, 2011). 
The infection of APCs by LASV prevents their maturation and activation, perturbing antigen 
presentation to CD4 and CD8 T cells (Baize et al., 2004; Mahanty et al., 2003) (Fig. 4). In contrast to 
other hemorrhagic fever viruses, such as e.g. Ebola, LASV infection of macrophages and DCs is not 
associated with the release of proinflammatory cytokines (Baize et al., 2004; Klewitz, Klenk, and ter 
Meulen, 2007). Another salient feature in infected patients is lymphopenia, which is most severe in 
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fatal cases, and is associated with a marked decrease in the number of CD4, CD8, B and NK cells, 
suggesting other mechanisms responsible for the virus-induced immunosuppression (McCormick and 
Fisher-Hoch, 2002). 
The pathophysiology of the multi-organs failure in fatal Lassa fever, concomitant with high 
levels of viral replication, remains still unclear since little cellular damage and only mild infiltration of 
inflammatory cells have been observed in histological examinations (Walker et al., 1982). A 
hypothetical mechanism may involve a general virus-induced impairment of the vascular endothelium, 
the liver (McCormick et al., 1986; Walker et al., 1982) and the adrenal cortex (Fig. 4) (Moraz and 
Kunz, 2011). In summary, the mechanisms underlying the shock associated with terminal stage of 
human fatal Lassa fever are still largely undefined. According to the current working model (Fig. 4), 
infection of several cell types in different tissues may result in a general impairment of the vascular 
permeability regulation in a direct or indirect way. 
Host cell attachment of LASV through dystroglycan 
In the host cell, the arenavirus receptor DG plays an important role in cell adhesion and 
regulation of cell-matrix interactions. Alpha-DG binds with high-affinity and in a calcium-dependent 
manner to ECM proteins such as laminin (Ervasti and Campbell, 1993), agrin (Sugiyama, Bowen, and 
Hall, 1994), perlecan (Talts et al., 1999), and to neurexins (Sugita et al., 2001). Alpha-DG is non-
covalently associated with the transmembrane β-DG subunit which in turn binds to the intracellular 
cytoskeletal adaptor proteins dystrophin (in muscle) and utrophin (other cell types), thus bridging the 
DG complex to the actin-based cytoskeleton (Fig. 5A). This provides a physical connection between 
the ECM and the cell (Barresi and Campbell, 2006). 
DG has a wide tissue distribution being expressed in muscle, in the central and peripheral 
nervous system, in epithelia, and endothelia (Durbeej and Campbell, 1999). Roles in the development, 
conservation and migration of several neuronal populations, as well as epithelial morphogenesis from 
different tissue origins, highlight the functional versatility of DG (Durbeej and Ekblom, 1997; Durbeej 
et al., 1995; Waite et al., 2009). In many different cell types, DG is found associated with additional 
cellular proteins including α, β, γ, δ-sarcoglycans (Ervasti and Campbell, 1991), dystrobrevins 
(Sadoulet-Puccio, Rajala, and Kunkel, 1997), the syntrophins (Peters, Adams, and Froehner, 1997) 
and sarcospan (Durbeej et al., 2000), forming together a large complex called the dystrophin-
glycoprotein complex (DGC) (Fig. 5A). These DG-associated proteins are decisive for the stability 
and cellular trafficking of the DGC and mutations therein are associated with sometimes severe 
neuromuscular diseases (Barresi and Campbell, 2006; Durbeej et al., 2000; Kanagawa and Toda, 
2006). 
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In mammals, DG is subject to a complex pattern of post-translational modifications important 
for its function as an ECM receptor (Barresi and Campbell, 2006; Kanagawa and Toda, 2006). DG is 
encoded by the DAG1 gene as a precursor polypeptide that is directed to the endoplasmic reticulum. 
The polypeptide is then post-translationally cleaved by an unidentified protease into two subunits, the 
α-DG and the β-DG subunits (Esapa et al., 2003; Holt et al., 2000). The large mucin-like region of α-
DG contains a number of Ser or Thr residues, which were very early identified as sites for extensive 
modification of numerous heterogeneous O-linked sugar chains (Chiba et al., 1997; Ibraghimov-
Beskrovnaya et al., 1992). Specific O-glycans of α-DG’s mucin type domain are of particular 
importance and their biosynthesis involves the glycosyltransferase protein O-mannosyltransferases 
POMT1 and POMT2, protein O-mannose β1,2-N-GlcNAc transferase (POMGnT1), LARGE, 
LARGE2, and the proteins fukutin (FKTN), and fukutin-related protein (FKRP) (Fig. 5B and Fig. 6A). 
In the endoplasmic reticulum, POMT, POMT2 and POMGnT1 catalyze the biosynthesis and 
attachment of atypical O-mannosyl glycans. Very recently, the isoprenoid synthase domain protein 
(ISPD) was also shown to play an important role in the DG O-mannosylation process (Willer et al., 
2012). Another essential glycan modification of α-DG involves the glycosyltransferases LARGE and 
LARGE2, which localize in the Golgi (Barresi et al., 2004; Kanagawa et al., 2004; Kanagawa and 
Toda, 2006) and are implicated in the biosynthesis of a glycan polymers whose building blocks are 3-
xylose-α1,3-glucuronic acid 1 (Inamori et al., 2012) (Fig. 6A). The lack of DG processing (Jayasinha 
et al., 2003), mutations in components of the DGC as well as in proteins implicated in the correct post-
translational modifications are implicated in several congenital muscular dystrophies. 
Dystroglycanopathies are mainly caused by defective glycosylation of α-DG accounting for its loss of 
function as an ECM receptor through its impairment of multiple interactions with its extracellular 
partners (Fig. 6B). Protein O-mannosylation and LARGE-dependent modifications are also necessary 
for α-DG’s function as a receptor for arenaviruses (Imperiali et al., 2005; Kunz et al., 2005) (Fig. 6A). 
Interestingly, both ECM proteins and arenaviruses recognize the same LARGE-derived sugars on α-
DG, suggesting that the viruses closely mimic the mechanisms of receptor recognition by ECM 
proteins (Rojek et al., 2007). Over-expression of LARGE can functionally bypass defects in other 
enzymes responsible for α-DG glycosylation by inducing the synthesis of glycan-enriched α-DG with 
high affinity for ECM ligands, indicating a key role in the receptor biosynthesis (Barresi et al., 2004). 
Hypoglycosylation causes α-DG to be non-functional as receptor for its common ECM proteins, such 
as laminin, agrin and neurexin (Michele et al., 2002). In the context of the role of DG as a viral 
receptor, mutations resulting in milder pathological alterations of the DG complex could somehow 
provide protection of cells and tissues against viral infection. Mutations that confer this type of 
resistance e.g. against the highly pathogenic LASV could represent molecular features positively 
selected for in human populations living in regions where LASV is endemic. Interestingly, a genome-
wide screen for positive selection among human populations supported the hypothesis that selective 
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pressure imposed by LASV may have led to the appearance of particular alleles conferring some 
resistance to the disease. Indeed, in the genome of the Yoruba population from Nigeria in Western 
Africa, where LASV is endemic, strong signals of positive evolutionary selection pressure on LARGE 
and interleukin 21 (IL21) genes, both involved in infectivity and immunity of LASV, were discovered 
(Andersen et al., 2012; Sabeti et al., 2007). These observations provide a first hint towards pathogen-
driven selection at the level of a viral receptor and entry. 
 
Figure 5. Schematic representation of DG. (A) DG complex with the ECM protein laminin (muscle model). 
(B) DG composed of the extracellular α-DG subunit non-covalently linked to the transmembrane β-DG 
subunit. (Adapted from Kevin Campbell, Howard Hughes Medical Institute, University of Iowa). 
Additionally, recent studies indicate that aberrations in the expression of DG commonly occur 
in human cancers and may play a role in both tumor progression and the formation of metastasis 
(Sgambato et al., 2003). In a well-studied paradigm, loss of functional DG and its interaction with the 
ECM has been correlated with enhanced invasiveness of cancer cells (Henry, Cohen, and Campbell, 
2001; Jing et al., 2004; Losasso et al., 2000; Sgambato et al., 2004; Singh et al., 2004). 
Mechanistically, dysfunctional DG would prevent the formation of robust contacts between basement 
membranes and the cytoskeleton, promoting tumor development and invasiveness. 
DG was considered for a long time as a relatively static membrane-anchored protein fulfilling 
mainly a structural role at cell-matrix contacts. However, recent investigations revealed that DG is a 
highly versatile receptor, interacting with many different partners, and thus represents a 
multifunctional signaling platform (Gould et al., 2010). Specifically, DG has been found to play a role 
in signaling cascades involved in the regulation of the host cell’s interaction with the ECM and the 
A B
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dynamics of the actin-based cytoskeleton. Moreover, DG was shown to functionally interact with β1 
integrins, another important class of ECM receptors. The cytoplasmic domain of β-DG was shown to 
interact with signaling molecules including the canonical MAP kinases MEK and ERK, the focal 
adhesion kinase (FAK) (Cavaldesi et al., 1999; Spence et al., 2004; Yang et al., 1995), the signaling 
adaptor molecule Growth factor receptor-bound protein (Grb2) (Yang et al., 1995), and non-receptor 
tyrosine kinases of the Src family (James et al., 2000b; Sotgia et al., 2003; Sotgia et al., 2001), (Fig. 
5A). Several studies have reported signaling crosstalk between integrins and DG modulating the 
activity of the canonical MEK/ERK pathway. One example is the signaling crosstalk between DG and 
the integrin α6Aβ1, which is a common receptor for laminin. DG and integrin α6Aβ1 exert 
antagonistic roles in the signaling of the MEK/ERK pathway in epithelial cells. Specifically, DG has 
an inhibitory effect on the α6Aβ1 integrin-mediated activation of the Ras-Raf-MEK-ERK pathway in 
response-to cell adhesion to laminin (Ferletta et al., 2003). Thus, synchronous binding of laminin to 
DG and α6Aβ1 integrin results in a regulated balance of MEK/ERK signaling that is crucial for the 
normal adhesion of cell to the laminin-based ECM. 
Earlier studies from our group revealed that OW arenaviruses closely mimic the molecular 
mechanisms of receptor recognition by ECM ligands as both recognize DG via highly conserved 
glycan epitope derived from LARGE (Rojek et al., 2007). This mimicry leads to a competition 
between LASV and the ECM proteins for DG binding, affecting its normal cell function (Kunz et al., 
2005). The impact of LASV binding on DG-mediated signal transduction was recently investigated in 
human lung epithelial cells in our laboratory. We showed that the engagement of LASV altered the 
interaction of DG with signaling molecules disturbing the signaling cross-talk with integrins (Rojek et 
al., 2012). More precisely, cell adhesion to laminin in the presence of LASV resulted in significantly 
reduced activation of MEK and ERK phosphorylation via the integrin α6Aβ1 signaling. However, the 
MEK/ERK signaling and activity are dispensable for the cell attachment and entry of LASV and the 
perturbation of this type of receptor signaling appears as a “collateral damage” inflicted by the virus. 
We currently speculate that the perturbation of ECM-induced cellular signaling by the virus, may 
contribute to functional alterations of vascular endothelial and epithelial cells that precede shock and 
death in fatal LASV cases (Fisher-Hoch et al., 1987). 
It is clear that DG accomplishes multiple and very diverse functions in different cell types and 
tissues. It remains to be elucidated how DG is regulated both spatially and temporally to fulfill its 
diverse functions. On the extracellular side, the glycosylation of the α-DG subunit is crucial for its 
interaction with laminin and other ECM ligands whereas, on the intracellular face, phosphorylation of 
the β-DG subunit regulates its association with the actin-based cytoskeleton and other interacting 
molecules (Barresi and Campbell, 2006). Tyrosine phosphorylation frequently represents a controller 
“molecular switch” through the modification of decisive tyrosine residues located in cytoplasmic 
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domains of adhesion receptors. As a consequence, the interacting protein networks are modified to 
ultimately modulate the adhesion-dependent processes. In non-muscle cells, the tyrosine 
phosphorylation of β-DG plays a crucial regulatory role in determining the cohesion of the DG 
complex (Moore and Winder, 2010). A Src tyrosine kinase member is responsible for the 
phosphorylation of the residue Y892 located within the C-terminal PPxY motif of the β-DG subunit. 
This tyrosine phosphorylation of Y892 prevented the association of -DG with the cytoskeletal 
adaptor protein utrophin (James et al., 2000a). This specific phosphorylation has further been shown to 
induce internalization of DG into large endosomal vesicular structures suggesting a role in targeting 
DG for its degradation (Miller et al., 2012; Sotgia et al., 2003; Sotgia et al., 2001). In line with these 
studies, Miller et al. have recently shown that inhibition of DG Y892 phosphorylation results in 
accumulation of DG on plasma membrane since DG is selectively internalized only when it acquires 
this post-translational modification at its C-terminus (Miller et al., 2012). Thus, impairment of Y892 
phosphorylation ameliorates pathological symptoms associated with dystrophin deficiency in a 
Duchenne muscular dystrophy (DMD) mouse model. Indeed, in a dystrophin-free biological 
background, the point mutated DG Y890F was shown to be protected from degradation, participating 
also in the maintenance of the other DG complex components. These recent discoveries identify DG 
tyrosine phosphorylation as a potential future therapeutic target for treatments, not only in muscular 
dystrophies, but in any pathogenic process such as cancer. As main viral entry and cell signal-
transducing receptor, changes in DG post-translational modification could also play a role in 
arenaviruses cell entry and inhibition of the receptor signaling may provide a new avenue for the 
development of anti-viral therapeutics. In my thesis work, I investigated the role of tyrosine 
phosphorylation of DG in LASV cell entry. 
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Figure 6. Post-translational modification of DG. (A) Functional glycosylation of α-DG that is crucial for its 
function as an ECM receptor. The binding of Lassa virus, as for LCMV, is indicated. For details, see text. (B) 
Defects in α-DG glycosylation cause loss of function of the receptor resulting in congenital neuromuscular 
disorders. (Modified from (Barresi et al., 2004; Kanagawa et al., 2004)). 
TAM kinases as alternative receptors for arenaviruses 
Tyro-3, Axl, and Mer compose the TAM family of receptor tyrosine kinases (RTKs). The 
extracellular domain of TAM receptors is comprised of tandems of two immunoglobulin (Ig) domains 
and two fibronectin type II domains. The transmembrane domain is linked to a cytoplasmic tyrosine 
kinase domain (Fig. 7). Similarly to DG, TAM kinases are subject to post-translational modifications, 
such as glycosylation and phosphorylation (Lu et al., 1999; O'Bryan et al., 1991; Sather et al., 2007). 
Tyro-3, Axl and Mer are expressed in a broad range of cell types, with the exception of lymphocytes 
and granulocytes, and have overlapping but unique expression patterns. Mer is predominantly 
expressed in cell of the hematopoietic lineage, such as monocytes/macrophages, DCs and NK cells but 
high expression levels are also found in kidney, brain, lung, skeletal muscle, retina and sexual organs 
(Angelillo-Scherrer et al., 2001; Behrens et al., 2003; Graham et al., 1994; Prasad et al., 2006). Tyro-3 
is primarily expressed in the nervous system and is also detected in lung, kidney, retina and sexual 
organs, in addition to hematopoietic cell lines (Angelillo-Scherrer et al., 2001; Lai, Gore, and Lemke, 
1994; Lu and Lemke, 2001; Mark et al., 1994; Prasad et al., 2006). Axl is ubiquitously expressed 
(O'Bryan et al., 1991) and detected in monocytes/macrophages, platelets, endothelial cells, heart, liver, 
kidney, skeletal muscle, testis (Angelillo-Scherrer et al., 2001; Graham et al., 1995; Neubauer et al., 
1994), as well as in the brain (Bellosta et al., 1995). 
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Figure 7. Structure of TAM receptors. Domain organization of Tyro-3, Axl and Mer are depicted (adapted 
from (Linger et al., 2008)). 
The first ligand identified for TAM kinases was the growth-arrest-specific protein 6 (Gas6) 
followed by the discovery of the anticoagulation factor, Protein S (ProS) (Stitt et al., 1995; Varnum et 
al., 1995). Usually, activation of the TAM receptors is mediated through ligand binding that induces 
dimerization and subsequent autophosphorylation of tyrosine residues located within the cytoplasmic 
domain (Schlessinger, 2000). These phosphorylation events allow other substrates to be 
phosphorylated, as well as the recruitment of signaling molecules to form elaborated molecular 
signaling complexes (Braunger et al., 1997; Ling, Templeton, and Kung, 1996). 
Upon stimulation, TAM kinases regulate a variety of cellular processes, including cell 
proliferation and survival, clearance of apoptotic cells (Lu and Lemke, 2001), regulation of the innate 
immune response (Rothlin et al., 2007; Rothlin and Lemke, 2010), cell adhesion (McCloskey et al., 
1997) and survival/migration of DCs (Scutera et al., 2009), blood clot stabilization through platelet 
aggregation (Angelillo-Scherrer et al., 2005), regulation of inflammatory cytokine release (Sharif et 
al., 2006) and differentiation/maturation of natural killer cells (NKs) (Caraux et al., 2006). Moreover, 
increasing evidence suggest a role for TAM receptors in oncogenesis, as family members are over-
expressed in a wide range of human cancers (Graham et al., 2006; Greenman et al., 2007; Keating et 
al., 2006). 
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The role of TAM receptors in apoptotic cell clearance 
The maintenance of normal and healthy cell numbers is mediated trough cell death via the 
apoptosis process. The clearance of apoptotic cells and membranes is crucial for many biological 
processes, such as homeostasis and tissue development, as well as pathological responses, including 
inflammation. Uncontrolled accumulation of apoptotic cell debris causes tissue necrosis and the 
discharge of intracellular contents that can lead to inflammation if not cleared by phagocytic cells. 
Although a number of professional phagocytes can engulf infectious particles and microorganisms, the 
removal of apoptotic cells is mostly mediated by macrophages and, to a lesser extent, DCs. Cell 
surfaces of phagocytes and apoptotic cells are both negatively charged and consequently need proteins 
that mediate the processes of cell identification and engulfment. Apoptotic cells specifically contain 
phosphatidylserine (PS) on their outer membrane that mediates direct binding to phagocytes through 
PS-receptors e.g. of the TIM family. Phagocytes can also indirectly bind to apoptotic cells via TAM 
kinases, using the TAM ligands Gas6 or Protein S as bridging factors (Anderson et al., 2003; Nakano 
et al., 1997; Stitt et al., 1995) (Fig. 8). Gas6 and ProS are soluble proteins characterized by an N-
terminal gamma-carboxylated glutamic acid (GLA) domain. The specific modification of glutamic 
acid by carboxylation at the γ-position depends on vitamin K and is crucial for binding to PS and thus 
the ability to mediate uptake of apoptotic debris. Following the N-terminal GLA-domain, Gas6 
contains four epidermal growth factor (EGF)-line domains that are followed by a C-terminal sex 
hormone binding globulin (SHBG)-like module, which is involved in TAM receptor activation. Gas6 
serves as ligand for all three TAM receptors, albeit with different affinity: Axl > Tyro3/Dtk >> Mer. 
A well-known example of TAM receptor-mediated removal of apoptotic cells is represented 
by the phagocytosis of the photoreceptor outer segment membranes, observed in retinal pigment 
epithelium cells. Mer-deficient mice develop a degeneration of the photoreceptor cell layer of the 
retina due to the incapacity of phagocytotic cells of the retinal pigment epithelia to remove apoptotic 
cell debris (Lu et al., 1999) and a similar phenotype is observed in RCS rats that lack functional Mer 
(Duncan et al., 2003; Nandrot et al., 2000). In humans, mutations in the Mer gene are associated with 
rare forms of the degenerative disease retinitis pigmentosa (McHenry et al., 2004; Thompson et al., 
2002). Knockout mice deficient for all three TAM receptors are viable at birth, however, after several 
weeks, mice start to develop degenerative phenotypes. Germ cells in the testis die due to the incapacity 
of Sertoli cells to engulf and remove apoptotic cells (Lu et al., 1999) leading to altered 
spermatogenesis and progressive infertility. 
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Figure 8. Phagocytosis of apoptotic cells by bridging. Model that proposes the mediation of phagocytosis of 
apoptotic cells through TAM receptors, expressed on professional phagocytic cells (macrophages and DCs) 
(Seitz et al., 2007). A “molecular” bridge is created by an interaction between PS-expressing cells and TAM 
receptor-expressing macrophages (Anderson et al., 2003). 
These two debilitating phenotypes are actually linked since both are the consequence of the incapacity 
of TAM-deficient local phagocytotic cells to correctly engulf the high amount of apoptotic cells and 
debris generated in these organs. In contrast to the testis and the retina that represent organs 
sequestered by a blood-organ barrier, removal of apoptotic cells from other organs seems to be 
mediated mainly by macrophages and DCs implicating TAM receptors as well (Scott et al., 2001; 
Seitz et al., 2007). 
TAM receptors are regulators of innate immunity 
Upon recognition of viruses and other microbes by sensors of the innate immune system like 
RIG-I helicases and Toll-like receptors (TLRs), antigen presenting cells (APCs) like macrophages and 
DCs, secrete cytokines that drive APC maturation and help priming the unfolding adaptive immune 
response. Secreted cytokine levels, including those of type I interferons (IFNs) and pro-inflammatory 
cytokines like TNF-α, are subject to tight regulation to avoid excessive immune responses and 
constitutive activation that can lead to immunopathology and autoimmunity. In murine APCs, Gas6 
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functions as a strong inhibitor of TLR-induced activation and production of type I IFNs and pro-
inflammatory cytokines (Rothlin et al., 2007). A similar observation has been made in human 
monocyte-derived DCs (MDDC) differentiated in the presence of type I IFNs (Scutera et al., 2009). 
TAM receptors function as inhibitors of the signaling pathways linked to TLR3, TLR4, and TLR9 
(Abbrederis et al., 2008). Mechanistically, exposure of DCs to type I IFNs induces expression of TAM 
receptors, in particular Axl (Abbrederis et al., 2008; Scutera et al., 2009). The induced TAM receptor 
seems to undergo a direct interaction with the type I IFN receptor (IFNAR), resulting in the induction 
of inhibitory transcription factors of cytokine signaling, the suppressors of cytokine signaling (SOCS)-
1 and SOCS-3. The up-regulation of TAM receptors in response to type I IFNs and their subsequent 
inhibition of cytokine signaling via induction of SOCS revealed the existence of a negative feedback 
mechanism ensuring the tight control of cytokine activity in the context of the unfolding anti-viral 
immune response.  
From the evidence at hand, the TAM receptors appear thus as major receptors involved in the 
removal of apoptotic cells and important negative regulators of the pro-inflammatory cytokine 
response. Accordingly, mice knockout for the TAM receptors are prone to develop autoimmune 
diseases, probably due to a combination of dysregulated cytokine secretion and accumulation of 
apoptotic cells (Cohen et al., 2002; Lemke and Lu, 2003). The accumulation of apoptotic debris likely 
leads to prolonged exposure of intracellular material, including nuclear antigens to the immune 
system. In combination with the hyperactivation of APCs, autoreactive B cells become activated and 
produce antibodies able to recognize nuclear antigens, like ribonucleoproteins or DNA, similar to the 
situation observed in the human autoimmune disorder systemic lupus erythematosus (Cohen et al., 
2002; Lu and Lemke, 2001). 
Other functions of the TAM receptor Axl 
Historically, the TAM receptor Axl, from the Greek word for uncontrolled “anexeleto” (O'Bryan et al., 
1991), was first discovered as an unknown transforming gene in patients suffering from chronic 
myelogenous leukemia (Liu, Hjelle, and Bishop, 1988). Axl over-expression and its increased activity 
have been observed in other cancers (Linger et al., 2010) and in several chronic immune disorders 
(Fig. 8) (Lemke and Rothlin, 2008). As mentioned above, compared with other TAM family members, 
Axl has the highest affinity for the soluble ligand Gas6, activating the so-called Gas6/Axl pathway, 
known to promote growth and survival of several cell types (Allen et al., 1999; Scutera et al., 2009; 
Shankar et al., 2006; Stenhoff, Dahlback, and Hafizi, 2004). Axl is further implicated in cellular 
functions such as neuronal cell migration. The Gas6/Axl pathway has been shown to confer protection 
of cells from apoptosis via multiple mechanisms (Demarchi et al., 2001; Goruppi et al., 1999; 
Hasanbasic et al., 2004; Lee et al., 2002), including activation of pathways participating in cell 
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proliferation (Fridell et al., 1996). Under pathological conditions, the Gas6/Axl pathway is also 
important for the cardiovascular system (Fig. 9), since its activation is implicated in cardiovascular 
disease progression (Berk, 2001). Indeed, Axl knockout mice suggest a role of Axl in vascular 
remodeling (Konishi et al., 2004; Korshunov et al., 2006) and Axl was shown to regulate thrombosis, 
important for cardiovascular homeostasis (Angelillo-Scherrer et al., 2005). 
 
Figure 9. Axl signaling involved in pathological conditions. Axl is implicated in immune cell functions 
inhibiting chronic immune activation. Axl has been shown to alter tumor cell function and to promote the 
development of cancer. Its activation is also critically involved in advanced cardiovascular diseases.  
Given the role of the Gas6/Axl pathway in a several disorders, therapeutic potential through 
the inhibition of Axl receptor is under investigation. Administration of Axl-Fc recombinant protein has 
been shown to impede the interaction of Gas6 with Axl, as illustrated by the protection of mice against 
thrombosis (Angelillo-Scherrer et al., 2005). Highly specific anti-Axl antibodies have also been used 
to target Axl, preventing its signaling. Antibodies are able to act on tumor cells and immune cell 
functions (Li et al., 2009; Smolock and Korshunov, 2010). However, because of poor 
pharmacokinetics in humans, anti-Axl antibodies are limited in their applications. Actually, the 
favorite therapeutic strategy targeting Axl in the context of cancer therapy is the use of Axl-specific 
small-molecule inhibitors (SMIs), (Linger et al., 2010). The inhibitor R428 from Rigel 
Pharmaceuticals was shown to be selective and effective in Axl signaling inhibition in multiple cell 
types, showing appropriate pharmacokinetic profiles (Holland et al., 2010). Detection and targeted 
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treatment of Axl-expressing tumors represent a promising new therapeutic strategy for breast cancer, 
where the presence of Axl predicts patient survival trough the metastasis progression (Gjerdrum et al., 
2010). 
In the co-evolution of virus and host, viruses have evolved several strategies to hijack and 
manipulate necessary cellular functions. Recently, studies revealed how viruses are able to hijack the 
host’s apoptotic clearance machinery for cell entry (Mercer and Helenius, 2008; Mercer and Helenius, 
2010; Morizono et al., 2011). As mentioned, apoptotic cells expose PS on their surface, acting as an 
“eat me” message for the endocytosis and removal of apoptotic debris (Fig. 8) via the TAM family 
members. Viruses have developed several strategies to profit from existing endocytic mechanisms 
including their ability to hijack the apoptotic debris clearance system. One of these strategies, called 
“apoptotic mimicry”, is the exposure of PS on the pathogen surface, allowing the virus’ uptake. This 
mimicking strategy was first suggested for hepatitis B virus (Vanlandschoot and Leroux-Roels, 2003), 
and afterwards for vaccinia virus (VACV) (Mercer and Helenius, 2008), possibly HIV (Callahan et al., 
2003), and more recently for Dengue virus (Meertens et al., 2012). Recently, Morizono and colleagues 
proposed a more generalized model in which a range of enveloped viruses displaying PS at their 
surface can hijack the Gas6/Axl system for cell entry in absence of specific cellular receptors 
recognized by their glycoproteins. The abuse of the host’s evolutionary conserved Gas6/Axl-
dependent apoptotic clearance mechanisms for cell invasion would thus broaden the cellular tropism 
of a virus.   
The use of the Gas6/Axl system for cell entry by “apoptotic mimicry” may be of particular 
relevance for viruses that have recently broken through species barriers. Examples are the filoviruses 
Ebola virus and Marburg virus that cause severe hemorrhagic fever in humans. Although filoviruses 
can replicate in diverse tissues and cell types, their broad tropism remains poorly understood. TAM 
kinases, especially Axl, have been implicated in cell entry of filoviruses. Ectopic expression of Axl 
and Tyro-3 renders resistant cells susceptible to infection with Ebola and Marburg pseudotypes and 
live Ebola virus (Shimojima et al., 2006). The susceptibility was reduced by antibodies to TAM 
members and soluble recombinant proteins. Axl was shown to enhance uptake of Ebola virus via 
macropinocytosis (Hunt et al., 2011). Interestingly, viral uptake did not appear to be due to direct Axl 
interaction with Ebola pseudotypes (Brindley et al., 2011). Recently, studies using a panel of Axl 
mutants demonstrated the need of Axl’s physiological functions to allow Ebola virusto enter cells 
(Shimojima, Ikeda, and Kawaoka, 2007). However, the exact role of PS in the viral envelope and 
“apoptotic mimicry” for Axl-mediated filovirus cell entry is still not clear.   
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Very recently, Shimojima and colleagues identified Axl and Tyro-3 as alternative receptors for LASV 
retroviral pseudotypes (Shimojima et al., 2012). These molecules have been shown to enhance LASV 
binding to cells and to mediate infection in a DG-independent manner. In my thesis work, I sought to 
further characterize Axl-mediated cell entry of LASV in the context of productive arenavirus 
infection. 
Figure 9. Model of Gas6/Axl-mediated 
virus apoptotic mimicry. Apoptotic cells 
expose PS in their outer leaflet of the 
plasma membrane serving as an “eat-me” 
signal for their removal. The uptake of 
apoptotic particles is mediated by Axl 
together with Gas6 that bridges PS with 
the receptor. Lentivirus vectors acquire PS 
at the cell surface during the budding 
process. VACV gain PS in the cytosol 
from a yet unknown source and leaves the 
cells by lysis or fusion. Both lentiviruses 
and VACV, that are mimicking apoptotic 
debris, can be recognized by secreted 
Gas6, linking the viral particles to Axl 
receptor, allowing an increase in the 
infectivity (adapted from (Mercer, 2011)). 
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Project 1: “Post-translational modification of the LASV receptor DG” 
Dystroglycan (DG) is best known for its functions in muscle where it mainly provides a 
molecular link between proteins of the ECM and the cellular actin-based cytoskeleton. The rather 
static role of DG in muscle cells as a structural component of cell-extracellular matrix contacts 
contrasts with the expected dynamics required in the context of LASV cell entry. Indeed, engagement 
of DG by LASV results in rapid internalization of the virus-receptor complex and transfer of the virus 
to endosomal compartments where fusion occurs. This rapid internalization and delivery suggests that 
virus binding to α-DG causes marked changes in the trafficking dynamics of DG. Considering these 
dynamic processes, we hypothesize that virus binding to α-DG results in the clustering of the receptor 
and the subsequent induction of receptor-mediated signaling. As a consequence, the cytoplasmic tail 
of the β-DG subunit may undergo post-translational modifications, which could serve as signals 
triggering the rapid internalization of the virus-receptor complex into vesicles that are then targeted to 
the endosomal pathway. Previous studies showed that the cytoplasmic tail of β-DG is subject to 
phosphorylation at tyrosine residue 892 and that this modification affects binding of DG to the 
cytoskeletal adapters, resulting in receptor internalization. In my first project, I investigated the effect 
of virus-receptor binding on the tyrosine phosphorylation of β-DG and tested if this post-translational 
modification was linked to the internalization of LASV-receptor complex. We found that engagement 
of cellular DG by LASV GP in human epithelial cells induced tyrosine phosphorylation of the 
cytoplasmic domain of DG. LASV GP binding to DG further resulted in dissociation of the adapter 
protein utrophin from virus-bound DG. This virus-induced dissociation of utrophin was affected by the 
tyrosine kinase inhibitor genistein, suggesting a role of receptor tyrosine phosphorylation in the 
process. 
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Project 2: “Characterization of LASV cell entry via the TAM receptor Axl” 
Very recently, Shimojima and colleagues identified the TAM receptors Axl and Tyro3 (Dtk) as 
candidate receptor for LASV, allowing infection of cells in a DG-independent manner (Shimojima et 
al., 2012). Axl is the widest expressed member of the TAM receptor family and is present on human 
cells known to be targeted by LASV in vivo. Compared with other members of TAM family, Axl has 
been shown to have the strongest affinity for the serum human protein Gas6 in the so called Gas6/Axl 
pathway. This pathway plays a role in two crucial physiological processes, the degradation of 
apoptotic cell debris and the negative regulation of cytokine signaling in antigen presenting cells like 
macrophages and DCs. So far, studies on the role of Axl and Tyro3 as candidate LASV receptors have 
been limited to retroviral pseudotypes, which pose some limitations. In my second project, I used a 
recombinant form of the prototypic OW arenavirus LCMV expressing the GP of LASV (rLCMV-
LASVGP) to study the role of TAM receptors, in particular Axl in LASV cell entry. Considering the 
close structural and genetic relationship between LASV and LCMV, this recombinant chimera 
represents a powerful tool to investigate the role of Axl in the context of a productive arenavirus 
infection. In line with previous studies, I found that Axl mediated LASV cell entry in a DG-
independent manner, albeit less efficient than DG. However, Axl-mediated productive infection with 
rLCMV-LASVGP showed kinetics similar to DG-dependent entry. Axl-mediated cell entry of LASV 
involved a clathrin-independent pathway that critically dependent on actin and dynamin, was sensitive 
to EIPA, but not to PAK inhibitors. Lastly, I addressed a possible role of PS displayed in the envelope 
of Old World arenaviruses in Axl-mediated cell entry. 
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ABSTRACT 
The extracellular matrix (ECM) receptor dystroglycan (DG) serves as a cellular receptor for 
the highly pathogenic arenavirus Lassa virus (LASV) that causes a hemorrhagic fever with high 
mortality in man. In the host cell, DG provides a molecular link between the ECM and the actin 
cytoskeleton via the adapter proteins utrophin or dystrophin. Here we investigated post-translational 
modifications of DG in the context of LASV cell entry. Using the tyrosine kinase inhibitor genistein, 
we found that tyrosine kinases are required for efficient internalization of virus particles, but not virus-
receptor binding. Engagement of cellular DG by LASV envelope glycoprotein (LASV GP) in human 
epithelial cells induced tyrosine phosphorylation of the cytoplasmic domain of DG. LASV GP binding 
to DG further resulted in dissociation of the adapter protein utrophin from virus-bound DG. This virus-
induced dissociation of utrophin was affected by genistein treatment, suggesting a role of receptor 
tyrosine phosphorylation in the process. 
 
  
RESULTS/PROJECT 1  38 
   
 
 
 
INTRODUCTION 
The Old World arenavirus Lassa virus (LASV) is the causative agent of a severe viral 
hemorrhagic fever in humans with several hundred thousand infections per year in Africa and 
thousands of deaths annually (McCormick and Fisher-Hoch, 2002). Fatal LASV infection is 
characterized by rapid viral replication and spread, resulting in uncontrolled viral infection with 
progressive signs and symptoms of hemorrhagic disease and shock (Geisbert and Jahrling, 2004). The 
death toll of LASV infection among hospitalized patients can reach 15-30%. There is no licensed 
vaccine against LASV and current therapeutic options are limited, making LASV arguably one of the 
most neglected tropical pathogens. 
Arenaviruses are enveloped negative-strand RNA viruses with a bi-segmented genome, whose 
replication takes place in the cytoplasm (Buchmeier, de la Torre, and Peters, 2007; de la Torre, 2009). 
The two viral RNA segments, L and S, include each two open reading frames. The S segment encodes 
the envelope glycoprotein precursor (GPC) and the nucleoprotein (NP) and the L segment codes for 
the matrix protein (Z) and the viral polymerase (L). LASV GPC is synthesized as a single polypeptide 
and undergoes processing by the host cell protease subtilisin kexin isozyme-1(SKI-1)/site-1 protease 
(S1P) (Beyer et al., 2003; Lenz et al., 2001; Rojek et al., 2008a), yielding the N-terminal GP1 and the 
transmembrane GP2. LASV GP1 is involved in binding to cellular receptors (Borrow and Oldstone, 
1992), whereas the GP2 part mediates fusion and resembles the membrane-proximal regions of other 
viral fusion proteins (Eschli et al., 2006; Igonet et al., 2011). 
Binding of a virus to its cellular receptor(s) and subsequent entry into target cells are the first 
steps of virus infection and a fundamental aspect of the virus-host cell interaction. These initial steps 
of infection are also promising targets to block the pathogen before it can take control over the host 
cell. Therapeutic intervention at the level of cell entry is of particular interest for highly pathogenic 
viruses like LASV. The first cellular receptor discovered for LASV and the prototypic Old World 
arenavirus lymphocytic choriomeningitis virus (LCMV) is dystroglycan (DG) a ubiquitous receptor 
for extracellular matrix (ECM) proteins (Cao et al., 1998; Oldstone and Campbell, 2011). More 
recently, additional candidate receptors for LASV have been reported, including the C-type lectins 
DC-SIGN, LSECtin, and the Tyro3/Axl/Mer (TAM) receptor tyrosine kinases Axl and Tyro3 
(Shimojima et al., 2012). However, in DG-expressing cells, DG appears to be the preferred receptor 
for LASV (Shimojima et al., 2012). 
Dystroglycan is a highly conserved protein initially translated as a single polypeptide chain 
that is cleaved into the extracellular -DG, and transmembrane -DG (Barresi and Campbell, 2006). 
DG is expressed in most developing and adult tissues in cells that adjoin basement membranes 
(Durbeej et al., 1998) and is crucial for normal cell-matrix interactions (Henry and Campbell, 1998; 
Henry et al., 2001). Alpha-DG has a central, highly glycosylated mucin-type domain that connects the 
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globular N-and C-terminal domains. At the extracellular site, -DG undergoes high-affinity 
interactions with the ECM proteins laminin, agrin, perlecan, and neurexins (Barresi and Campbell, 
2006). Alpha-DG is non-covalently associated with -DG, which binds intracellular to the adaptor 
proteins dystrophin or utrophin that link DG to the actin cytoskeleton. DG is also associated with a 
number of signaling molecules, including the adaptor molecule grb2 (Yang et al., 1995), the canonical 
MAP kinases MEK and ERK (Spence et al., 2004), and the focal adhesion kinase (Cavaldesi et al., 
1999). Upon receptor binding, LASV and LCMV are internalized via an endocytotic pathway that is 
independent of clathrin, caveolin, and dynamin and bypasses classical Rab5-dependent incoming 
routes of vesicular trafficking (Quirin et al., 2008; Rojek et al., 2008b). During cell entry, LASV and 
LCMV pass through the multivesicular endosome, where the virus-receptor complex undergoes 
sorting by the endosomal sorting complex required for transport (ESCRT) delivering the viruses to late 
endosomes, where low pH-induced fusion occurs after 20-30 minutes (Pasqual et al., 2011; Quirin et 
al., 2008; Rojek et al., 2008b). 
In the host cell, DG appears as a structural component of cell-matrix contacts, which suggest a 
rather static role. Considering the receptor dynamics expected in the context of LASV cell entry, we 
hypothesized that virus binding may alter DG trafficking, e.g. by inducing post-translational 
modifications that target the DG complex towards rapid endocytosis. Studies in prototypic primate and 
human cells had demonstrated that cell adhesion to ECM proteins can induce phosphorylation of 
tyrosine Y892 located within a PPxY motif present at the C-terminus of the cytoplasmic domain of -
DG by non-receptor tyrosine kinases of the src family (James et al., 2000; Sotgia et al., 2003; Sotgia et 
al., 2001). This tyrosine phosphorylation of Y892 prevented the association of -DG with the 
cytoskeletal adaptor protein utrophin (James et al., 2000) and resulted in a redistribution of the DG 
complex from the plasma membrane to intracellular compartments (Sotgia et al., 2003), linking 
tyrosine phosphorylation of β-DG to receptor internalization. More recent studies confirmed a role of 
tyrosine phosphorylation of β-DG at Y892 for the endocytosis of DG in myoblasts and provide 
evidence for a role of tyrosine phosphorylation of DG in the development of muscle pathophysiology 
in an animal model for muscular dystrophy (Miller et al., 2012). In the present study we investigated 
the role of receptor tyrosine phosphorylation for cell entry of LASV. 
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RESULTS 
Tyrosine kinases are involved in endocytosis of rLCMV-LASVGP 
Recent studies using the broadly specific tyrosine kinase inhibitor genistein revealed a role for 
tyrosine kinases in cell entry of LASV (Kolokoltsov et al., 2012). However, the specific step(s) of the 
viral entry process that depend on tyrosine kinases had not yet been defined. In a first step, we sought 
to confirm and extend these earlier studies and tried to distinguish effects of genistein on virus-cell 
attachment from endocytosis. Since LASV is a BSL4 pathogen, work with live virus is restricted to 
laboratories with high security containment. To circumvent these biosafety restrictions, we used a 
recombinant form of the prototypic LCMV expressing the envelope GP of LASV (rLCMV-LASVGP) 
(Rojek et al., 2008b). The chimera rLCMV-LASVGP does not show significant attenuation in vitro 
when compared to the parental LCMV strain and grows to robust titers.  Since receptor binding and 
host cell entry of arenaviruses are mediated exclusively by the viral GP, rLCMV-LASVGP adopts the 
receptor binding characteristics of LASV (Rojek et al., 2008b) and represents a suitable BSL2 
surrogate for our studies on LASV-receptor interaction and cell entry. As a cell culture model, we 
chose the human lung epithelial cell line WI-26 VA4, which had previously been utilized for studies 
on DG signaling (Ferletta et al., 2003) and the interaction of LASV with its receptor DG (Rojek et al., 
2012). 
First, we verified that cell attachment and entry of LASV into WI-26 VA4 cells was mediated 
by DG. Cells were pre-treated with increasing concentration of the monoclonal antibody (mAb) IIH6 
that recognizes a functional glycan epitope on -DG (Kanagawa et al., 2004) and competes with virus 
binding (Kunz et al., 2005a). Cells were then infected with rLCMV-LASVGP and infected cells 
detected after 16 hours by immunofluorescence (IF) staining of the viral nucleoprotein (NP). Pre-
treatment with mAb IIH6, but not an IgM isotype control significantly blocked infection with rLCMV-
LASVGP in a dose-dependent manner, confirming DG as a major receptor for LASV in these cells 
(Fig. 1A), as shown previously (Rojek et al., 2012). 
To exclude unspecific cytotoxicity caused by genistein, WI-26 VA4 cells were treated with 
increasing concentrations of the drug for 4 hours, followed by a wash out and incubation for a total of 
16 hours. Cell viability was assessed by Cell Titer Glo® assay, which measures intracellular levels of 
ATP. WI-26 VA4 cells tolerated genistein up to a concentration of 100 μM with only mild loss of cell 
viability (Fig. 1B). To test the effect of genistein on early infection with LCMV-LASVGP, WI-26 
VA4 cells were pre-treated with increasing concentrations of genistein for one hour and infected with 
rLCMV-LASVGP at multiplicity of 1. At four hours post infection, the drug was removed by wash 
out. To prevent further infection, the lysosomotropic agent ammonium chloride was added to the fresh 
medium. When added to cells ammonium chloride raises the endosomal pH rapidly and blocks low 
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pH-dependent membrane fusion without causing overall cytotoxicity (Ohkuma and Poole, 1978; 
Ohkuma and Poole, 1981). After 12 hours in presence of ammonium chloride, cells were fixed and 
infection detected by IF staining for LCMV NP. As shown in Fig. 1C, genistein blocked infection with 
rLCMV-LASVGP in a dose-dependent manner. 
Using expression of LCMV NP in infected cells as readout for infection did not allow 
discriminating between effects of genistein on LASVGP-mediated cell entry and post-entry steps of 
early viral infection. To specifically validate the effects of genistein on LASV cell entry in our system, 
we used recombinant vesicular stomatitis virus (VSV) pseudotyped with the envelope GPs of LASV 
(rVSV-LASVGP) and VSV (rVSV-VSVG). These pseudotypes are replications deficient and contain 
a green fluorescent protein (GFP) reporter in their genome. Previous studies demonstrated that rVSV-
LASVGP closely mimic the receptor binding and entry characteristics of LASV (Kunz et al., 2005b; 
Pasqual et al., 2011). Increasing concentrations of genistein blocked infection of rVSV-LASVGP 
more efficient than rVSV-VSVG (Fig. 1D), consistent with previous reports (Kolokoltsov et al., 
2012). Notably, the dose-response characteristic of rVSV-LASVGP closely matched the one of 
rLCMV-LASVGP (Fig. 1C, D), indicating that at least some of the inhibitory effect of genistein on 
early infection with rLCMV-LASVGP was due to perturbation of LASVGP-mediated cell entry. 
To differentiate between effects of genistein on LASVGP-mediated cell attachment from 
perturbation of endocytosis, we used a well-established assay previously used to study virus 
internalization (Pelkmans, Puntener, and Helenius, 2002; Rojek, Perez, and Kunz, 2008), 
schematically shown in Fig. 1E. Briefly, rLCMV-LASVGP was purified over a renografin gradient 
and purified virus labeled with the reagent NHS-SS-biotin, resulting in a biotin label that is cleavable 
by reducing agents. As long as the virus stays bound to the cell surface, the biotin label can be cleaved 
efficiently with the potent, membrane-impermeable reducing agent Tris(2-carboxyethyl)phosphine 
(TCEP) (Fig. 1E). Once internalized via endocytosis, the biotin-labeled virus is protected from TCEP 
and retains its biotin moiety after exposure of cells to TCEP. To assess possible effects of genistein on 
virus cell attachment and internalization, WI-26 VA4 cells were pre-treated with 50 μM of genistein or 
vehicle control. After one hour, cells were cooled on ice and incubated with biotin-labeled rLCMV-
LASVGP (100 particles/ cell) for one hour in the cold. Unbound virus was removed and cells shifted 
to 37 °C in presence of genistein. After the indicated time points, cells were rapidly chilled on ice and 
immediately treated with cold TCEP or reaction buffer only. After quenching of residual TCEP with 
iodacetamide, cells were lysed and the viral GP isolated by immunoprecipitation (IP) with mAb 83.6 
to GP2. Proteins were separated by SDS-PAGE and biotinylation of GP2 detected by Western-blot 
under non-reducing conditions. In specimens treated with reaction buffer only, similar amounts of 
cell-associated biotinylated virus were detected in presence and absence of genistein (Fig. 1F), 
indicating that genistein treatment did not affect virus attachment to the receptor. In control samples 
treated with TCEP, biotinylated virus became detectable after circa 5 min, with an increase over the 
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next 20 min. In cells treated with genistein and TCEP, the signals for biotinylated GP2 were markedly 
reduced, indicating a block in an early step of virus internalization in presence of the inhibitor.  In 
sum, our studies revealed that genistein does not affect virus-cell attachment, but inhibits the 
subsequent early steps of virus internalization. 
 
 
Fig. 1. Genistein inhibits internalization of rLCMV-LASVGP. (A) LASV infection in WI-26 VA4 cells is 
mediated by DG. Monolayers of WI-26 VA4 cells in M96 plates were blocked with MAb IIH6 or an unrelated 
mouse IgM (Control IgM) at the indicated concentrations for 2 h at 4°C. Next, 200 PFU of rLCMV-LASVGP 
was added for 45 min. Infection was assessed after 16 hours by immunofluorescence (IF) staining for LCMV 
NP. Infected foci were counted in each well (means + SD, n = 3). (B) Cytotoxicity of genistein. WI-26 VA4 cells 
were treated with the indicated concentrations of the drug for 4 hours, followed by a wash out and incubation for 
a total of 16 hours. Cell viability was assessed by Cell Titer Glo® assay. Data are triplicates + SD. (C) Inhibition 
of rLCMV-LASVGP infection with genistein. WI-26 VA4 cells were treated with the indicated concentrations of 
genistein for one hour, followed by infection with rLCMV-LASVGP at multiplicity of 1, followed by wash out 
of the drug at 4 hours. After 12 hours of culture in presence of 20 mM ammonium chloride, cells were fixed and 
infection detected by IF for LCMV NP. Data are triplicates + SD. (D) Inhibition of infection of VSV 
pseudotypes with genistein. WI-26 VA4 cells were treated with the indicated concentrations of genistein for one 
hour, followed by infection with rVSV-LASVGP and rVSV-VSVG (200 PFU/well). After 24 hours, infection 
was assessed by detection of GFP positive cells in direct fluorescence microscopy (n = 3 + SD). (E) Schematic 
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of the virus internalization assay (for details, please see text). (F) Genistein treatment prevents internalization of 
rLCMV-LASVGP. WI-26 VA4 cells were pre-treated with 50 μM of genistein or vehicle control (DMSO). After 
one hour, cells were chilled on ice and incubated with biotin-S-S-labeled rLCMV-LASVGP (100 particles/cell) 
for one hour in the cold. Unbound virus was removed, cells shifted to 37 °C in presence or absence of genistein. 
After the indicated time points, cells were chilled on ice and treated with TCEP (+TCEP) or reaction buffer only 
(-TCEP). After quenching of residual TCEP, cells were lysed, viral GP isolated by IP with mAb 83.6 to GP2. 
Biotinylated GP2 was detected with streptavidin-HRP in Western-blot under nonreducing conditions using 
enhanced chemiluminescence (ECL). The Upper blot (+TCEP) was exposed for 10 minutes, the lower blot (-
TCEP) was exposed for 1 minute. 
Binding of LASV to cellular DG induced tyrosine phosphorylation of β-DG 
Since the binding of LASV to DG is of high affinity and virtually irreversible under neutral 
pH (Kunz et al., 2005b), we speculated that virus-bound DG may be internalized during endocytosis of 
the virus. The apparent block of virus internalization in presence of genistein at an early time point (5-
20 min) (Fig. 1E) opened therefore the possibility that uptake of the virus-receptor complex could 
involve tyrosine phosphorylation of the receptor and/or receptor-associated cellular factors. Since 
phosphorylation of β-DG at residue Y892 had previously been linked to internalization of the DG 
complex (Miller et al., 2012; Sotgia et al., 2003), we monitored phosphorylation of DG at Y892 during 
LASV cell entry. For this purpose, we applied mAb cl14a that specifically recognizes -DG 
phosphorylated at Y892 (Sotgia et al., 2003). In a first step, we confirmed the specificity of mAb cl14a 
in our system. To this end, we co-expressed recombinant full-length DG containing a C-terminal HA-
tag (DGHA, Fig. 2A) with recombinant c-src in HEK293 cells. Previous studies demonstrated that C-
terminal tagging of -DG had no influence on the biosynthesis, transport, and function of DG (Rojek 
et al., 2007a).  Cells were either treated with the specific src tyrosine kinase family inhibitor PP2 (20 
μM) or mock treated. After 48 hours, DGHA was isolated by IP with HA matrix and phosphorylation 
of Y892 detected with mAb cl14a in Western-blot. As expected, DGHA isolated from cells over-
expressing c-src was specifically recognized by mAb cl14a, whereas treatment with PP2 markedly 
reduced the signal, confirming the specificity of the assay (Fig. 2B). 
To examine the effect of LASV binding on tyrosine phosphorylation of DG at Y892, 
monolayers of WI-26 VA4 cells were incubated with rLCMV-LASVGP (100 particles per cell). Virus 
attachment was performed in the cold to allow virus binding but preventing lateral movement of 
receptor molecules in the membrane. As a control, we used the New World arenavirus Pichinde 
(PICV) that does not bind to -DG (Spiropoulou et al., 2002). After removal of unbound virus, cells 
were rapidly shifted to 37°C to restore membrane fluidity. At the indicated time points, cells were 
lysed in presence of the phosphatase inhibitor sodium orthovanadate. Cleared cell lysates were 
subjected to lectin purification with wheat germ agglutinin (WGA). Precipitated proteins were 
separated by SDS-PAGE and probed with mAb cl14a anti- -DGPY892 and mAb 8D5 to -DG that 
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binds independently of phosphorylation. Binding of rLCMV-LASVGP, but not PICV resulted in 
transient phosphorylation of -DG at Y892 (Fig. 2C) with maximal signals observed after 5-10 
minutes. To confirm the role of src family kinases in the apparent virus-induced receptor 
phosphorylation at Y892, we treated cells with the src kinase inhibitor PP2 for 30 minutes prior to 
addition of virus. As shown in Fig. 2D, pretreatment with PP2 markedly reduced virus-induced 
tyrosine phosphorylation of -DG at Y892, indicating a direct or indirect involvement of src kinases. 
In some experiments, we observed an apparent decrease in total β-DG at later time points (Fig. 2C, D). 
However, this was not observed consistently. 
To address a possible role of the observed virus-induced receptor phosphorylation at Y892 for 
viral entry, we monitored the entry kinetics of LASV in presence of PP2. Upon receptor binding, 
LASV is taken up by clathrin- and caveolin-independent endocytosis and rapidly delivered to late 
endosomes, where low pH-dependent membrane fusion occurs (Borrow and Oldstone, 1994; Quirin et 
al., 2008; Rojek, Perez, and Kunz, 2008; Rojek et al., 2008b). To assess how fast receptor-bound 
rLCMV-LASVGP trafficked to late endosomes in presence and absence of PP2, we determined the 
time required for the virus to become resistant to ammonium chloride. Briefly, WI-26 VA4 cells were 
either pretreated with PP2 for one hour, or mock treated with vehicle (DMSO) only. Cells were then 
incubated with rLCMV-LASVGP in the cold, allowing virus attachment without internalization. 
Unbound virus was removed and cells quickly shifted to 37 ºC to allow virus internalization in 
presence or absence of PP2. After different time points, 20 mM ammonium chloride was added to 
cells and kept throughout the experiment. At 16 h post infection, cells were fixed and infection 
assessed by IF detection NP. As shown in Fig. 2E pretreatment of cells with PP2 had no significant 
effect on the entry kinetics of rLCMV-LASVGP, suggesting that tyrosine phosphorylation of β-DG at 
Y892 was dispensable for virus cell entry. To complement these inhibitor studies, we examined the 
entry kinetics of rLCMV-LASVGP in murine embryonic fibroblasts (MEFs) derived from mice 
deficient for the src-family kinases src, fyn, and yes (Newsome et al., 2006). When compared to wild-
type MEFs, src/fyn/yes-deficient cells were infected with similar kinetics (data not shown), in line 
with our src kinase inhibitor studies (Fig. 2E). 
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Fig. 2. Binding of LASV to cellular DG induces tyrosine phosphorylation of -DG by src-family kinases 
(A) Schematic representation of C-terminally tagged DG (DGHA). The N-terminal domain (white), the mucin-
type domain (black) and the C-terminal domain (gray) of -DG, -DG, and the C-terminal HA tag are indicated. 
(B) Detection of tyrosine phosphorylation at residue Y892 with mAb cl14a. DGHA was transiently expressed 
either alone or in combination with c-src. Parallel specimens were pretreated with 20 μM PP2 or mock treated 
with vehicle (DMSO). After 48 hours, DGHA was isolated by pull-down with HA matrix. Proteins were 
separated and probed in Western blot with an antibody to HA (anti-HA) or mAb cl14a to -DG phosphorylated 
at tyrosine 892 (anti- -DG PY892). Apparent molecular masses and the positions of -DG are indicated. (C) 
Attachment of rLCMV-LASVGP to cells induces tyrosine phosphorylation of -DG. Monolayers of WI-26 VA4 
cells were incubated with rLCMV-LASVGP or PICV (100 particles/cell) for 1 hour in the cold. Unbound virus 
was removed and cells shifted to 37°C. At the indicated time points, cells were lysed and DG enriched by WGA 
affinity purification. WGA-bound glycoproteins were probed in Western-blot with mAb cl14a (anti- -DG 
PY892) and antibody 8D5 to -DG. The positions of -DG and -DG PY892 are indicated. (D) Virus induced 
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tyrosine phosphorylation of -DG is blocked by PP2. Monolayers of WI-26 VA4 cells were pretreated with 
20 μM PP2 or DMSO (Control) for 1 hour prior to exposure to rLCMV-LASVGP. Virus-induced 
phosphorylation of β-DG at Y892 was assessed as in (C). (E) The phosphorylation of -DG at PY892 is not 
required for LASV cell entry. Monolayers of WI-26 VA4 cells were pretreated with 20 μM PP2 or DMSO 
(Control) for 1 hour as in (D), followed by incubation with rLCMV-LASVGP (MOI = 1) in the cold in presence 
of the drug. After 1 hour, unbound virus was removed and pre-warmed (37 °C) medium containing the drug 
added. At the indicated time points, 20 mM ammonium chloride was added and left throughout the experiment. 
At 16 hours post infection, cells were fixed and infection detected by intracellular staining for LCMV NP (means 
+ SD, n = 3). The apparent differences in infection at 60 minutes were not statistically significant. 
Despite the marked inhibition of rLCMV-LASVGP internalization by genistein (Fig. 1F), treatment of 
cells with the src inhibitor PP2 did not affect LASV cell entry, which was rather unexpected. 
Examination of the sequence of the cytoplasmic tail of β-DG revealed the presence of four putative 
sites of tyrosine phosphorylation, in addition to Y892 (Fig. 3A). To assess tyrosine phosphorylation of 
β-DG in response to LASV binding at sites other than Y892, WI-26 VA4 cells were pretreated with 
PP2 or vehicle, followed by exposure to rLCMV-LASVGP as described above. After the indicated 
time points, β-DG was isolated by IP using mAb 8D5 that does not discriminate between 
phosphorylated and unphosphorylated β-DG. Immunocomplexes were separated by SDS-PAGE and 
probed in Western blot using mAb cl14a to β-DGPY892 and mAb 4G10 to tyrosine phosphate. Total 
β-DG was detected with polyclonal antibody AP83. As expected, treatment with PP2 prevented virus-
induced phosphorylation at Y892 (Fig. 3B). However, immunoblotting with the broadly specific anti-
phosphotyrosine mAb 4G10 revealed significant tyrosine phosphorylation of β-DG in response to 
virus binding that was not affected by PP2 (Fig. 3B). This suggested that binding of rLCMV-LASVGP 
to cellular DG induced tyrosine phosphorylation of -DG at sites other than Y892, possibly 
implicating non-src family tyrosine kinases. Pre-treatment of cells with genistein (50 μM) for 30 
minutes reduced virus-induced tyrosine phosphorylation of β-DG altogether (Fig. 3C). 
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Fig. 3. Binding of LASV to cellular DG induces tyrosine phosphorylation of -DG by non-src tyrosine 
kinases (A) Sequence of the cytoplasmic domain of human β-DG. The putative transmembrane domain is 
underlined in black and tyrosine residues indicated with gray arrows. Putative phosphorylation sites for src-
family kinases are underlined and Y residues marked (arrows). The PPxY motif including Y892 is double 
underlined. (B) Detection of virus-induced tyrosine phosphorylation β-DG in presence of PP2. WI-26 VA4 cells 
were pretreated with 20 μM PP2 or vehicle, followed by exposure to rLCMV-LASVGP as in Fig. 2D). After the 
indicated time points, β-DG was isolated by IP using mAb 8D5 against β-DG covalently coupled to Sepharose 
4B. Immunocomplexes were eluted under non-reducing conditions, separated by SDS-PAGE and probed in 
Western blot using mAb cl14a to β-DGPY892 and mAb 4G10 to tyrosine phosphate (pY). For detection of 
bound mouse IgG a TrueBlot® detection system was used to avoid cross-reaction with the murine IgG heavy 
and light chains. Total β-DG was detected with rabbit polyclonal antibody AP83. (C) Genistein blocks virus-
induced tyrosine phosphorylation of β-DG. Cells were pre-treated with 50 μM genistein or vehicle (DMSO) 
only. After 30 minutes, rLCMV-LASVGP was added (100 particles/cell) for the indicated time points and 
tyrosine phosphorylation of β-DG was assessed as in (B). 
Engagement of DG by LASV detaches the DG complex from the adaptor utrophin 
In the host cell, DG provides a molecular link between the ECM and the actin cytoskeleton by 
anchorage of the cytoplasmic domain of β-DG to the cytoskeletal adapter proteins dystrophin or 
utrophin. Cell entry of LASV occurs independently of the dynamics and stability of the actin 
cytoskeleton (Rojek et al., 2008b). We hypothesized that virus binding, possibly involving receptor 
clustering and signaling, may somehow detach DG from the cytoskeletal adaptors, allowing 
subsequent actin-independent endocytosis. A major challenge to test this hypothesis was to assess 
specific changes in utrophin binding to the relatively small fraction of virus-bound DG as compared to 
total cellular DG. To overcome this problem, we used recombinant retroviruses bearing the 
recombinant GP of LASV. Retroviral pseudotypes containing the GP of the New World virus Amapari 
(AMPV), which does not use DG as a receptor (Spiropoulou et al., 2002), served as a negative control. 
These arenavirus pseudotypes, which have been previously generated and extensively characterized in 
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our laboratory, adopt the receptor binding characteristics and cellular tropism of the viruses from 
which the GPs are derived (Rojek et al., 2007b). Importantly, the use of retroviral pseudotypes 
allowed the insertion of a C-terminal FLAG-tag into LASV GP and AMPV GP (Fig. 4A) allowing co-
IP of the viral GP with associated cellular receptor proteins. The C-terminal FLAG-tag had no adverse 
effect on the function of the viral GPs in host cell attachment and entry (Rojek et al., 2008a). 
Retroviral pseudotypes containing FLAG-tagged LASV GP and AMPV GP were produced and 
purified as described (Rojek et al., 2008a; Rojek et al., 2007b) and detection of GP in purified 
pseudotypes by ELISA revealed more efficient incorporation of LASV GP when compared to AMPV 
GP (Fig. 4B). As previously shown, infection of cells with LASV pseudotypes, but not AMPV 
pseudotypes or pseudotypes of VSV depended on DG (Fig. 4C), confirming their receptor specificity. 
 
Fig. 4. Retroviral pseudotypes. (A) Schematic representation of Flag-tagged LASV GP. The receptor-binding 
GP1 and transmembrane GP2 parts are indicated. The transmembrane domain of GP2 is represented as a grey 
box and the C-terminal FLAG-tag indicated. (B) Detection of GP in retroviral pseudotypes. Retroviral 
pseudotypes were generated by co-transfection of packaging cell line GP2293 expressing retroviral Gag/Pol with 
a GP expression plasmid and an expression plasmid for a packable retroviral genome bearing a luciferase and a 
GFP reporter gene. Pseudotypes were purified by ultracentrifugation through a sucrose cushion and re-suspended 
in HBSS. Purified pseudotypes of LASV (LAS), AMPV (AMP), and VSV, as well as pseudotypes lacking GP 
(C) were immobilized in microtiter plates and the viral GP detected with mAb 83.6, combined with an HRP-
conjugated secondary antibody in a colour reaction (means + SD, n = 3). (C) Infection of cells with LASV 
pseudotypes depends on DG. DG (-/-) murine embryonic stem (ES) cells and parental DG (+/-) ES cells were 
infected with pseudotypes of LASV (LAS), AMPV (AMP), and VSV, as well as pseudotypes lacking GP (C). 
After 48 hours, infection was detected by luciferase assay (means + SD, n = 3). 
RESULTS/PROJECT 1  49 
   
 
 
 
To assess the impact of LASV GP binding on the association of cellular DG with utrophin, we 
incubated LASV or AMPV pseudotypes with monolayers of WI-26 VA4 cells. A parallel set of cells 
was incubated with medium only. This step was carried out in the cold to allow receptor binding 
without clustering or internalization. Cells were either kept on ice or shifted to 37 °C for 10 minutes, 
followed by cell lysis in the cold. Lysates prepared from cells incubated with pseudotypes were 
subjected to IP with FLAG matrix. Lysates of untreated control cells were incubated with mAb 16G4 
to α-DG, combined with protein G sepharose. Immunocomplexes and total cell lysates were probed for 
β-DG and utrophin in Western blot. As shown in Fig. 5A, IP anti-FLAG in specimens incubated with 
LASV, but not AMPV pseudotypes resulted in the detection of β-DG and co-IP of utrophin, 
suggesting specific pull-down of LASV GP-associated DG complex. As expected, IP of α-DG resulted 
in robust co-IP of utrophin under all conditions. To quantify possible changes in the ratio of 
utrophin/β-DG upon exposure of cells to LASV pseudotypes, we performed densitometric analysis of 
the signals for both conditions and normalized to the utrophin/β-DG detected in the IP of α-DG (Fig. 
5B). In cells kept at 4°C, we consistently observed a significantly lower utrophin/β-DG ratio in the 
LASV GP-associated receptor fraction when compared to the DG-utrophin complexes isolated by IP 
with anti-α-DG antibody. This suggested that the LASV pseudotypes associate preferentially with 
cellular DG that shows a weaker or more transient association with utrophin. As shown in Fig. 5B, the 
temperature shift to 37 °C, which allows clustering of the receptor and signaling to occur, resulted in a 
reduction of the utrophin/β-DG ratio in LASV GP-associated DG when compared to cells kept in the 
cold. This suggests that virus-induced receptor clustering and/or signaling promotes the dissociation of 
the DG complex from utrophin. 
To address the role of tyrosine phosphorylation in the observed virus-induced dissociation of 
utrophin from DG, we tested the effect of genistein and PP2. To this end, cells were pre-treated with 
genistein and PP2 for one hour, followed by exposure to LASV pseudotypes. After removal of 
unbound virus, cells were shifted to 37 °C in presence of the drugs. Virus-associated DG was isolated 
by IP with FLAG matrix and the ratio of utrophin/β-DG assessed as described above. Treatment with 
genistein significantly reduced virus-induced dissociation of utrophin from DG, whereas PP2 had only 
a weak effect (Fig. 5C, D). This suggested that the phosphorylation of β-DG at Y892 was dispensable 
for the virus-induced dissociation of utrophin from the DG complex. 
To complement our inhibitor studies, we examined LASV cell entry into murine ES cells 
expressing a DG variant lacking the last 15 C-terminal amino acids of β-DG (DGΔC), including the 
PPxY motif containing Y892. Briefly, ES cells expressing either wild type DG or DGΔC were 
infected with rLCMV-LASVGP at low multiplicity. To exclude differences at the level of post-entry 
steps in LCMV replication, a recombinant LCMV expressing VSVG was used as a control. At four 
hours of infection, 20 mM ammonium chloride was added to prevent secondary infection. After 16 
hours, cells were fixed and infection detected by IF for LCMV NP. As shown in Fig. 5E, ES cells 
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expressing DGΔC were as permissive as wild-type cells, suggesting that the last 15 amino acids of β-
DG are dispensable for LASV cell entry. 
 
Fig. 5. Effect of LASV pseudotype binding on the association of DG with utrophin. Monolayers of WI-26 
VA4 cells were chilled on ice and incubated with either LASV or AMPV pseudotypes (LASV-PS, AMPV-PS) at 
a multiplicity of infection (MOI) of 50 transforming units (TU)/cell. Parallel specimens were incubated with 
mAb 16G4 to α-DG (anti-DG). After one hour, unbound virus or mAb were removed by washing. Cells were 
either kept on ice (virus binding 4°C) or shifted to 37 °C for 10 minutes (temperature shift 37°C). Cells were 
quickly chilled on ice, lysed and subjected to IP using FLAG matrix or protein G-conjugated Sepharose 4B. 
Immunocomplexes were separated by SDS-PAGE using 100% of the IPs anti-FLAG and 5% of the IP anti-DG. 
Beta-DG and utrophin were detected on Western-blot using monoclonal antibodies 8D5 and combined with 
HRP-conjugated secondary antibodies in a TrueBlot® detection system to avoid cross-reaction with the IgG 
heavy chain.  For the detection of total protein in cell lysates, 1/20 of the lysate were separated by SDS-PAGE 
and subjected to Western-blot detection. (B) Quantification of the signals in (A). Blots were scanned in a 
densitometer and the ratios of the signals for utrophin normalized to β-DG (utrophin/β-DG) for the IPs anti-
FLAG (LASV pseudotypes only) and the IP anti-DG. For each series, the utrophin/β-DG ratio detected in the IP 
anti-DG was defined as 1.0.  (C) Pre-treatment with genistein, but not PP2 reduced virus-induced dissociation of 
utrophin from DG. Monolayers of WI-26 VA4 cells were pre-treated with DMSO only (control), 20 μM PP2 and 
50 μM genistein for one hour. Cells were then chilled on ice and incubated with LASV pseudotypes (LASV-PS) 
for one hour in the cold in presence of drugs. Cells were then quickly shifted to 37 °C, lysed, and subjected to IP 
with FLAG matrix as in (A). Precipitated β-DG and utrophin were detected in Western blot and the ratios 
utrophin/β-DG determined as in (B). (D) Quantification of the data in (C). (E) The 15 C-terminal amino acids of 
β-DG are dispensable for LASV cell entry. Murine ES cells expressing either wild-type DG (DG wt) or DG 
lacking the C-terminal 15 amino acids of β-DG (DGΔC) were infected with rLCMV-LASVGP or rLCMV-
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VSVG at a multiplicity of 0.1. Infection of the cells expressing wild-type DG was set at 100% (means + SD, 
n = 3). 
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DISCUSSION 
In the present study we investigated the role of tyrosine phosphorylation for cell entry of 
LASV. We show that tyrosine kinases are required for endocytosis of the virus-receptor complex, but 
dispensable for virus-receptor binding. Binding of LASV to cellular dystroglycan (DG) induced 
phosphorylation of DG at Y892 by src family kinases and other tyrosine residues of β-DG by non-src 
kinases. Virus-induced receptor phosphorylation was accompanied by dissociation of DG from the 
cytoskeletal adaptor protein utrophin, which might facilitate virus endocytosis. 
In the host cell, DG provides a molecular link between the ECM and the actin-based 
cytoskeleton and has a slow turnover. However, engagement of DG by LASV results in rapid 
internalization of the virus and delivery to the late endosome (Quirin et al., 2008; Rojek et al., 2008b), 
suggesting marked changes in trafficking dynamics of DG induced by virus binding. In our study, we 
investigated if attachment of LASV affects post-translational modifications of DG, altering receptor 
trafficking in the membrane. Extending previous studies (Kolokoltsov et al., 2012; Vela et al., 2008), 
we found that treatment of cells with the broadly-specific tyrosine kinase inhibitor genistein prevented 
LASV cell entry at an early step of virus internalization without affecting virus-receptor binding, 
providing a first link between tyrosine phosphorylation and viral endocytosis.  Since tyrosine 
phosphorylation of β-DG at Y892 by src family kinases has previously been implicated in 
internalization of DG (Miller et al., 2012; Sotgia et al., 2003), we tested the effect of LASV binding on 
phosphorylation of the receptor at Y892. Engagement of cellular DG by rLCMV-LASVGP rapidly 
induced phosphorylation of β-DG at Y892 that was blocked by the src kinase inhibitor PP2. The 
observed kinetics of Y892 phosphorylation was compatible with a role in viral endocytosis. However, 
rather unexpected, treatment of cells with PP2 had no effect on the entry kinetics of the virus. Since 
the cytoplasmic tail of β-DG contains four additional putative sites of tyrosine phosphorylation, in 
addition to Y892, we examined virus-induced phosphorylation at tyrosines. We found that LASV 
binding induced tyrosine phosphorylation of β-DG at sites other than Y892 with similar kinetics. 
These tyrosine phosphorylation events were not sensitive to PP2 and likely involved non-src tyrosine 
kinases. Virus-induced tyrosine phosphorylation of β-DG was entirely abrogated by genistein. 
Using a pseudotype platform, we assessed the composition of DG complexes associated with 
LASV GP upon virion attachment. We found that LASV pseudotypes associated with a fraction of 
cellular DG that showed less association with utrophin. The reasons for this are currently unclear, but 
may be related to different accessibility of DG as a function of its association with utrophin and the 
actin cytoskeleton. In cells, DG associated with cell-substrate adhesion structures at the lower plasma 
membrane tends to co-localize with utrophin (Belkin and Smalheiser, 1996). Due to the close 
association with the substratum at the basal face of the cell, DG located in such substrate-adhesion 
complexes may be less accessible to the virus. 
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Our analysis further revealed that engagement of DG by LASV GP results in dissociation of utrophin 
from β-DG. This virus-induced dissociation of utrophin could be perturbed by genistein, but not PP2, 
suggesting that phosphorylation of β-DG at Y892 by src kinases was dispensable. The efficient virus-
induced dissociation of utrophin from DG in presence of PP2 is in line with the inability of the 
inhibitor to perturb viral entry. However, our findings are different from reports supporting a role for 
phosphorylation of β-DG at Y892 by src kinases in the regulation of utrophin binding and endocytosis 
of DG in prototypic primate cells (James et al., 2000; Sotgia et al., 2003) and myoblasts (Miller et al., 
2012) in response to endogenous substrates. The reasons for this discrepancy are currently unclear. 
One possibility is that, contrary to our initial assumption, DG may not stay associated with the virus 
during the entry process. In this scenario, DG would serve as an attachment factor rather than a true 
entry receptor. One would have to postulate the existence of another, yet unknown receptor molecule 
that would mediate viral endocytosis. The recently discovered alternative LASV receptors Axl and 
Dtk (Shimojima et al., 2012) appear as interesting candidates in this context. Alternatively binding of 
the multivalent virion particle to cellular DG may induce extensive clustering and activate signaling 
pathways that are not triggered by DG’s ECM ligands, allowing the virus to “bypass” a block in Y892 
phosphorylation. To address these possibilities, studies aiming at tracking the virus-DG complex in 
live cells are currently launched in our laboratory. 
Since virus-induced phosphorylation of β-DG is blocked by genistein, which inhibits 
internalization of the virus, it is tempting to speculate that virus-induced phosphorylation of β-DG is 
necessary for virus entry. However, in the host cell, DG is found associated with a number of cellular 
proteins that are required for the correct assembly and stability of the DG complex in the membrane, 
as well as its anchorage to the actin cytoskeleton (Barresi and Campbell, 2006). Such “pre-formed” 
DG complexes represent the functional units of virus attachment. Our data have shown that virus 
binding to DG results in receptor signaling. Such virus-induced signaling may affect the composition 
of the virus-receptor complex by recruiting new proteins into the virus-DG complex and/or excluding 
others. During the entry process, the “interactome” of the virus-DG complex may therefore change in 
a dynamic manner resulting in sorting at the plasma membrane required for subsequent cell entry. 
Candidate cellular proteins that interact with the virus-DG complex during the entry process and are 
part of this “interactome” would represent potential substrates for tyrosine phosphorylation. We 
cannot exclude the possibility that tyrosine phosphorylation of such receptor-associated proteins, and 
not β-DG itself, is the actual target of genistein in the viral entry process. 
In sum, the data at hand suggest that attachment of LASVGP to cellular DG induces tyrosine 
phosphorylation of β-DG at Y892 and other tyrosine residues accompanied by the dissociation of DG 
from utrophin. The consequent detachment of virus-bound DG from the actin-based cytoskeleton may 
facilitate subsequent endocytosis of the virus-receptor complex, providing a possible link between 
virus-induced post-translational modification of DG and virus entry. 
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MATERIALS AND METHODS 
Cell lines and viruses 
WI-26 VA4 cells (ATCC CCL-95.1) were cultured in DMEM, 10 % (vol/vol) FBS, supplemented 
with glutamine, and penicillin/streptomycin. Embryonic stem (ES) cells DG (+/-), DG (-/-) have been 
described (Henry and Campbell, 1998). Transgenic ES cells expressing DG lacking the last 15 amino 
acids (DGΔC) were generated through introduction of a triple premature stop codon affecting all 
possible reading frames via targeted homologous recombination (gift from Kevin P. Campbell). 
The recombinant virus rLCMV-LASVGP has been described elsewhere (Rojek et al., 2008b) and was 
produced and the titers determined as previously described (Dutko and Oldstone, 1983). Recombinant 
LASV GP and AMPV GP containing a C-terminal FLAG-tag have been described (Rojek et al., 
2008a). Retroviral pseudotypes expressing GFP and luciferase reporters were produced and 
concentrated, and titers determined as described (Rojek, Spiropoulou, and Kunz, 2006). Concentrated 
pseudotypes were diluted in HBSS at 107 transforming units per ml. For detection of viral GP in 
ELISA, purified pseudotypes were immobilized in microtiter plates at 106 TU/ml and the viral GP 
detected as described (Rojek, Perez, and Kunz, 2008). Recombinant VSV pseudotyped with LASV GP 
-LASVGP), and VSV -VSVG) were generated as reported previously (Kunz 
et al., 2005b). Virus titers were determined by the infection of Vero E6 cell monolayers and detection 
of GFP-positive cells by fluorescence microscopy. 
Antibodies and reagents 
Monoclonal antibodies (mAbs) 113 (anti-LCMVNP) and 83.6 (anti-LCMVGP) have been described 
(Buchmeier et al., 1981; Weber and Buchmeier, 1988), as has mAb IIH6 anti- -DG (Ervasti and 
Campbell, 1991). Other mAbs included mouse IgG 8D5 anti-β-DG (Novocastra) and mouse IgG 16C4 
to α-DG (provided by Kevin P. Campbell), mouse IgG anti-utrophin from St. Cruz Biotechnology (St. 
Cruz, CA),  mAb cl14a to phospho-β-DG PY982 (BD Bioscience), and mAb 4G10 to phospho-
tyrosine (St. Cruz, CA) . Rabbit anti-influenza HA (Y11) was from St. Cruz Biotechnology (St. Cruz, 
CA). Polyclonal rabbit anti-mouse secondary antibodies conjugated to HRP were from Dako 
(Glostrup, Denmark) and goat anti-mouse antibody conjugated with Rhodamin Red X were from 
Jackson Immuno Research Laboratories. Genistein and PP2 were purchased from Calbiochem. The 
Bright-Glo® luciferase assay and Cell Titer Glo® assay systems were obtained from Promega 
(Madison WI). 
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Immunoblotting 
Proteins were separated by gel electrophoresis using 12% polyacrylamide gels and transferred to 
nitrocellulose. After blocking in 5% (wt/vol) skim milk in PBS, membranes were incubated with Abs 
used at following concentrations: mAb 8D5, mAb cl14a, mAb 4G10, and polyclonal Abs AP83, and 
Y11 (10 μg/ml) in 2% (wt/vol) skim milk, PBS for 12 h at 6 ºC. Secondary Abs coupled to HRP were 
applied 1: 5, 000 in PBS, 0.1 % (wt/vol) Tween for 1 hour at room temperature. Blots were developed 
by enhanced chemiluminescence (ECL) using Super Signal West Pico ECL Substrate or TrueBlot® 
detection system (Pierce), where indicated. 
Infection of cells with retroviral pseudotypes 
Cells were plated in 96-well plates in a density of 104 cells/well. After 24 hours, retroviral pseudotypes 
were added at the indicated MOI and incubated for 1 hour at 37oC. The viral particles were removed, 
cells washed twice with DMEM, and fresh medium added. Infection was quantified by Bright Glo® 
luciferase assay. Luminescence was calculated as fold-increase over background signals obtained from 
uninfected cells. 
Infection of cells with rLCMV-LASVGP 
Cells were plated in 96-well plates in a density of 104 cells/well. After 24 hours, cells were pre-treated 
with genistein or PP2 as indicated, followed by infection with rLCMV-LASVGP at the indicated MOI 
for 1 hour at 37oC. Unbound virus were removed, cells washed twice with DMEM, and fresh medium 
added. Infection was quantified by detection of LCMV NP in IF as described (Kunz et al., 2004). Cell 
entry kinetics of rLCMV-LASV in presence and absence of PP2 were performed as described (Rojek 
et al., 2008b). Blocking of infection with mAb IIH6 was done as reported (Kunz et al., 2005a). 
Virus internalization assay 
Purification of rLCMV-LASVGP was performed by ultracentrifugation on a renografin gradient. 
Purified LCMV was labeled with the thiol-cleavable reagent NHS-SS-biotin (Pierce). The cleavage of 
the biotin label was verified by reaction with the membrane-impermeable reducing agent Tris (2-
carboxyethyl) phosphine (TCEP) (10 mM) (Pierce) for 30 min, which resulted in a loss of >95% of the 
biotin label. Internalization assay was performed as described previously (Rojek, Perez, and Kunz, 
2008). Briefly, cells were cultured in 10-cm dishes to obtain closed monolayers. Medium was 
removed, and cells were washed twice with cold HBSS and chilled on ice for 5 min. Cold solution 
containing NHS-SS-biotinylated rLCMV-LASVGP (107 PFU/ml) in HBSS was added. After 
incubation for 1 h on ice, unbound virus was removed and cells were washed with cold HBSS. For 
internalization, cells were shifted to 37°C. After the indicated incubation times, medium was removed 
and cells chilled on ice. TCEP (15 mM) in 50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM CaCl2, 
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1 mM MgCl2 was added (5 ml/dish) and applied twice for 30 min on ice. Cells were washed three 
times with cold HBSS, and the remaining TCEP was quenched with 100 mM iodoacetamide for 10 
min, and cells were lysed immediately. LCMV GP2 was isolated by IP as described (Rojek, Perez, and 
Kunz, 2008). Immunocomplexes were separated by nonreducing SDS-PAGE. Biotinylated LCMV 
GP2 was detected by Western blotting with HRP-conjugated streptavidin as described above. 
Detection of DG-utrophin complexes associated with LASV GP 
Triplicate cultures of WI-26 VA4 cells were cultured in 10 cm plates over night to obtain closed 
monolayers. Retroviral pseudotypes of LASV and AMPV (107 TU/ml in HBSS) were added at 50 
TU/cell. Parallel specimens were incubated with 10 μg/ml mAb 16C4 to α-DG in HBSS. After 
incubation for one hour in the cold, cells were washed 3 times with cold HBSS. One series of cultures 
was kept on ice whereas the other was quickly shifted to 37°C in a water bath. After 10 minutes, cells 
were chilled on ice. Cells were lyzed for 30 minutes in 1% (wt/vol) β-octylglucoside, 1 mM CaCl2, 1 
mM MgCl2, 150 mM NaCl, 50 mM Hepes pH 7.5, 10% (wt/vol) glycerin supplemented with protease 
inhibitor cocktail Complete® (Roche) and 1 mM PMSF. Cleared lysates were subjected to IP with 
FLAG matrix (Sigma) or protein G-conjugates sepharose 4B (Sigma) for 2 hours at 6°C. After three 
short washes in lysis buffer, the matrix was eluted with non-reducing SDS-PAGE sample buffer to 
minimize elution of IgG from the FLAG matrix. After addition of 100 mM DTT (final concentration) 
and boiling for another 5 minutes Western blot performed as described above. For quantification, X-
ray films were scanned with a Storm densitometer, and acquired data were processed using Image 
Quant software. 
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ABSTRACT 
The Old World arenavirus Lassa (LASV) is the causative agent of a severe hemorrhagic fever 
in humans causing several hundred thousand infections per year in Western Africa. The first cellular 
receptor discovered for LASV is dystroglycan (DG) a versatile receptor for proteins of the 
extracellular matrix (ECM). Recognition of DG by LASV critically depends on functional 
glycosylation of DG involving the glycosyltransferase LARGE, which occurs in a tissue-specific 
manner. Recent studies identified the TAM-family receptor tyrosine kinases Axl and Dtk as alternative 
cellular receptors for LASV in cells lacking functional DG. Here we further characterized Axl-
mediated cell entry of LASV in the context of productive arenavirus infection using a chimera of the 
prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) expressing the LASV envelope 
glycoprotein (rLCMV-LASVGP). In line with previous studies, we found that cell entry of rLCMV-
LASVGP via Axl was less efficient when compared to functional DG. However, Axl-mediated 
productive infection with rLCMV-LASVGP showed kinetics similar to DG-dependent entry. Axl-
mediated cell entry of LASV involved a clathrin-independent pathway that critically depended on 
actin and dynamin, was sensitive to EIPA, but not to PAK inhibitors. 
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INTRODUCTION 
The Old World arenavirus Lassa (LASV) is the causative agent of a severe hemorrhagic fever 
with high mortality in humans (McCormick and Fisher-Hoch, 2002). LASV is endemic in Western 
Africa from Senegal to Cameroon and causes several hundred thousand infections per year with 
thousands of deaths. Considering the number of people affected, the current lack of a licensed vaccine 
and the limited therapeutic options at hand, LASV represents a serious public health problem. LASV 
is an enveloped negative strand RNA virus with a non-lytic life cycle (Buchmeier, de la Torre, and 
Peters, 2007). The genome of LASV consists of two single-stranded RNA species, a large segment 
encoding the virus polymerase (L) and a small zinc finger motif protein (Z), and a small segment 
encoding the virus nucleoprotein (NP) and glycoprotein precursor (GPC). GPC is processed into GP1, 
implicated in receptor binding, and the transmembrane GP2, which contains the viral fusion 
machinery, allowing fusion of the viral and the cellular membrane during viral entry (Nunberg and 
York, 2012). 
The first cellular receptor discovered for LASV and the prototypic Old World arenavirus 
lymphocytic choriomeningitis virus (LCMV) is dystroglycan (DG) an ubiquitously expressed receptor 
for extracellular matrix (ECM) proteins (Cao et al., 1998; Oldstone and Campbell, 2011). Binding of 
LASV and LCMV to DG critically depends on the functional glycosylation of the α-DG subunit that 
critically depends on the glycosyltransferase LARGE (Kunz et al., 2005). Upon binding to DG, LASV 
and LCMV enter the host cell via an endocytotic pathway that is independent of clathrin, caveolin, 
dynamin, and actin (Quirin et al., 2008; Rojek, Perez, and Kunz, 2008; Rojek et al., 2008). Upon 
internalization, the virus is delivered to acidified endosomes via a pathway that is independent of the 
small GTPases Rab5 and Rab7, suggesting an unusual route of incoming vesicular trafficking. Recent 
studies revealed that LASV passes through the multivesicular body (MVB), where it undergoes sorting 
into intraluminal vesicles (ILV) by hijacking the host cell’s endosomal sorting complex required for 
transport (ESCRT) machinery (Pasqual et al., 2011). Upon sorting into ILV, the virus is delivered to 
late endosomes, where fusion occurs at an unusually low pH (Klewitz, Klenk, and ter Meulen, 2007). 
Using an expression cloning approach, Shimojima and colleagues identified the C-type lectins DC-
SIGN and LSECtin, as well as the Tyro3/Axl/Mer (TAM) receptor tyrosine kinases Axl and Tyro3 
(Dtk) as alternative LASV receptors (Shimojima et al., 2012). The data at hand convincingly show that 
Axl and Tyro-3 enhance LASV binding to DG-deficient cells and were able to mediate infection in a 
DG-independent manner. 
Tyro-3, Axl, and Mer compose the TAM family of receptor tyrosine kinases (RTKs), whose 
extracellular domain is comprised of tandems of two immunoglobulin (Ig) domains and two 
fibronectin type II domains (Linger et al., 2008). Tyro-3, Axl and Mer are expressed in a wide variety 
of cell types, with overlapping but unique patterns. Among the TAM receptors implicated in LASV 
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cell entry, Axl shows the widest expression pattern (O'Bryan et al., 1991) and is found on epithelial 
cells, platelets, endothelial cells, in the heart, liver, kidney, skeletal muscle, testis (Angelillo-Scherrer 
et al., 2001; Graham et al., 1995; Neubauer et al., 1994), and the brain (Bellosta et al., 1995). Tyro-3 is 
primarily expressed in the nervous system and is also detected in lung, kidney, retina and sexual 
organs, as well as hematopoietic cells (Angelillo-Scherrer et al., 2001; Lai, Gore, and Lemke, 1994; 
Lu and Lemke, 2001; Mark et al., 1994; Prasad et al., 2006). TAM receptors undergo interactions with 
serum protein S, and growth-arrest-specific protein 6 (Gas6), and proteins of the tubby family 
(Caberoy, Zhou, and Li, 2010; Lemke and Burstyn-Cohen, 2010; Lemke and Rothlin, 2008). Gas6 
serves as ligand for all three TAM receptors, albeit with different affinity: Axl > Tyro3/Dtk >> Mer. 
Ligand binding induces homo- or hetero-dimerization of TAM receptors with consequent activation of 
their cytoplasmic tyrosine kinase domain. TAM-receptors are involved in many cellular functions, 
including chemotaxis (Fridell et al., 1998), cell survival (Lee et al., 1999), the modulation of innate 
immunity (Lemke and Rothlin, 2008; Rothlin and Lemke, 2010), and clearance of apoptotic debris 
(Lemke and Burstyn-Cohen, 2010). Apoptotic cells display the phospholipid phosphatidylserine (PS) 
that is recognized by Gas6 and ProS via their N-terminal gamma-carboxylated glutamic acid (GLA) 
domain. Subsequent engagement of TAM receptors by the C-terminal domains of Gas6 and ProS 
results in the endocytosis of apoptotic cell debris. 
In the co-evolution with their hosts, viruses developed several strategies to hijack and 
manipulate cellular functions. Recent studies revealed that viruses are able to hijack the host’s 
apoptotic clearance machinery for cell entry (Mercer and Helenius, 2008; Mercer and Helenius, 2010; 
Morizono et al., 2011). Enveloped viruses display PS at their surface, which can act as an “eat me” 
signal triggering endocytosis. This strategy of “apoptotic mimicry” to gain access to the host cell was 
initially described for vaccinia virus (Mercer and Helenius, 2008). Subsequent studies demonstrated 
that a variety of enveloped viruses expose PS and can hijack the Gas6/TAM system to enter the host 
cell (Morizono et al., 2011), providing an entry mechanism that is not dependent on specific 
interaction between viral envelope proteins and cellular receptors, thus enlarging the tropisms of 
viruses. TAM kinases have been implicated in cell entry of the filoviruses Ebola and Marburg virus 
(Shimojima et al., 2006), as well as Dengue virus (Meertens et al., 2012). Axl was shown to enhance 
uptake of Ebola virus via macropinocytosis (Hunt et al., 2011) and cell entry via Axl did not involve a 
direct interaction with the viral glycoprotein (Brindley et al., 2011). Mutagenesis of Axl highlighted 
the importance of a functional ligand-binding domain and signal transduction for Ebola virus entry 
(Shimojima, Ikeda, and Kawaoka, 2007), however, the exact underlying mechanism remains unclear. 
In the present study, we sought to characterize the unknown endocytotic pathway involved in Axl-
mediated cell entry of LASV. 
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RESULTS 
Axl mediates cell entry of rLCMV-LASVGP independently of DG 
LASV is a BSL4 pathogen and work with the live virus requires high containment 
laboratories. To circumvent the biosafety restrictions associated with live LASV, we used a 
recombinant LCMV expressing the LASV envelope GP (rLCMV-LASVGP) (Rojek et al., 2008). 
Based on the close structural and genetic relationship between LASV and LCMV and the fact that 
receptor binding and entry of arenaviruses are mediated exclusively by the viral envelope, rLCMV-
LASVGP represents a suitable BSL2 surrogate for studies on LASV cell entry in the context of 
productive arenavirus infection (Pasqual et al., 2011; Rojek et al., 2012; Rojek et al., 2008). 
Previous studies had shown that Axl can function as a cellular receptor for lentiviral 
pseudotypes of LASV in the human fibrosarcoma cell line HT1080 (Shimojima et al., 2012). 
Consistent with earlier studies (Shimojima et al., 2012; Shimojima et al., 2006), Western-blot analysis 
revealed abundant Axl, but only low amounts of functionally glycosylated α-DG in HT1080 cells, 
whereas HEK293H cells expressed high amounts of functional DG, but lacked Axl (Fig. 1A, B). To 
exclude a possible contribution of residual functional DG to rLCMV-LASVGP entry into HT1080 
cells, we depleted the DG core protein by RNA interference (RNAi). For this purpose, HT1080 cells 
were stably transduced with a lentiviral vector expressing a small hairpin (sh)RNA targeting DG or a 
scrambled control siRNA. Selected cells stably transfected with DG shRNA showed a reduction in DG 
expression of > 95%, as assessed in Western-blot (Fig. 1C). DG-depleted and control HT1080 were 
infected with rLCMV-LASVGP at low multiplicity (0.1). At 16 hours post infection, cells were fixed 
and infection detected by immunofluorescence assay (IFA). As shown in Fig. 1D, depletion of DG in 
HT1080 cells did not affect infection of rLCMV-LASVGP (Fig. 1B), indicating a negligible role for 
residual functional DG. 
In line with published data, HT1080 cells expressed only Axl, but lacked the candidate LASV 
receptors Dtk, DC-SIGN (Fig. 2A and B), and LSECtin (data not shown). Two consecutive 
transfections of HT1080 cells with Axl-specific siRNA resulted in depletion of > 95% of the protein 
after 72 hours (Fig. 2C). Axl-depleted and control cells treated with scrambled siRNA were infected 
with rLCMV-LASVGP and a recombinant LCMV expressing the G protein of vesicular stomatitis 
virus (rLCMV-VSVG) (Pinschewer et al., 2003), which mediates infection in an Axl-independent 
manner (Morizono et al., 2011). As expected, depletion of Axl markedly reduced infection with 
rLCMV-LASVGP, but not rLCMV-VSVG, confirming a crucial role of Axl in LASV entry into 
HT1080 cells (Fig. 2D). To address the relative efficiency of Axl and DG as cellular receptors for 
LASV, functional DG was rescued in HT1080 cells by over-expression of LARGE (Fig. 2E). 
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Expression of functional DG greatly enhanced infection with rLCMV-LASVGP (Fig. 2F), confirming 
that DG acts as preferred receptor (Shimojima et al., 2012). 
 
 
Fig. 1. DG is dispensable for infection of rLCMV-LASVGP in HT1080 cells. (A) Detection of Axl in 
HT1080 cells. HT1080, HeLa, and HEK293H cells were lysed, total proteins separated by SDS-PAGE, and 
blotted to nitrocellulose. Blots were probed with a polyclonal rabbit antibody to Axl and an HRP-conjugated 
secondary antibody using enhanced chemiluminescence (ECL) for development. As a loading control, α-tubulin 
was detected. The positions of Axl and α-tubulin (Tub) are indicated. (B) Detection of functional DG. HT1080, 
HeLa, and HEK293H cells (5 x 106 cells) were lysed and subjected to jacalin affinity purification as described 
(Rojek et al., 2007b). Lectin-bound proteins were eluted by boiling in reducing SDS-PAGE sample buffer and 
analyzed in Western-blot (IB) using mAb IIH6 to functionally glycosylated α-DG (Kanagawa et al., 2004) and 
mAb 8D5 to β-DG. Prolonged exposure time (exp) of blots for glycosylated α-DG revealed a weak, but specific 
band for HT1080 cells (asterisk) indicating the presence of residual functional DG. The positions of glycosylated 
α-DG in HeLa and HEK293H, as well as β-DG are indicated. (C) Depletion of DG core protein by RNAi. 
HT1080 cells were transduced with a lentiviral vector expressing a shRNA targeting human DG (sh-DG) or a 
scrambled control shRNA that does not target any known human gene (sh-sc). After 48 hours of transfection, 
transduced cells were subjected to antibiotic selection with puromycin for a total of ten days. Resistant colonies 
were isolated and expanded. Depletion of DG by RNAi was validated by Western-blot for β-DG. Shown are 
selected clones for HT1080 cells expressing DG-specific shRNA (HT1080-sh-DG), scrambled shRNA 
(HT1080-sh-sc), and wild-type HT1080 cells. Beta-DG and α-tubulin (loading control) were detected as in (B). 
Prolonged exposure of β-DG blots lead to the detection of an unspecific band of circa 50-55 kDa (*). The 
positions of β-DG and α-tubulin are indicated. The efficiency of DG depletion was quantified by normalization 
of the β-DG signals with α-tubulin in densitometry. The rate of β-DG/α-tubulin (DG/Tub) in parental HT1080 
cells was set as 100. (D) Infection of DG-depleted HT1080 cells with rLCMV-LASVGP. HT1080-sh-DG cells 
(DG) and HT1080-sh-sc cells (Sc) were infected with rLCMV-LASVGP at multiplicity of 0.1. After 4 hours, 20 
mM ammonium chloride was added to prevent secondary infection. At 16 hours post infection, cells were fixed 
and infection detected by intracellular staining of LCMV NP using mAb 113 combined with a Rhodamine-
conjugated secondary antibody as described (Pasqual et al., 2011). Data are total numbers of infected foci per 
well (means + DG, n = 3). 
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Fig. 2. Detection of the TAM receptors Axl, Mer, and Dtk in HT1080 cells. Live non-permeabilized HT1080 
cells were stained with a polyclonal rabbit antibody to Axl, combined with a PE-conjugated secondary antibody 
in the cold. Dtk and Mer were detected with PE-conjugated mAb to Dtk and mAb to Mer, respectively. Cells 
were fixed and analyzed by flow cytometry in a FACSCalibur flow cytometer (Becton Dickinson) using the 
CellQuest Pro® acquisition and analysis software. Empty peaks: secondary antibody only, shaded peaks: 
primary and secondary antibody. (B) Detection of DC-SIGN in HT1080 cells. Live non-permeabilized HT1080 
cells and human monocyte-derived dendritic cells (MDDC) were stained with mAb 120507 to DC-SIGN and a 
PE-conjugated secondary antibody. Cells were fixed and analyzed by flow cytometry as in (A). Empty peaks: 
secondary antibody only, shaded peaks: primary and secondary antibody. (C) Depletion of Axl by RNAi. 
HT1080 cells were transfected with Axl-specific siRNA (siRNA Axl) and a scrambled control RNA (siRNA sc) 
by reverse transfection as described (Pasqual et al., 2011). After 24 hours, cells were subjected to a second round 
of transfection with the same siRNAs (forward transfection). At 72 hours after the first transfection, cells were 
lysed and Axl detected by Western-blot as in 1A, using α-tubulin for normalization. The efficiency of Axl 
depletion was assessed by normalization of the Axl signals with α-tubulin in densitometry and the rate of Axl/α-
tubulin (Axl/Tub) in HT1080 cells transfected with scrambled RNA set at 100. (D) Infection of Axl-depleted 
cells with rLCMV-LASVGP. HT1080 cells transfected with siRNA to Axl (Axl) or scrambled siRNA (sc) were 
infected with rLCMV-LASVGP and rLCMV-VSVG at multiplicity of 0.1 and infection detected after 16 hours 
as in 1D. Data represent total numbers of infected foci per well (means + DG, n = 3). (E) Rescue of functional 
DG in HT1080 cells. HT1080 cells were infected with adenoviral vectors expressing GFP (AdV-GFP) or 
LARGE (AdV-LARGE) at the indicated multiplicities of infection (MOI). After 48 hours, DG was extracted by 
jacalin affinity purification as in (B). Functionally glycosylated α-DG and β-DG were detected as in 1B. The 
broad band in cells transfected with AdV-LARGE at MOI = 100 corresponds to glycosylated α-DG. (F) 
Infection with rLCMV-LASVGP. HT1080 cells were infected with AdV-LARGE and AdV-GFP at MOI = 100 
as in (E). After 48 hours, cells were infected with rLCMV-LASVGP at multiplicity of 1 and infection detected 
after 16 hours as in (D). Shown are percentages of infected cells (means + DG, n = 3). 
Axl-mediated cell entry of rLCMV-LASVGP occurs rapidly 
In a next step, we compared the entry kinetics of rLCMV-LASVGP via Axl and DG. To 
assess how fast receptor-bound rLCMV-LASVGP trafficked to late endosomes, we assessed the time 
required for the viruses to become resistant to ammonium chloride a lysosomotropic agent that raises 
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the endosomal pH rapidly and prevents low pH-dependent membrane fusion without causing overall 
cytotoxicity (Ohkuma and Poole, 1978; Ohkuma and Poole, 1981). The virus was bound to HEK293H 
cells that express functional DG, but lack Axl, and HT1080 cells in the cold, allowing receptor 
attachment without internalization. Unbound virus was removed and cells rapidly shifted to 37°C to 
restore membrane mobility. Ammonium chloride was added at different time points post infection and 
kept throughout the experiment. Cells were fixed and infection assessed by IFA. In line with published 
data, DG-mediated infection allowed rLCMV-LASVGP to escape from late endosomes after circa 20 
minutes (Fig. 3) (Rojek et al., 2008). The kinetics of the infection of HT1080 cells mediated by Axl 
followed a similar kinetics with escape from the late endosome after only 15-20 minutes. In sum, the 
data confirm and extend published results by showing that Axl can serve as a cellular receptor in DG-
deficient cells. While Axl seems significantly less efficient in mediating LASV cell entry when 
compared to DG, the two receptors mediate productive infection with similar kinetics. 
 
Fig. 3. Entry kinetics of rLCMV-LASVGP in HEK293H and HT1080 cells. (A) Cells were incubated with 
rLCMV-LASVGP at multiplicity of 3 for one hour in the cold. Unbound virus was removed and cells shifted to 
37°C. At the indicated time points, 20 mM ammonium chloride was added and left throughout the experiment. 
After 16 hours cells were fixed and infection detected by FACS. The percentage of infected cells was plotted 
against time. Data are triplicates means + SEM. (B) Data from (A) normalized with the 240 minutes time point 
set as 100%. 
Axl-dependent cell entry of rLCMV-LASVGP resembles macropinocytosis 
Next, we sought to characterize the Axl-mediated entry pathway for LASV using our rLCMV-
LASVGP chimera in HT1080 cells. To characterize the Axl-dependent LASV entry pathway, we first 
perturbed clathrin-mediated endocytosis (CME) using chlorpromazine (CPZ), which prevents 
assembly of clathrin-coated pits at the plasma membrane. As control, we used a recombinant LCMV 
expressing the glycoprotein of vesicular stomatitis virus (VSV) that enters cells via CME 
(Johannsdottir et al., 2009). Treatment of HT1080 cells with up to 8 μM CPZ did not significantly 
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affect infection with rLCMV-LASVGP, but diminished infection with rLCMV-VSVG in a dose-
dependent manner (Fig. 4A). Next, we addressed the role of dynamin employing the dynamin inhibitor 
dynasore. As shown in Fig. 4B, infection of rLCMV-LASVGP in HT1080 was blocked by dynasore in 
a dose-dependent manner, similar to rLCMV-VSVG, which depends on dynamin for cell entry 
(Johannsdottir et al., 2009). In contrast, infection of rLCMV-LASVGP in HEK293H cells was not 
inhibited by dynasore, suggesting a specific role of dynamin in LASV entry via Axl, but not DG. 
To address a possible role of actin in Axl-mediated LASV cell entry, HT1080 and HEK293H 
cells were treated with cytochalasin B or latrunculin A, which disrupt actin fibers, as well as 
jasplakinolide, an actin-polymer stabilizing drug that blocks the dynamics of actin filaments. Staining 
of actin fibers in drug-treated HT1080 cells with fluorescence-labeled phalloidin revealed the 
characteristic disruption of F-actin by cytochalasin B or latrunculin A, whereas jasplakinolide reduced 
phalloidin staining, as expected (Fig. 4C). Drug treatment did not affect cell viability as assessed by 
Cell titer Glo® assay (Fig. 4D). Perturbation of actin by all three inhibitors significantly reduced 
infection of rLCMV-LASVGP in HT1080 cells, whereas DG-mediated infection in HEK293H cells 
was unaffected. 
The marked actin- and dynamin-dependence of Axl-mediated LASV provided first hints 
towards a possible role of macropinocytosis. To address this possibility, HT1080 cells were treated 
with ethylisopropyl amiloride (EIPA), an inhibitor of Na+/H+ exchangers (Mercer and Helenius, 2009). 
Pre-treatment with EIPA reduced infection with rLCMV-LASVGP, but did not affect infection with a 
recombinant Murine Mooney leukemia virus (MMLV) pseudotypes bearing an amphotropic envelope 
that mediated fusion at the cell membrane (Fig. 4F). Using the inhibitor IPA-3, we blocked PAK1, 
which plays a central role in macropinocytosis of some viruses (Mercer and Helenius, 2008). As 
shown in Fig. 4G, IPA-3 had no significant effects on infection with rLCMV-LASVGP, but 
significantly reduced infection with vaccinia virus, in line with published data (Mercer and Helenius, 
2008). Although by no means comprehensive, our first characterization of Axl-dependent rLCMV-
LASVGP entry revealed the involvement of a pathway that shares some characteristics of 
macropinocytosis (Mercer and Helenius, 2009; Mercer, Schelhaas, and Helenius, 2010) and is 
strikingly different from DG-mediated entry (Rojek et al., 2008). 
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Fig. 4. Characterization of the Axl-associated cell entry pathway of rLCMV-LASVGP in HT1080 cells. (A) 
Effect of CPZ on the infection of rLCMV-LASVGP. HT1080 cells were treated with the indicated 
concentrations of CPZ or PBS only (0) for one hour, followed by infection with rLCMV-LASVGP or rLCMV-
VSVG at a multiplicity of 0.01. After 4 hours, 20 mM ammonium chloride were added to prevent secondary 
infection, and infected cells detected after 16 hours by IFA as in 1D (means + SEM, n = 3). (B) Blocking of 
infection of rLCMV-LASVGP with dynasore. HT1080 and HEK293H cells were pre-treated with the indicated 
concentrations of dynasore or vehicle control (0), followed by infection with rLCMV-LASVGP (LASV) or 
rLCMV-VSVG (VSV). Infection was detected after 16 hours as in (A) (means + SEM, n = 3). (C) Treatment of 
HT1080 cells with actin inhibitors. HT1080 cells were treated with cytochalasin B (20 μM), latrunculin A (5 
μM), and jasplakinolide (1 μM) for 30 minutes. Cells were fixed and permeabilized. F-actin was stained with 
Rhodamine-conjugated phalloidin (red) and nuclei counter-stained with DAPI (blue). Please note the reduced 
phalloidin staining in cells treated with jasplakinolide due to a competition of the drug for the phalloidin binding 
site. Bar = 20 μm. (D) Cytotoxicity of actin inhibitors. HT1080 cells were treated with 20 μM cytochalasin D 
(Cyto), 5 μM latrunculin A (Lat), and 1 μM jasplakinolide (Jas), or solvent control (Ctrl) for 4 hours, followed 
by a wash out and incubation for a total of 16 hours. Cell viability was assessed by Cell Titer Glo® assay 
according to the manufacturer’s recommendations. Data are triplicates + SD. (E) Axl-mediated infection of 
rLCMV-LASVGP in HT1080 cells is actin-dependent. HT1080 and HEK293H cells were treated with 20 μM 
cytochalasin D (Cyto), 5 μM latrunculin A (Lat), and 1 μM jasplakinolide (Jas), or solvent control (Ctrl) for 30 
minutes, followed by infection with rLCMV-LASVGP. After 4 hours, drugs were washed out and fresh medium 
containing 20 mM ammonium chloride added. Infection was detected after a total of 16 hours post-infection as 
in (A) (means + SEM, n = 3). (F) Inhibition of rLCMV-LASVGP infection in HT1080 cells by EIPA. HT1080 
cells were pre-treated with the indicated concentrations of EIPA or vehicle control (0) for 30 minutes, prior to 
infection with rLCMV-LASVGP as in (A) (means + SEM, n = 3). As a control, we employed a recombinant 
Moloney murine leukemia virus expressing an Amphotropic (Ampho) envelope and a GFP reporter in its 
genome generated in the Retro-XTM Universal Packaging System (Clontech) as described (Rojek, Spiropoulou, 
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and Kunz, 2006). Infection by the Ampho retrovirus was detected by direct fluorescence at 24 hours post 
infection. (G) Effect of the PAK1 inhibitor IPA-3 on infection of rLCMV-LASVGP. HT1080 cells were pre-
treated with the indicated concentration of IPA-3 or vehicle control (0) for 30 minutes, followed by infection 
with rLCMV-LASVGP (LASV) or recombinant vaccinia virus expression GPF (VV) (Mercer and Helenius, 
2008). Infection with rLCMV-LASVGP was assessed as in (A) and infection with VV by detection of the GFP 
reporter in direct fluorescence microscopy at 12 hours post infection (means + SEM, n = 3). 
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DISCUSSION 
In line with previous studies (Shimojima et al., 2012), our results confirmed the TAM 
receptor Axl as an entry receptor for LASV in absence of DG. However, the molecular mechanisms 
of Axl recognition by LASV are largely unknown. Recently, a general model for cell entry of 
enveloped viruses via TAM receptors has been proposed based on the concept of “apoptotic 
mimicry”. According to this model, viral entry via Axl critically depends on PS of the viral 
envelope, which is bound by the serum proteins Gas6 or ProS that provide a bridge to cellular TAM 
receptors (Morizono et al., 2011). Previous studies detected PS in the envelope of the Clade A New 
World arenavirus Pichinde (Soares, King, and Thorpe, 2008), and studies in our laboratory revealed 
that virions of LCMV and rLCMV-LASVGP also display PS at their surface (Moraz et al., 
unpublished results). Current efforts in our laboratory investigate the exact role of virus-derived PS, 
Gas6, and proS in Axl mediated cell entry of LASV and Old World arenaviruses in general. 
Alternatively, LASV GP may be able to directly bind to cellular Axl, a possibility we are likewise 
testing. 
Previous work on cell entry of the Old World arenaviruses, revealed that these viruses use 
an unusual pathway to invade the host cell. Upon DG binding, LASV is internalized via a 
cholesterol-dependent endocytic pathway that seems independent of classical regulatory proteins 
like clathrin, caveolin, and dynamin and apparently bypasses the classical Rab5-dependent 
incoming pathways of vesicular trafficking, suggesting an unusual way of delivery to late 
endosomes (Quirin et al., 2008; Rojek, Perez, and Kunz, 2008; Rojek et al., 2008; Vela et al., 
2007). Here we performed an initial characterization of the LASV entry pathway linked to Axl. We 
found that Axl-mediated cell entry of rLCMV-LASVGP was clathrin-independent, but critically 
depended on actin and dynamin. Combined with the exquisite sensitivity to EIPA, these initial 
findings suggest the involvement of a macropinocytosis-like pathway that has recently been 
implicated in cell entry of several viruses, including poxviruses and filoviruses (Mercer and 
Helenius, 2009; Mercer, Schelhaas, and Helenius, 2010). Comparison of the entry kinetics of 
rLCMV-LASVGP via DG or Axl revealed similar rapid escape of the virus from the late endosome 
after less than 20 minutes. Rescue of functional DG in HT1080 cells revealed much higher 
efficiency of cell entry of rLCMV-LASVGP when compared to Axl. This suggests that in cells co-
expressing the two receptors, like e.g. epithelial or endothelial cells, LASV cell entry occurs 
predominantly via DG. 
A hallmark of LASV infection in most cell types is the inability of the infected host cell to 
induce a type I interferon (IFN) response. One reason for this is the ability of the arenavirus NP to 
counteract the activation of the IFN regulatory factor (IRF)-3 (Martinez-Sobrido et al., 2009; 
Martinez-Sobrido et al., 2006) and NF-κB (Rodrigo et al., 2012). The NP contains a 3’-5’ exonuclease 
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activity that is linked to its immunosuppressive activity (Hastie et al., 2011; Qi et al., 2010) and targets 
the non-canonical interferon regulatory factor-activating kinase IKKε (Pythoud et al., 2012). Since the 
viral NP acts as an IFN antagonist in the cytoplasm, the suppression of IFN production by NP depends 
on productive viral infection with expression of sufficiently high levels of NP. During viral entry, the 
virus is located in extracellular space where NP cannot act as an IFN antagonist. It is thus possible that 
incoming arenaviruses could be detected by pathogen recognition receptors (PRRs) located in 
endosomal compartments, e.g. Toll-like receptors (TLRs). Upon DG binding, Old World arenaviruses 
are internalized via a pathway of endocytosis that bypasses the early endosome where PRRs like TLRs 
localized (Rojek et al., 2008), possibly allowing the virus to evade innate detection. It will be of 
interest to investigate if LASV entry via Axl likewise allows the virus to evade innate detection and if 
its entry via Axl results in innate detection with the consequent induction of IRF3 and NF-κB or not. 
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MATERIALS AND METHODS 
Cell lines and viruses 
HT1080, HEK293H and A549 cells were cultured in DMEM, 10 % (vol/vol) FBS, supplemented with 
penicillin/streptomycin. The recombinant virus rLCMV-LASVGP and rLCMV-VSVG have been 
described (Pinschewer et al., 2003; Rojek et al., 2008). Viruses were produced and titers determined as 
previously described (Dutko and Oldstone, 1983). Recombinant vaccinia virus expressing GFP (VV-
GFP) was kindly provided by Jason Mercer and produced as described (Mercer and Helenius, 2008). 
A recombinant Moloney murine leukemia virus expressing an Amphotropic envelope was generated 
as reported (Rojek, Spiropoulou, and Kunz, 2006). Recombinant adenoviral vector (AdV)-Ad5-
LARGE-enhanced green fluorescent protein (EGFP) and (AdV)-Ad5-EGFP have been described and 
were produced and titered as previously defined (Barresi et al., 2004). 
Virus infection 
For virus infection, 5 x 104 HT1080 cells per well were seeded in 96-well microtiter plates and 
cultured overnight. For infection of cells with rLCMV-LASVGP and rLCMV-VSVG, seed stocks 
were diluted to the indicated MOI and added to cells for 1 hour at 37°C. After 1 hour of incubation, 
the inoculum was removed; cells were washed once with serum-free medium and replaced with 
normal medium. To prevent secondary infection, 20 mM ammonium chloride (NH4Cl) was added to 
the cells 4 hours post-infection. Cells were fixed at 16 hours post-infection and infected cells 
quantified by immunofluorescence assay (IFA) for LCMV NP using mAb 113 combined with 
fluorescence-labeled secondary antibodies (Kunz et al., 2004). 
Antibodies and reagents 
Monoclonal antibody (mAb) 113 (anti-LCMVNP) and mAb clone 83.6 (anti-LCMVGP) have been 
previously described (Buchmeier et al., 1981; Weber and Buchmeier, 1988). The mAb IIH6 anti- -
DG was used to detect functional DG (Ervasti and Campbell, 1991). To detect the DG core protein, 
the mouse mAb anti-β-DG clone 56 from BD Biosciences was used (NJ, USA). TAM kinases were 
detected using the polyclonal goat anti-Axl Ab, anti-Dtk and anti-Mer PE-conjugated mouse mAbs 
from R&D Systems® (AF154, FAB859P, FAB8912P, MN, USA). DC-SIGN was detected using the 
mAb DCN46 anti-CD209 (DC-SIGN)-PE purchased from BD Pharmingen. Mouse mAb anti-α-
tubulin was purchased from Sigma-Aldrich (MO, USA). The rabbit polyclonal anti-Adenovirus Type 
5 was purchased from Abcam® (ab6982, UK) and directed against all capsid proteins. To detect 
Vaccinia virus (VV), an anti-A27L viral protein rabbit polyclonal antibody was used from LifeSpan 
BioSciences (Cat. No. LS-C19415, WA, USA). Horseradish peroxidase (HRP) conjugated polyclonal 
rabbit secondary antibodies anti-goat and anti-mouse IgG were purchased from Dako (P0449, P0260, 
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(Glostrup, Denmark). The HRP-conjugated polyclonal goat anti-mouse IgM antibody was purchased 
from Thermo Scientific (PA1-85999). Rhodamine Red-X-AffiniPure goat anti-mouse IgG from 
Jackson ImmunoResearch (EU) and Alexa Fluor 488 goat anti-mouse IgG2b were from Molecular 
Probes (A11017, Eugene, OR). Streptavidin HRP-conjugated secondary antibody was used to detect 
biotinylated annexin-V (ANX5) purchased from Thermo Fisher Scientific Inc. Dharmacon (Lafayette, 
CO). 
Cytochalasin B, jasplakinolide, latrunculin A, Phalloidin-FITC, chlorpromazine hydrochloride, 
dynasore hydrate, p21-activated kinase (PAK)-1 inhibitor 2,2’-dihydroxy-1, 1’-dinaphthyldisulfide 
(IPA-3) and 5-(N-Ethyl-N-isopropyl) amiloride (EIPA) were purchased form Sigma-Aldrich. 
LIVE/DEAD® fixable dead cell stain kit was from Molecular probes® Invitrogen. The annexin-V-
Biotin conjugated from Roche-applied-science (Cat. No. 11 828 690 001) was used to detect the 
phosphatidylserine on purified viral particles. HT1080 cells transduced with lentiviral vectors were 
then selected using the Puromycin antibiotic from Calbiochem® (Merck Millipore, MA, USA). For all 
experiments, HT1080 cells were plated in poly-L-lysine-coated wells purchased from Sigma-Aldrich® 
(P8920). 
Lentivirus shRNA production and transduction of HT1080 cells 
To deplete DG core protein in HT1080 cells, lentiviral vectors expressing validated shRNA targeting 
human DG (sh-DG) (ID clone: TRCN0000056191, Thermo Scientific RHS3979-9623375) or a 
scrambled control shRNA (sh-sc) were generated following the manufacturers recommendations. 
Briefly, 3 x 106 HEK293T cells were cultured in 10-cm-diameter dishes in serum-free 293 SFM II 
medium (Gibco™, Cat. No. 11686-029). At 24 hours post-seeding, fresh medium was added to cells 4 
hours before the transfection. CaCl2 (250 mM CaCl2, ultrapure H2O) and HBS (50 mM Hepes, 1.5 mM 
Na2HPO4, 140 mM NaCl, ultrapure H2O) solutions were used to co-transfect the four required 
plasmids: pLP1 helper (gag/ pol), pLP2 helper (rev), pCAGGS/ VSVGP, with sh-DG 56191 (human 
pLKO.1) or with sh-sc (human pLKO.1) shRNA control. Transfected cells were incubated for16 hours 
at 37°C, 5% CO2. After 16 hours, the transfection medium was replaced by fresh serum-free 293 SFM 
II medium and cells incubated for circa 24 hours more at 37°C, 5% CO2. Circa 40 hours post-
transfection, cell supernatants were collected and centrifuged for 5 min at 500 g to remove cellular 
debris. Each lentivirus was concentrated using the Amicon® Ultra-15 Centrifugal Filter Devices by 
ultra-centrifugation according to the manufacturer’s instructions (Millipore, Ultracel® 100KREF. 
UFC910024). Then, 5 x 105 HT1080 cells/well were seeded in 6-well plate format and cultured for 24 
hours at 37°C, 5% CO2. The day after, cell medium was replaced by classical medium supplemented 
with [6 μg/ml] Polybrene® in which 100 μl of each crude lentivirus stock was added. The cells were 
spinoculated at 2600 rpm for 3 hours at 23°C. Cells were then washed twice with supplemented 
classical medium to remover Polybrene®. The transduced cells were then incubated for 72 hours at 
RESULTS/PROJECT 2  78 
   
 
 
 
 
37°C, 5% CO2. After 72 hours, cells were washed once with 1 x PBS and [2 μg/ml] puromycin 
selective medium added. After 48 hours, cell death was checked and the selective medium replaced 
each two days by fresh one during all the selective process. Depletion of DG was verified by Western-
blot detecting the β-DG core protein. 
Immunoblotting 
Proteins were separated by gel electrophoresis using 6% or 8% polyacrylamide gels and transferred to 
nitrocellulose. After blocking in 3% (wt/vol) skim milk in PBS, membranes were incubated with 
primary Abs used at 5-10 μg/ml in 3% (wt/vol) skim milk in PBS for 1 hour at room temperature. 
After several washes in PBS, 0.1 % (wt/vol) Tween, secondary Abs coupled to HRP were applied 
1:6000 in PBS, 0.1% (wt/vol) Tween for 1 hour at room temperature. Blots were developed by 
enhanced chemiluminescence (ECL) using Super Signal West Pico ECL Substrate or TrueBlot® 
detection system (Pierce). 
Rescue of functional DG in HT1080 cells 
Functional DG was rescued in HT1080 cells by over-expression of LARGE using recombinant 
adenoviral vector (AdV)-Ad5-LARGE-EGFP and (AdV)-Ad5-EGFP as control (Barresi et al., 2004). 
Briefly, 3 x 105 HT1080 and A549 cells per well were seeded in poly-L lysine-coated 6-well plate 
format and incubated for 24 hours at 37°C, 5% CO2. At 24 hours post-seeding, AdV-LARGE and 
AdV-EGFP vectors were added to cells at indicated MOI and incubated for 4 hours at 37°C, 5% CO2. 
4 hours post-transduction, inoculums were removed, cells washed with fresh normal medium and 
incubated overnight at 37°C, 5% CO2. Twenty-four hours post-transduction, transduced cells were re-
seeded in 96-well plate format at 5 x 104 cells/well. At 48 hours post-transduction, cells were either 
infected with rLCMV-LASVGP at MOI = 1 and infection quantified by detection of LCMV NP in 
IFA, or lysed to extract functional DG using Jacalin affinity purification as described (Rojek et al., 
2007b). Lectin-bound proteins were then subjected to SDS-PAGE and Western-blotting using mAb 
IIH6 to functionally glycosylated α-DG (Kanagawa et al., 2004) and mAb anti-β-DG clone 56 to β-DG 
core protein. 
Flow cytometry analysis 
For extracellular staining with enzyme-free cell dissociation solution, resuspended in FACS buffer 
(1% (vol/vol) FCS, 0.1% (wt/vol) sodium azide, PBS), and plated in conical 96-well plates, followed 
by one hour on ice with FACS buffer diluted with corresponding primary antibody. Cells were then 
washed twice in FACS buffer and labeled with secondary antibodies (as needed) for 1 hour on ice in 
the dark. After two wash-steps in 1% (vol/vol) FBS in PBS, cells were fixed with 1:10 CellFix® 
solution for 10 minutes at room temperature. Cells were washed twice with PBS, and fluorescence 
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intensity assessed using a FACS Calibur flow cytometer (Becton Dickinson) using the CellQuest Pro® 
acquisition and analysis software. Intracellular FACS staining of LCMV NP antigen was performed as 
described (Rojek et al., 2007a). 
RNA interference (RNAi) 
RNA interference (RNAi) was performed using validated small interfering RNAs (siRNAs) ON-
TARGETplus SMARTpool for Axl (L-003104-00-0005) and scrambled siRNA (D-001820-10-05) as 
control from Thermo Scientific Dharmacon (Lafayette, CO). Briefly, 3 x 106 HT1080 cells were 
reverse transfected with 0.72 μM siRNA using a10-cm-diameter dish and Lipofectamine RNAiMAX 
(Invitrogen, Paisley, United Kingdom) according to the manufacturer’s recommendation. Twenty-four 
hours after transfection, cells were replated in 96-well plate format, and 48 hours post-transfection, 
cells were infected with rLCMV-LASVGP (MOI = 0.1) and rLCMV-VSVG (MOI = 0.02) or mock 
infected or lysed to confirm by Western-blotting Axl knock-down using specific antibodies. To 
prevent secondary infection, 20 mM ammonium chloride (NH4Cl) was added to the cells 4 hours post-
infection. Cells were fixed 16 hours post-infection and infected cells quantified by 
immunofluorescence assay (IFA) detection of LCMV NP using mAb 113 (anti- LCMVNP) and 
combined with fluorescence-labeled secondary antibody. 
Inhibitor studies in HT1080 cells 
HT1080 cells were seeded in round bottom 96-well plates (Costar) pretreated for 2 hours in the 
presence of chlorpromazine or for 30 minutes in presence of the actin inhibitors cytochalasin B, 
latrunculin A, and jasplakinolide, dynasore, EIPA, and IPA-3 at the indicated concentrations at 37°C. 
Cells were then infected in the presence of inhibitors for 1 hour with rLCMV-LASVGP at 37°C. At 4 
hours post-infection, 20 mM NH4Cl was added to prevent secondary infection. Infection was detected 
16 hours post-infection by IFA as mentioned above. The viability of drug-treated cells was determined 
by staining of single-cell preparations with Live and dead staining. 
Entry kinetics of rLCMV-LASVGP in HT1080 cells 
The kinetics of rLCMV-LASVGP cell entry by NH4Cl treatment was performed as described (Rojek 
et al., 2008). Briefly, 3 x 105 HEK293 and HT1080 cells per well were seeded in 24-well plate format 
coated with poly-L-lysine and incubated for 24 hours. The day after, seeded cells were incubated on 
ice for 30 min and fresh ice cold medium containing rLCMV-LASVGP (MOI 3; 10) was added and 
cells incubated on ice for 1 hour to allow virus attachment. Unbound virus was removed by washing 
with cold medium. Pre-warmed complete medium was added and cells rapidly shifted to 37°C at 5% 
CO2. 20 mM NH4Cl was added at 0, 10, 20, 30, 40, 50, 60, 75, 90, 120 and 240 min. After 16 hours, 
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rLCMV-LASVGP infection was quantified by intracellular staining of the viral proteins by flow 
cytometry as described above. 
 
  
RESULTS/PROJECT 2  81 
   
 
 
 
 
REFERENCES 
Angelillo-Scherrer, A., de Frutos, P., Aparicio, C., Melis, E., Savi, P., Lupu, F., Arnout, J., Dewerchin, 
M., Hoylaerts, M., Herbert, J., Collen, D., Dahlback, B., and Carmeliet, P. (2001). Deficiency 
or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat 
Med 7(2), 215-21. 
Barresi, R., Michele, D. E., Kanagawa, M., Harper, H. A., Dovico, S. A., Satz, J. S., Moore, S. A., 
Zhang, W., Schachter, H., Dumanski, J. P., Cohn, R. D., Nishino, I., and Campbell, K. P. 
(2004). LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct 
congenital muscular dystrophies. Nat Med 10(7), 696-703. 
Bellosta, P., Costa, M., Lin, D. A., and Basilico, C. (1995). The receptor tyrosine kinase ARK 
mediates cell aggregation by homophilic binding. Mol Cell Biol 15(2), 614-25. 
Brindley, M. A., Hunt, C. L., Kondratowicz, A. S., Bowman, J., Sinn, P. L., McCray, P. B., Jr., Quinn, 
K., Weller, M. L., Chiorini, J. A., and Maury, W. (2011). Tyrosine kinase receptor Axl 
enhances entry of Zaire ebolavirus without direct interactions with the viral glycoprotein. 
Virology 415(2), 83-94. 
Buchmeier, M. J., de la Torre, J. C., and Peters, C. J. (2007). Arenaviridae: the viruses and their 
replication. 4th ed. In "Fields Virology" (D. L. Knipe, and P. M. Howley, Eds.), pp. p. 1791-
1828. Lippincott-Raven, Philadelphia. 
Buchmeier, M. J., Lewicki, H. A., Tomori, O., and Oldstone, M. B. (1981). Monoclonal antibodies to 
lymphocytic choriomeningitis and pichinde viruses: generation, characterization, and cross-
reactivity with other arenaviruses. Virology 113(1), 73-85. 
Caberoy, N. B., Zhou, Y., and Li, W. (2010). Tubby and tubby-like protein 1 are new MerTK ligands 
for phagocytosis. The EMBO journal 29(23), 3898-910. 
Cao, W., Henry, M. D., Borrow, P., Yamada, H., Elder, J. H., Ravkov, E. V., Nichol, S. T., Compans, 
R. W., Campbell, K. P., and Oldstone, M. B. (1998). Identification of alpha-dystroglycan as a 
receptor for lymphocytic choriomeningitis virus and Lassa fever virus [see comments]. 
Science 282(5396), 2079-81. 
Dutko, F. J., and Oldstone, M. B. (1983). Genomic and biological variation among commonly used 
lymphocytic choriomeningitis virus strains. J Gen Virol 64(Pt 8), 1689-98. 
Ervasti, J. M., and Campbell, K. P. (1991). Membrane organization of the dystrophin-glycoprotein 
complex. Cell 66(6), 1121-31. 
Fridell, Y. W., Villa, J., Jr., Attar, E. C., and Liu, E. T. (1998). GAS6 induces Axl-mediated 
chemotaxis of vascular smooth muscle cells. J Biol Chem 273(12), 7123-6. 
Graham, D. K., Bowman, G. W., Dawson, T. L., Stanford, W. L., Earp, H. S., and Snodgrass, H. R. 
(1995). Cloning and developmental expression analysis of the murine c-mer tyrosine kinase. 
Oncogene 10(12), 2349-59. 
Hastie, K. M., Kimberlin, C. R., Zandonatti, M. A., MacRae, I. J., and Saphire, E. O. (2011). Structure 
of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity 
essential for immune suppression. Proceedings of the National Academy of Sciences of the 
United States of America 108(6), 2396-401. 
Hunt, C. L., Kolokoltsov, A. A., Davey, R. A., and Maury, W. (2011). The Tyro3 receptor kinase Axl 
enhances macropinocytosis of Zaire ebolavirus. J Virol 85(1), 334-47. 
Johannsdottir, H. K., Mancini, R., Kartenbeck, J., Amato, L., and Helenius, A. (2009). Host cell 
factors and functions involved in vesicular stomatitis virus entry. J Virol 83(1), 440-53. 
Kanagawa, M., Saito, F., Kunz, S., Yoshida-Moriguchi, T., Barresi, R., Kobayashi, Y. M., Muschler, 
J., Dumanski, J. P., Michele, D. E., Oldstone, M. B., and Campbell, K. P. (2004). Molecular 
recognition by LARGE is essential for expression of functional dystroglycan. Cell 117(7), 
953-64. 
Klewitz, C., Klenk, H. D., and ter Meulen, J. (2007). Amino acids from both N-terminal hydrophobic 
regions of the Lassa virus envelope glycoprotein GP-2 are critical for pH-dependent 
membrane fusion and infectivity. J Gen Virol. 88(Pt 8), 2320-8. 
RESULTS/PROJECT 2  82 
   
 
 
 
 
Kunz, S., Rojek, J. M., Kanagawa, M., Spiropoulou, C. F., Barresi, R., Campbell, K. P., and Oldstone, 
M. B. (2005). Posttranslational modification of alpha-dystroglycan, the cellular receptor for 
arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. J Virol 79(22), 
14282-96. 
Kunz, S., Sevilla, N., Rojek, J. M., and Oldstone, M. B. (2004). Use of alternative receptors different 
than alpha-dystroglycan by selected isolates of lymphocytic choriomeningitis virus. Virology 
325(2), 432-45. 
Lai, C., Gore, M., and Lemke, G. (1994). Structure, expression, and activity of Tyro 3, a neural 
adhesion-related receptor tyrosine kinase. Oncogene 9(9), 2567-78. 
Lee, W. P., Liao, Y., Robinson, D., Kung, H. J., Liu, E. T., and Hung, M. C. (1999). Axl-gas6 
interaction counteracts E1A-mediated cell growth suppression and proapoptotic activity. Mol 
Cell Biol 19(12), 8075-82. 
Lemke, G., and Burstyn-Cohen, T. (2010). TAM receptors and the clearance of apoptotic cells. Ann N 
Y Acad Sci 1209, 23-9. 
Lemke, G., and Rothlin, C. V. (2008). Immunobiology of the TAM receptors. Nat Rev Immunol 8(5), 
327-36. 
Lu, Q., and Lemke, G. (2001). Homeostatic regulation of the immune system by receptor tyrosine 
kinases of the Tyro 3 family. Science 293(5528), 306-11. 
Mark, M. R., Scadden, D. T., Wang, Z., Gu, Q., Goddard, A., and Godowski, P. J. (1994). rse, a novel 
receptor-type tyrosine kinase with homology to Axl/Ufo, is expressed at high levels in the 
brain. J Biol Chem 269(14), 10720-8. 
Martinez-Sobrido, L., Emonet, S., Giannakas, P., Cubitt, B., Garcia-Sastre, A., and de la Torre, J. C. 
(2009). Identification of amino acid residues critical for the anti-interferon activity of the 
nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol 83(21), 
11330-40. 
Martinez-Sobrido, L., Zuniga, E. I., Rosario, D., Garcia-Sastre, A., and de la Torre, J. C. (2006). 
Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus 
lymphocytic choriomeningitis virus. J Virol 80(18), 9192-9. 
McCormick, J. B., and Fisher-Hoch, S. P. (2002). Lassa fever. Curr Top Microbiol Immunol 262, 75-
109. 
Meertens, L., Carnec, X., Lecoin, M. P., Ramdasi, R., Guivel-Benhassine, F., Lew, E., Lemke, G., 
Schwartz, O., and Amara, A. (2012). The TIM and TAM Families of Phosphatidylserine 
Receptors Mediate Dengue Virus Entry. Cell Host Microbe 12(4), 544-57. 
Mercer, J., and Helenius, A. (2008). Vaccinia virus uses macropinocytosis and apoptotic mimicry to 
enter host cells. Science 320(5875), 531-5. 
Mercer, J., and Helenius, A. (2009). Virus entry by macropinocytosis. Nat Cell Biol 11(5), 510-20. 
Mercer, J., and Helenius, A. (2010). Apoptotic mimicry: phosphatidylserine-mediated 
macropinocytosis of vaccinia virus. Ann N Y Acad Sci 1209, 49-55. 
Mercer, J., Schelhaas, M., and Helenius, A. (2010). Virus entry by endocytosis. Annu Rev Biochem 79, 
803-33. 
Morizono, K., Xie, Y., Olafsen, T., Lee, B., Dasgupta, A., Wu, A. M., and Chen, I. S. (2011). The 
soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor 
tyrosine kinase Axl to mediate viral entry. Cell Host Microbe 9(4), 286-98. 
Neubauer, A., Fiebeler, A., Graham, D. K., O'Bryan, J. P., Schmidt, C. A., Barckow, P., Serke, S., 
Siegert, W., Snodgrass, H. R., Huhn, D., and et al. (1994). Expression of axl, a transforming 
receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 84(6), 1931-41. 
Nunberg, J. H., and York, J. (2012). The curious case of arenavirus entry, and its inhibition. Viruses 
4(1), 83-101. 
O'Bryan, J. P., Frye, R. A., Cogswell, P. C., Neubauer, A., Kitch, B., Prokop, C., Espinosa, R., 3rd, Le 
Beau, M. M., Earp, H. S., and Liu, E. T. (1991). axl, a transforming gene isolated from 
primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell 
Biol 11(10), 5016-31. 
Ohkuma, S., and Poole, B. (1978). Fluorescence probe measurement of the intralysosomal pH in living 
cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A 75(7), 3327-31. 
RESULTS/PROJECT 2  83 
   
 
 
 
 
Ohkuma, S., and Poole, B. (1981). Cytoplasmic vacuolation of mouse peritoneal macrophages and the 
uptake into lysosomes of weakly basic substances. J Cell Biol 90(3), 656-64. 
Oldstone, M. B., and Campbell, K. P. (2011). Decoding arenavirus pathogenesis: essential roles for 
alpha-dystroglycan-virus interactions and the immune response. Virology 411(2), 170-9. 
Pasqual, G., Rojek, J. M., Masin, M., Chatton, J. Y., and Kunz, S. (2011). Old world arenaviruses 
enter the host cell via the multivesicular body and depend on the endosomal sorting complex 
required for transport. PLoS Pathog 7(9), e1002232. 
Pinschewer, D. D., Perez, M., Sanchez, A. B., and de la Torre, J. C. (2003). Recombinant lymphocytic 
choriomeningitis virus expressing vesicular stomatitis virus glycoprotein. Proc Natl Acad Sci 
U S A 100(13), 7895-900. 
Prasad, D., Rothlin, C. V., Burrola, P., Burstyn-Cohen, T., Lu, Q., Garcia de Frutos, P., and Lemke, G. 
(2006). TAM receptor function in the retinal pigment epithelium. Mol Cell Neurosci 33(1), 
96-108. 
Pythoud, C., Rodrigo, W. W., Pasqual, G., Rothenberger, S., Martinez-Sobrido, L., de la Torre, J. C., 
and Kunz, S. (2012). Arenavirus nucleoprotein targets interferon regulatory factor-activating 
kinase IKK epsilon. J Virol. 
Qi, X., Lan, S., Wang, W., Schelde, L. M., Dong, H., Wallat, G. D., Ly, H., Liang, Y., and Dong, C. 
(2010). Cap binding and immune evasion revealed by Lassa nucleoprotein structure. Nature 
468(7325), 779-83. 
Quirin, K., Eschli, B., Scheu, I., Poort, L., Kartenbeck, J., and Helenius, A. (2008). Lymphocytic 
choriomeningitis virus uses a novel endocytic pathway for infectious entry via late endosomes. 
Virology 378(1), 21-33. 
Rodrigo, W. W., Ortiz-Riano, E., Pythoud, C., Kunz, S., de la Torre, J. C., and Martinez-Sobrido, L. 
(2012). Arenavirus nucleoproteins prevent activation of nuclear factor kappa B. J Virol 
86(15), 8185-97. 
Rojek, J. M., Campbell, K. P., Oldstone, M. B., and Kunz, S. (2007a). Old World Arenavirus Infection 
Interferes with the Expression of Functional {alpha}-Dystroglycan in the Host Cell. Mol Biol 
Cell 29, 29. 
Rojek, J. M., Moraz, M. L., Pythoud, C., Rothenberger, S., Van der Goot, F. G., Campbell, K. P., and 
Kunz, S. (2012). Binding of Lassa virus perturbs extracellular matrix-induced signal 
transduction via dystroglycan. Cell Microbiol 14(7), 1122-34. 
Rojek, J. M., Perez, M., and Kunz, S. (2008). Cellular entry of lymphocytic choriomeningitis virus. J 
Virol 82(3), 1505-17. 
Rojek, J. M., Sanchez, A. B., Nguyen, N. T., de la Torre, J. C., and Kunz, S. (2008). Different 
mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J 
Virol 82(15), 7677-87. 
Rojek, J. M., Spiropoulou, C. F., Campbell, K. P., and Kunz, S. (2007b). Old World and clade C New 
World arenaviruses mimic the molecular mechanism of receptor recognition used by alpha-
dystroglycan's host-derived ligands. J Virol 81(11), 5685-95. 
Rojek, J. M., Spiropoulou, C. F., and Kunz, S. (2006). Characterization of the cellular receptors for the 
South American hemorrhagic fever viruses Junin, Guanarito, and Machupo. Virology 349(2), 
476-91. 
Rothlin, C. V., and Lemke, G. (2010). TAM receptor signaling and autoimmune disease. Curr Opin 
Immunol 22(6), 740-6. 
Shimojima, M., Ikeda, Y., and Kawaoka, Y. (2007). The mechanism of Axl-mediated Ebola virus 
infection. J Infect Dis 196 Suppl 2, S259-63. 
Shimojima, M., Stroher, U., Ebihara, H., Feldmann, H., and Kawaoka, Y. (2012). Identification of cell 
surface molecules involved in dystroglycan-independent lassa virus cell entry. J Virol 86(4), 
2067-78. 
Shimojima, M., Takada, A., Ebihara, H., Neumann, G., Fujioka, K., Irimura, T., Jones, S., Feldmann, 
H., and Kawaoka, Y. (2006). Tyro3 family-mediated cell entry of Ebola and Marburg viruses. 
J Virol 80(20), 10109-16. 
Soares, M. M., King, S. W., and Thorpe, P. E. (2008). Targeting inside-out phosphatidylserine as a 
therapeutic strategy for viral diseases. Nat Med 14(12), 1357-62. 
RESULTS/PROJECT 2  84 
   
 
 
 
 
Vela, E. M., Zhang, L., Colpitts, T. M., Davey, R. A., and Aronson, J. F. (2007). Arenavirus entry 
occurs through a cholesterol-dependent, non-caveolar, clathrin-mediated endocytic 
mechanism. Virology 369(1), 1-11. 
Weber, E. L., and Buchmeier, M. J. (1988). Fine mapping of a peptide sequence containing an 
antigenic site conserved among arenaviruses. Virology 164(1), 30-8. 
 
 
 
 
RESULTS/DIAGNOSTIC ACTIVITIES  85 
   
 
 
 
 
Diagnostic activities: Serology: Detection of anti-LCMV antibodies in patient serum 
BACKGROUND AND RATIONALE 
The worldwide distributed prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) 
is a neglected human pathogen of clinical relevance (Barton and Mets, 1999; Barton, Mets, and 
Beauchamp, 2002; Bonthius, 2009). In adult immunocompetent individuals, LCMV causes aseptic 
meningitis and encephalitis, which is usually self-limiting and rarely leads to complications. However, 
LCMV is a severe human pathogen in cases of congenital infection. LCMV infection during the first 
trimester of pregnancy is associated with an increased risk of spontaneous abortion. Infection during 
the second and third trimester has been linked to severe brain abnormalities including hydrocephalus, 
psychomotor retardation, macrocephaly or microcephaly, and chorioretinitis. In addition, LCMV poses 
special threat to immuno-compromised individuals, as tragically illustrated by recent cases of 
transplant-associated infections by LCMV with fatal outcome (Fischer et al., 2006; Palacios et al., 
2008). Immunofluorescence assay (IFA) is currently the preferred serological method for the diagnosis 
of human arenavirus infections, including LCMV. However, this method is time consuming, labour 
intensive, and the interpretation of results requires significant experience in the field. Over past years, 
faster and reliable serological tests based on enzyme-linked immunosorbent assay (ELISA) have been 
developed for other arenaviruses, in particular Lassa virus (Bausch et al., 2000; Emmerich et al., 2006; 
Saijo et al., 2007) and Junin virus (Ure et al., 2008). ELISA-based tests for Lassa virus have recently 
been successfully used for serological survey of Lassa in Africa, proving the power of this method 
(Emmerich, Gunther, and Schmitz, 2008). Recent efforts by veterinary research centers in Japan 
resulted in the development of an ELISA for the detection of LCMV antibodies in sera of mice, 
hamsters, cotton rats (Mastomys sp.), and gerbils, which has however not yet been licensed (Takimoto 
et al., 2008).  
STUDIES AND RESULTS 
 During my thesis, I participated to diagnostic activities concerning the serology of LCMV in 
serum of hospitalized newborns (mainly TORCH negative), young children and mothers (CHUV). I 
was in charge to detect anti-LCMV antibodies in the patient serum using IFA. A few days after 
primary LCMV infection in patients, IgM directed against LCMV NP and to a lesser extent GP can be 
detected. A few weeks after the primary IgM response, anti-viral IgG against NP and GP become 
detectable. Specific antibody titers in early acute infection (mainly IgM) should be at least 4-fold over 
the background control and in convalescent patients or late infection (IgM + IgG), at leat 10-fold over 
background. However, in each case, the observation of a significant above-background signal in IFA 
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was hardly detectable. Even with our experience in the field, no significant above-background signal 
in IFA was detected in any of our patient’s samples. 
To circumvent this lack of sensitivity and specificity, we contributed to the elaboration of a specific 
LCMV real-time RT-PCR assay, based on the detection of genomic sequences of the viral 
nucleoprotein NP to assess the presence of LCMV in cerebrospinal fluids (CSF). This work was done 
in collaboration with the diagnostic platform from the CHUV and the Swiss National Reference 
Center for Emerging Viral Diseases from the University of Geneva. Collaborators from Geneva 
validated the specificity and sensitivity of the real-time RT-PCR assay for the diagnosis of LCMV 
infections. First results showed that LCMV infections are extremely rare in hospitalized patients 
Western in Switzerland. The results of these studies have been published in: Cordey S., Sahli R., 
Moraz M.L., Estrade C., Morandi L., Cherpillod P., Charrel R..N., Kunz S., and Kaiser L. (2011) 
Analytical validation of a lymphocytic choriomeningitis virus real-time RT-PCR assay. J. Virol. 
Methods. 177(1):118-22. 
In addition, I have been involved in the development of an ELISA-based test for the detection of 
antibodies to LCMV in human sera using recombinant LCMV NP produced in insect cells. This has 
been established and optimized and first quality control experiments revealed a high degree of 
sensitivity and specificity. This novel ELISA-based test for serology of LCMV will be applicable in 
human medicine and epidemiological studies to investigate the seroprevalence of LCMV in patient 
groups of interest. 
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Project 1: “Post-translational modification of the LASV receptor DG” 
Binding of pathogens to their receptors often induces signaling that facilitates the entry 
process into the host cell. The entry step is a promising target for therapeutic intervention against 
viruses before they are able to take control over the host cell. The molecular mechanisms underlying 
this fundamental aspect of virus-host cell interaction are therefore of particular interest from a basic 
science standpoint as well as for translational research aiming at the development of novel anti-viral 
therapeutics. Research over the past decades revealed that viruses can hijack virtually all known 
existing pathways of endocytosis that are used in the cell for transport of proteins, lipids and other 
cargo (Mercer and Helenius, 2010). The study of pathogen entry greatly contributed to our current 
understanding of these fundamental cellular processes. Interestingly, in recent years, evidence started 
to accumulate that, in addition to using existing pathways, pathogens can manipulate the host cell’s 
endocytotic machinery in order to “create” their own pathways of entry specifically tailored to their 
needs. This novel concept in pathogen-host cell interaction is illustrated by several lines of evidence, 
including recent work on the toxin of the bacterium Bacillus anthracis, the causative agent of anthrax 
(Abrami et al., 2010; Abrami, Kunz, and van der Goot, 2010). Previous work on cell entry of the Old 
World arenaviruses, including the studies performed in the context of my thesis revealed that these 
viruses likewise use an unusual pathway to invade the host cell. Upon DG binding, LASV is 
internalized via a cholesterol-dependent endocytic pathway that seems independent of regulatory 
proteins like clathrin, caveolin, and dynamin and apparently bypasses the classical Rab5-dependent 
incoming pathways of vesicular trafficking, suggesting an unusual way of delivery to late endosomes 
(Quirin et al., 2008; Rojek, Perez, and Kunz, 2008; Rojek et al., 2008; Vela et al., 2007). DG is well 
known for its function as a molecular bridge between the ECM and the actin cytoskeleton of the cell. 
This apparently static role as a structural component of cell-matrix contacts seems to contrast with the 
dynamics observed upon the engagement of LASV with DG. Indeed, the binding of LASV to DG 
results in a fast endocytosis of the virus-receptor complex, followed by targeting to the multivesicular 
endosome, where the complex undergoes sorting by the endosomal sorting complex required for 
transport (ESCRT), and is delivered to late endosome within circa 20 minutes (Pasqual et al., 2011; 
Rojek et al., 2008). Considering the experimental evidence at hand, we hypothesize that virus binding 
may induce receptor-mediated signaling resulting in subsequent internalization of the virus-receptor 
complex via either an existing pathway linked to degradation of DG or a novel pathway “created” de 
novo by the pathogen, which does not exist in uninfected cells. The virus-induced signaling events 
uncovered in my work may serve as a “knock on the door” resulting in the modification and assembly 
of receptor-associated proteins that form the functional receptor complex that mediates viral entry. In 
follow-up studies to my thesis, I propose two lines of further research: 1) the identification of DG-
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associated cellular proteins required for LASV cell entry and 2) the investigation of cellular signaling 
pathways involved in the regulation of DG-mediated LASV cell entry. 
Identification of DG-associated cellular proteins involved in viral entry 
In our studies, we provide evidence that LASV binding to DG affects receptor signaling 
and its interaction with cellular proteins, illustrated by the observed virus-induced tyrosine 
phosphorylation of DG’s cytoplasmic domain and the dissociation of DG from utrophin. We 
hypothesize that this virus-induced-detachment of virus-bound DG from the actin cytoskeleton, in a 
direct or indirect way, facilitates the subsequent endocytosis of the virus-receptor complex. So far, 
our studies focused mainly on the post-translational modification of DG itself. However, in most 
cell types, DG is associated with several other cellular proteins forming molecular complexes that 
likely represent the functional “receptor units” for the attachment and internalization of 
arenaviruses (Barresi and Campbell, 2006). In some cell types, DG is found associated with the 
sarcoglycans (Yoshida et al., 1994), a family of transmembrane proteins that play important roles in 
the stability of the DG complex. Abnormalities of sarcoglycans are a common molecular feature in 
several muscular dystrophies (Bonnemann, McNally, and Kunkel, 1996; Campbell, 1995). Thus, it 
will be interesting to address the role of sarcoglycans and other DG-associated proteins in LASV 
cell entry. It is conceivable that specific DG-associated host cell proteins may function as co-
receptors or auxiliary factors in the viral entry process. Considering the multivalent nature of the 
virion particles and the experimental evidence at hand, attachment of LASV to cellular DG likely 
results in receptor clustering and induces receptor-mediated signal transduction. In addition to DG, 
virus binding may affect post-translational modification of other cellular proteins that comprise the 
functional DG complex and modulate their interactions. We expect that during LASV attachment 
and entry, the composition of the virus-associated DG complex may change in a dynamic manner. 
In the context of human LASV infection, epithelial cells of the lung represent the first 
barrier for aerosol transmission and are the initial site of replication. Efficient productive infection 
of lung epithelium is likely crucial for the subsequent invasion of the lymphatic system and the 
bloodstream resulting in dissemination of the virus to lymphatic organs and other sites of secondary 
replication, like the liver, adrenal gland, and vascular endothelium. Our initial studies on LASV-
receptor interactions and signaling, as well as endocytosis focused therefore on human lung 
epithelial cells (Pasqual et al., 2011; Rojek et al., 2012). Many of the DG-associated molecules 
found in skeletal muscle are also expressed in other tissues, including most sarcoglycans, sarcospan, 
synthophins and several dystrophin isoforms (Crosbie et al., 1997; Grady, Merlie, and Sanes, 1997; 
James et al., 1996; Jung et al., 1996; Peters, Adams, and Froehner, 1997; Vainzof et al., 1996). This 
broad pattern of expression suggests that distinct DG complexes may occur in different tissues, 
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compatible with the possible roles of DG outside of skeletal muscle. A previous study investigating 
the DG complexes in epithelial cells from lung and kidney revealed that the “epithelial” DG 
complexes apparently lack sarcoglycans, suggesting a distinct biochemical composition when 
compared to the classical DG complex from muscle (Durbeej and Campbell, 1999). As a first step, I 
propose to define the cellular binding partners or the “interactome” of DG in human lung epithelial 
cells. 
Conventional affinity purification protocols used in the past (Durbeej and Campbell, 1999) 
were limited to the detection of known interacting partners of DG and thus represented “closed 
systems” approaches. Moreover, the stringent washing conditions used restricted the analysis to 
components that bind DG with relative high affinity bearing the risk of losing more transient 
interaction partners. In contrast to stably associated proteins, more transiently interacting proteins 
may associate with and dissociate from DG and in response to virus-induced signals. Upon LASV 
binding and virus-induced receptor clustering, such transiently interacting proteins may be recruited 
to or dissociate from the DG complex in a dynamic manner. To characterize the dynamic DG 
“interactome” during the process of LASV cell entry in a comprehensive manner, I propose the use 
of a novel sensitive technology of proteomic analysis based on quantitative mass spectroscopy 
involving stable isotope labeling by amino acids in cell culture (SILAC). The SILAC system is a 
straightforward approach for in vivo incorporation of a label into proteins for mass spectrometry 
(MS)-based quantitative proteomics (for more details see http://silac.org/index_html). SILAC 
combined with quantitative MS has recently been used to identify dynamic components of 
multiprotein complexes (Wang and Huang, 2008). In a first step, we will define the DG 
“interactome” in resting lung epithelial cells, prior to addition of virus. For this purpose, human 
lung epithelial cells will be stable transfected with DG containing a C-terminal HA-tag separated by 
a flexible spacer to prevent interference with interacting partners. Cells will be differentially labeled 
using media supplemented with amino acids containing heavy isotopes (e.g. Arg13C615N4 or 
Lys13C615N2) or normal medium. DG complexes will be isolated by immunoprecipitation (IP) 
with a mAb to HA or an isotype control. IP conditions should be optimized to allow the detection of 
weaker and more transient interactions. After washing, IPs will be combined and isolated proteins 
analyzed by MS. Due to the differential labeling by SILAC, unspecifically bound proteins can be 
subtracted, minimizing the background “noise” of the method. After setting the “baseline” with the 
identification of the composition of the DG complex in uninfected cells, we will look at possible 
changes in the composition of DG complexes in cells subjected to attachment of rLCMV-LASVGP. 
For this purpose, SILAC labeled and unlabelled cells will be exposed to rLCMV-LASVGP at a 
virus/particle ratio of 100 in the cold, to allow receptor binding without signaling and 
internalization. Unbound virus will be removed and cells rapidly shifted to 37°C. At different time 
points, cells will be chilled on ice, lysed and IP performed with anti-HA (heavy amino acid labeled 
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cells) or isotype controls (normal medium). Differential MS analysis will be performed for each 
time point and specifically bound proteins for the distinct points compared to identify candidates 
whose association with DG is altered upon viral attachment and/or during entry. Candidate proteins 
that are found to be specifically associated with DG at any point of viral attachment and 
internalization will then be tested for their role in viral entry. For this purpose, candidate proteins 
will be depleted by RNA interference (RNAi) using specific siRNAs and effects on early infection 
tested by infection with rLCMV-LASVGP. We expect that some of the DG-associated proteins will 
affect the stability of the DG complex, whereas others may be specifically required for viral entry 
but not expression of functional DG per se. It will be of particular interest to see if virus binding 
results in the recruitment of cellular proteins that are not normally associated with DG and that may 
play a role in the pathway that the virus “creates” to invade human cells. 
Detection of changes in protein phosphorylation during LASV entry 
We and others showed that treatment of cells with the broadly-specific tyrosine kinase 
inhibitor genistein affects LASV cell entry into at an early step of virus internalization without 
affecting the binding. Since tyrosine phosphorylation of β-DG at Y892 by src family kinases has 
previously been linked to the internalization of DG (Miller et al., 2012; Sotgia et al., 2003), we 
tested the impact of a src family kinase specific inhibitor (PP2) on rLCMV-LASVGP infection. 
Unexpectedly, the treatment of cells with PP2 had no effect on the entry of LASV, thus excluding 
phosphorylation at Y892 as an event crucial for entry. Since the broad phosphorylation inhibitor 
genistein significantly blocks LASV cell entry, we suppose that non-src tyrosine kinases play a role 
in the entry process of LASV by modifying β-DG and possibly other DG-associated proteins. 
Specifically, we hypothesize that virus induced-phosphorylation of DG-associated proteins could 
affect receptor trafficking, possibly targeting the receptor for lysosomal degradation via the 
MVB/late endosome. In a next step, I propose a comprehensive examination of tyrosine 
phosphorylation of DG and DG-associated proteins in function of virus-cell attachment and entry. 
The SILAC technology introduced above has been efficiently used by Olsen and colleagues to 
study temporal dynamics of signaling pathways by exploiting phosphorylation-based enrichment 
methods coupled to mass spectrometry (Olsen et al., 2006). This method has been successfully used 
to perform temporal dynamic studies of the EGFR pathway. In our context, a similar approach can 
be used to investigate the dynamic phosphorylation state of candidate proteins comprising the 
“interactome” of the virus-DG complex during the viral entry process (see above). Moreover, by 
using double-isotope labeling, the SILAC system allows the identification and mapping of novel 
phosphorylation sites within proteins (Ibarrola et al., 2003). Despite its promise, there are obstacles 
for the SILAC system, including the culture process that is time consuming, some samples cannot 
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be obtained through culture processes and some cell types cannot accommodate certain amino 
acids. Thus, many aspects have to be considered for this type of study. 
An alternative approach to the SILAC-based “phosphoproteomic” strategy is provided by 
antibody arrays that allow the detection of hundreds of phosphorylated motifs in cellular proteins on 
the basis of immunoblot with specific antibodies. Powerful platforms are the Kinex™ antibody 
microarrays and the Kinetworks™ multi-immunoblotting systems, provided by Kinexus Inc. The 
two approaches use phosphorylation site-specific antibodies. In a first step, antibody microarrays 
are performed with non-denatured, native proteins in lysates to detect phosphorylated candidate 
proteins. Hits are then validated using Kinetworks™ multi-immunoblotting in which antibody leads 
from the Kinex™ Antibody microarray can be confirmed using an immunoblot approach. Human 
lung epithelial cells will be exposed to rLCMV-LASVGP for different time points and cell lysates 
scanned sequentially by both Kinexus approaches. This approach will allow the detection of 
changes in phosphorylation of cellular proteins induced by the virus covering major kinases and 
signaling pathways. Although by no means comprehensive, this screen could identify novel 
candidate cellular proteins affected by the virus that may play a role in the entry process. 
Identification of the tyrosine kinases involved in LASV cell entry 
Phosphorylation by cellular protein is crucial for the regulation of cellular signaling 
cascades and it is known that the binding of pathogens to their receptors often induces cell signaling 
that facilitate subsequent internalization. A requirement for kinase activity for LASV cell entry had 
already been shown with broadly active kinase inhibitors (Vela et al., 2008). This requirement has 
also been shown for the alternative LASV receptor Axl (Shimojima et al., 2012). We confirmed that 
tyrosine kinases are required for the endocytosis of LASV, but that they are dispensable for the 
binding of the virus to DG. We demonstrated that the binding of LASV to cellular DG induced 
phosphorylation of DG at Y892 by src family kinases and other tyrosine residues of β-DG by yet 
unknown kinases. Cellular kinases specifically required for LASV entry would represent promising 
targets for therapeutic intervention. 
To identify specific cellular candidate kinases implicated in LASV cell entry, several 
approaches can be used. One of them is the screening available libraries of kinase inhibitors. 
Screening of such defined kinase libraries may allow to identify cellular kinases required for the 
early steps of LASV infection and may give us at the same time potential inhibitors of LASV 
infection with drug-like properties. Candidate compounds showing an effect on LASV entry steps 
or infection could then be assessed for their mechanism of action and which step of viral infection 
they perturb. We have already launched in our laboratory the screening of a small library of 80 
kinase inhibitors (Screen-Well™, Enzo® Life Sciences). Some interesting hits have been identified 
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and are currently validated. In a next step, larger libraries may be tested (e.g. InhibitorSelect™ 384-
Well Protein Kinase, Millipore). However, we have to keep in mind that we could have off-target 
effects and toxicity due to the use of inhibitors and adequate dose-response studies as well as 
necessary controls are imperative for the validation of the hits obtained by screening. 
A broad screening technique using RNAi silencing technology can be employed to identify 
cellular kinases involved in LASV cell entry. Predicted human kinases that are implicated in 
endocytic pathways will be systematically silenced by specific siRNAs and consequences of the 
silencing on LASV entry will be tested using infection with rLCMV-LASVGP as readout. To 
identify kinases specifically affecting LASV GP-mediated cell entry, we will use rLCMV-VSVG 
for a counter-screen. Only candidates whose silencing affects rLCMV-LASVGP, but not rLCMV-
VSVG will be retained. Since the human genome comprises hundreds of known and putative 
kinases, it will be necessary to focus on kinases already known to play a role in cell entry pathways. 
Pelkmans and colleagues identified several candidate kinases implicated in clathrin-mediated 
endocytosis as caveolae/raft endocytosis using high-throughput RNA interference technology 
(Pelkmans et al., 2005). We could base our study on the library of validated siRNAs characterized 
by Pelkmans and colleagues. 
Another approach to identify candidate cellular kinases implicated in LASV entry is to use 
correspondent kinases’ substrates. To this end, a high-throughput kinase substrate arrays can be 
applied to perform a systematic analysis of changes in cellular kinase activity induced by LASV 
binding and entry. Pepscan Inc. developed the PepChip kinase assay (Peptide arrays Pepchip™, 
http://www.pepscan.com/presto/products-services/kinase-profiling/) that is based on arrays of 
kinase substrates making this tool very potent for our application since it allows the analysis of 
pathogen-induced changes in cell signaling in response to the infection. We can then compare 
LASV infected cells versus uninfected ones at different time points. The identification of cellular 
kinases activated by LASV may also allow pinpointing possible altered signaling pathways upon 
LASV infection. 
Candidate kinases obtained from each approach will be then compared to identify a “short 
list” of candidates identified by both methods. It will be of interest to compare the kinase candidate 
list with the signaling pathways identify in our phosphoproteomic studies using SILAC outlined 
above. Promising candidates will be validated using corresponding inhibitors and dominant 
negative mutants, if available. If candidate kinases are specifically able to block LASV infection, 
their role in the different viral entry steps will be investigated, including attachment of the virus to 
the cell, the endocytosis process, the intracellular transport as well as the fusion process. If an effect 
is observed, virus-receptor internalization could be then tracked by microscopy in co-localization 
experiments, using specific antibodies to see which step of the entry pathway is affected. The 
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identification of cellular kinases, involved in the entry pathway of LASV entry would represent 
promising “druggable” targets for therapeutic intervention. 
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Project 2: “Characterization of LASV cell entry via the TAM receptor Axl” 
Molecular characterization of the interaction of LASV with cellular Axl 
In line with previous studies (Shimojima et al., 2012), our results confirmed Axl as an entry 
receptor for LASV in a DG-independent manner. However, the molecular mechanism of Axl 
recognition by LASV needs to be further investigated. Recently, Morizono et al. (Morizono et al., 
2011) proposed a general model for cell entry of enveloped viruses via TAM receptors. In this 
model, the serum proteins Gas6 or protein S attach to the lipid phosphatidylserine (PS) present in 
the membrane of the viral envelope and provide a bridge to cellular TAM receptors. This model is 
proposed as a possible mechanism of internalization for enveloped viruses in cell that lack specific 
receptors. Shimojima and colleagues showed that binding of LASV pseudovirion particles to Axl 
was detectable in cells expressing Axl but not with purified recombinant Axl protein (Shimojima et 
al., 2012). This observation suggested that LASV pseudotypes may bind Axl through an indirect 
mechanism, possibly via Gas6 or protein S. To test this possibility, a mutant of Axl (Axl E59R) 
which is deficient in Gas6 binding (Sasaki et al., 2002) was expressed in otherwise refractory cells. 
When compare to the wild-type, Axl E59R was apparently not impaired in its function as a LASV 
receptor (Shimojima et al., 2012), suggesting that Gas6 is not involved in LASV cell entry via Axl. 
However, the Axl mutant E59R is not a complete loss-of-function mutant and has not been fully 
characterized (Sasaki et al., 2006). Furthermore, the binding capacity of Axl E59R to bovine protein 
S present in the experiment was not investigated. Considering the limited data at hand, a possible 
role for PS, Gas6, and protein S in Axl-mediated LASV entry can in my opinion not be 
categorically excluded and need to be further investigated. 
While previous studies detected PS in the envelope of the Clade A New World arenavirus 
Pichinde (Soares, King, and Thorpe, 2008), no data were available on the PS content of Old World 
arenaviruses. To address this issue, we tested the binding of the prototypic LCMV to ANX5, a high 
affinity ligand for PS. As positive control, we used vaccinia virus (VACCV) that uses “apoptotic 
mimicry” to infect cells and whose envelope is rich in PS (Mercer and Helenius, 2008). As a 
negative control, we used human adenovirus (AdV)-5, which lacks a lipid envelope. In a first 
approach, viruses were incubated with biotinylated ANX5, followed by ultracentrifugation through 
a sucrose cushion, separating virion particles from the supernatant. Pellets were lysed in SDS-
PAGE sample buffer and virion-associated ANX5 detected in Western blot using HRP-conjugated 
streptavidine. As shown in Fig. 1A, LCMV and VACCV, but not AdV-5 associated with ANX5, 
indicating the presence of PS in the outer leaflet of the LCMV envelope. The marked reduction of 
ANX5 binding in presence of the chelator EGTA underscored the specificity of the Ca2+-dependent 
PS-ANX5 interaction. In a complementary experiment, biotinylated ANX5 was incubated with 
viruses, followed by pull-down with streptavidin-conjugated magnetic beads. Bound material was 
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eluted and examined in Western-blot using specific antibodies to viral proteins. Consistent with the 
previous experiment, ANX5 was able to pull down LCMV and VACCV, but not AdV-5 (Fig. 1B). 
Comparison of ANX5 binding between LCMV and rLCMV-LASVGP revealed similar specific 
binding, indicating comparable content of PS in the outer leaflets of LCMV and the rLCMV-
LASVGP chimera. To exclude unlikely differences between LCMV and LASV, we will perform 
detection of PS via ANX5 with inactivated LASV Josiah that we will receive from the Centers of 
Disease Control in Atlanta. Our preliminary data show that the prototypic Old World arenavirus 
and the rLCMV-LASVGP chimera display PS in their envelope. Since an arenavirus particle has a 
size comparable to that of an apoptotic body this suggest that Old World arenaviruses may very 
well be capable of “apoptotic mimicry”, hijacking Axl or other TAM receptors in cells where DG is 
absent. We therefore started to re-evaluate the molecular mechanism underlying the interaction of 
rLCMV-LASVGP with Axl addressing this possibility. 
Recognition of PS in viral envelopes by Gas6/protein S is dependent on divalent cations, in 
particular Ca2+. In a first step, we performed infection of HT1080 cells with rLCMV-LASVGP in 
presence of the chelators EDTA/EGTA and observed a marked reduction in infection, suggesting 
dependence on divalent cations (data not shown). In a next step, we will assess serum-dependence 
to determine whether Axl-mediated infection of rLCMV-LASVGP requires the presence of protein 
S for its entry into HT1080 cells. In a complementary approach to address the role of PS in the viral 
envelope in Axl mediated entry, we will pre-treat rLCMV-LASVGP with recombinant ANX5, prior 
to addition to HT1080 cells. The combination of these experiments addressing cation-dependence, 
serum-dependence, and blocking by ANX5 will provide evidence for a possible involvement of PS 
and an “apoptotic mimicry”-like mechanism for LASV cell entry via Axl. 
In case we find no evidence for an involvement of PS or serum proteins in Axl-mediated 
LASV cell entry, we will pursue the possibility of a direct binding of the viral GP to Axl. 
Productive infection of LASV mediated by the viral GP requires binding of GP1 to cellular 
receptors to allow subsequent pH-induced membrane fusion via GP2. In a first step, to assess the 
role of GP1 in binding to Axl, we will perform solid phase binding assays of rLCMV-LASVGP to 
immobilized Axl in microtiter plates. rLCMV-LASVGP produced in serum-free medium will be 
treated with 1 M NaCl to remove GP1 and then tested for Axl binding. Bound virus will be detected 
with a mAb to GP2. A reduction of virus binding to Axl after high salt treatment would suggest a 
role for GP1, but not PS, in binding. 
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Figure 1. Old World arenaviruses display PS in the outer leaflet of their envelope. (A) ANX5 binds to PS in the 
envelope of LCMV. Equal amounts of LCMV, VACCV, and AdV-5 were incubated with biotinylated ANX5 (25 μg/ml) 
in presence and absence of 5 mM EGTA. Samples were subjected to ultracentrifugation through a sucrose cushion and 
pellets subjected to Western-blot analysis. Biotinylated ANX5 was detected by HRP-conjugated streptavidine (top). The 
presence of viruses was detected in pellets by detection of hexon/penton proteins of Ad-V, protein A27L of VACCV, and 
LCMV GPs. (B) Pull-down of viruses with biotinylated ANX5. LCMV, VACCV, and AdV5 were incubated with 
biotinylated ANX5 as in (A) followed by pull-down with streptavidine conjugated to magnetic beads. After several 
washes, bound material was eluted and viral proteins detected in Western-blot as in (A). (C) ANX5 binding to LCMV and 
rLCMV-LASVGP. Viruses were incubated with biotinylated ANX5, followed by pull-down as in (B). Bound virus was 
eluted and LCMV GP2 and LASV GP2 detected in Western-blot with mAb 83.6. 
 
A complementary way to investigate the implication of LASV GP in Axl-mediated 
productive infection is the detection of a direct molecular interaction between LASV GP1 and Axl. 
With the help of the laboratory of Prof. Erica Ollman-Saphire (Scripps Research Institute, La Jolla), 
we produced soluble recombinant fusion proteins of LASV GP1 with the IgG Fc moiety of rabbit 
Fc (LASV GP1-Fc). These LASV GP1 “immunoadhesins” are fully functional and bind to DG with 
nanomolar affinity (Ana Rita Gonçalves, unpublished results). To assess a direct binding between 
LASV GP1 and Axl, we will perform solid-phase binding assays of LASV GP1-Fc to immobilized 
recombinant human Axl fused to human IgG Fc (Axl-Fc). Bound LASV GP1-Fc will then be 
detected with an HRP-conjugated secondary antibody in a color reaction. This ELISA-format solid-
phase binding assays will allow the detection of interactions that are not detectable in classical pull-
downs performed by Shimojima et al. However, limited sensitivity remains a possible concern, in 
particular when we consider a possibly low affinity binding of LASV GP1 to Axl, as suggested by 
the poor efficiency of Axl as a LASV receptor. In case we are unable to detect an interaction by 
solid-phase binding assay, we envisage the use of surface plasmon resonance (SPR) that allows 
detection of weaker interactions (Kd < 105 mol/l). For SPR, we will have access to a BiaCore 
platform available at the Institute of Pathology (IPA) of UNIL/CHUV. 
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In a third approach, we will use our LASV GP1-Fc immunoadhesins to block cellular Axl 
in HT1080 cells prior to the addition of rLCMV-LASVGP. A dose-dependent reduction of viral 
infection by pre-treatment of cells with LASV GP1-Fc would further support a role for GP1 in Axl-
mediated LASV cell entry. 
Together, these studies will shed light on the molecular recognition of rLCMV-LASVGP 
by Axl and help to distinguish if the virus uses “apoptotic mimicry” via PS-Gas6/protein S or if a 
direct interaction of GP1 with Axl is involved. In the latter case, it would be of interest to map the 
Axl binding site on GP1 and to see to what extent it overlaps with the binding site for DG in future 
work. Such studies could help to understand the interaction of LASV GP with Axl and DG on cells 
co-expressing the two receptors, like e.g. epithelial and endothelial cells, which are important in 
vivo targets of LASV. 
The role of Axl-mediated signaling in LASV cell entry 
Does binding of LASV activate Axl tyrosine kinase activity? 
Binding of Gas6 induces the dimerization of Axl with consequent auto-phosphorylation of 
tyrosine residues of its intracellular domain. Recently, a study demonstrated that Y702 and Y703 
undergo phosphorylation upon Gas6 stimulation (Pao-Chun et al., 2009). However, none of these sites 
has been shown to directly regulate or interact with downstream effectors of Axl. Three other 
tyrosines, Y779, Y821, and Y866, within the Axl cytoplasmic domain were implicated in binding of 
several substrates, highlighting them as potential candidates for auto-phosphorylation sites (Braunger 
et al., 1997; Fridell et al., 1996). The residue Y779 provides a docking site for PI3K, while Y866 plays 
a role in binding of phospholipase C (PLC). Using Axl mutants deficient in tyrosine kinase activity, 
Shimojima and colleagues demonstrated that Axl-mediated infection of LASV pseudotype virus in 
Jurkat cells requires intracellular Axl signaling (Shimojima et al., 2012). We will extend these studies 
looking at the interaction of LASV GP and Axl in cells that normally express Axl. 
In a first step, we will investigate if attachment of rLCMV-LASVGP induces activation of 
Axl. To examine activation of Axl signaling in response to virus attachment, HT1080 cells will be 
subjected to serum starvation to reduce endogenous Axl signaling. Cell will be chilled on ice and 
rLCMV-LASVGP added in the cold to allow virus binding without signaling and/or internalization. 
Unbound virus will be removed and cells shifted to 37°C. At different time points, cells will be lysed 
and tyrosine phosphorylation of Axl monitored over time using specific antibodies directed against 
phosphorylated forms of the receptor. These studies will show if virus binding to cellular Axl induces 
its activation and auto-phosphorylation and may reveal quantitative or qualitative differences with 
respect to activation via Gas6. Virus-induced autophosphorylation of specific Y residues on Axl may 
give first hints towards signaling pathways that are activated upon virus binding. In case we are able to 
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detect virus-induced tyrosine phosphorylation of Axl in HT1080 cells, it will be interesting to extend 
the analysis to other cell types, which co-express Axl with functional DG. It will be of particular 
interest to see if the presence of functional DG can prevent virus-induced autophosphorylation of Axl, 
suggesting that binding of the virus to DG prevents the interaction with Axl. 
Is Axl activation and/or signaling required for LASV entry? 
In case we are able to detect virus-induced tyrosine phosphorylation and thus activation of 
Axl, it will be interesting to investigate whether this receptor activation is needed for viral entry. 
Previous studies using the broadly specific tyrosine kinase inhibitor genistein provided evidence for 
tyrosine phosphorylation to be involved in Axl-mediated LASV cell entry (Shimojima et al., 2012). 
However, neither the kinases nor the substrates involved were characterized. To address the role of 
tyrosine phosphorylation of specific Y residues of Axl, we will employ a panel of point mutations 
of Axl (Y702F, Y703F, Y779F, Y821F, and Y866F). These mutations will be introduced in a 
recombinant form of human Axl containing silent mutations in the target sequence of the shRNA 
that was used to deplete Axl in my studies. HT1080 cells will be depleted of endogenous Axl by 
siRNA, followed by transfection with the siRNA-resistant mutants and wild-type Axl. Cells will 
then be infected with our rLCMV-LASVGP chimera and early infection assessed by IFA. These 
experiments could give first hints towards Axl-associated signaling pathways may be implicated in 
LASV cell entry. 
Targeting of Axl is a novel strategy to combat human arenavirus infection 
According to the role of Axl-dependent signaling in several disorders, the inhibition of its 
activation is already under investigation. Indeed, extracellular targeting of Axl with specific 
inhibitory antibodies has been already shown to prevent downstream signaling mediated by Gas6, 
especially in the context of cancer (Li et al., 2009; Ye et al., 2010). Thus, we could use these 
available antibodies and evaluate them in the context of LASV entry. A second approach will be the 
use of Axl-specific small-molecule inhibitors able to block its signaling. The majority of studies on 
Axl inhibition by small-molecule inhibitors have been performed in the context of cancer (Linger et 
al., 2010). The candidate inhibitor R428 (Rigel Pharmaceuticals) has been shown to be effective 
and has favorable pharmacokinetic profiles. This inhibitor potently blocks auto-phosphorylation of 
Axl on the multiple docking site Tyr821, stimulated by either antibody-mediated cross-linking or 
Gas6 (Holland et al., 2010). In addition, R428 shows specificity to Axl and strong inhibitory effect 
in multiple cell lines (Smolock and Korshunov, 2010). Thus, treatment of cells with R428 followed 
by infection with rLCMV-LASVGP could reveal whether the inhibitor affects viral entry. 
Successful inhibition of LASV cell entry via Axl by antibodies or drugs like R428 would provide 
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proof-of-concept identifying Axl as a novel therapeutic target to combat LASV infection. However, 
considering the roles that Axl is playing in the host cell, potential side effects may be a concern. 
Moreover, given the preeminent role of DG as a LASV receptor in many important human cell 
types involved in infection in vivo, antibodies or drugs targeting Axl would represent only one 
component of an anti-viral drug cocktail. 
A role of Axl in innate immune evasion or immunosuppression by LASV 
Does LASV cell entry via Axl allow the virus to evade innate detection? 
Pathogenic arenaviruses are able to subvert the cellular mechanisms of innate pathogen 
recognition. The genomic RNA of arenaviruses can be recognized by the cytoplasmic RNA 
helicases of the retinoic acid-inducible gene I (RIG-I) family, which represent principal innate 
sensors for viral RNA and, as a consequence, induce the production of type I interferons (IFNs) 
(Habjan et al., 2008; Zhou et al., 2010). However, cells infected with arenaviruses fail to induce 
type I IFN because the viral NP acts as a potent IFN antagonist and prevents activation of the IFN 
regulatory factor (IRF)-3 (Martinez-Sobrido et al., 2009; Martinez-Sobrido et al., 2006) and NF-κB 
(Rodrigo et al., 2012). The NP contains a 3’-5’ exonuclease activity that is linked to its 
immunosuppressive activity (Hastie et al., 2011; Qi et al., 2010) and targets the non-canonical 
interferon regulatory factor-activating kinase IKKε (Pythoud et al., 2012). Since the viral NP act as 
an IFN antagonist in the cytoplasm, the suppression of IFN production by NP depends on 
productive viral infection with expression of sufficiently high levels of NP. During viral entry, the 
virus is located in extracellular space where NP cannot act as an IFN antagonist. It is thus possible 
that incoming arenaviruses could be detected by pathogen recognition receptors (PRRs) located in 
endosomal compartments, e.g. Toll-like receptors (TLRs). Upon DG binding, Old World 
arenaviruses are internalized via a pathway of endocytosis that apparently bypasses the early 
endosome where PRRs like TLRs mostly localize (Rojek et al., 2008), possibly allowing the virus 
to evade innate detection. It will be of interest to investigate if LASV entry via Axl likewise allows 
the virus to evade innate detection or its entry via Axl results in innate detection with the 
consequent induction of IRF3 and NF-κB. 
The major PRRs that can detect viral RNAs leaking out of damaged virions during entry 
are TLR3 and TLR7/8 located in endosomal compartments. TLR3 recognizes double-stranded viral 
RNA whereas TLR7/8 recognizes viral single-stranded RNAs (Boehme and Compton, 2004). After 
stimulation, TLR3 recruits the adapter protein TRIF which then activates TBK1 and the canonical 
IKK complex, resulting in activation of IRF3 and NF-κB, respectively. TLR7/8 requires MyD88 to 
activate the signaling proteins TRAF6 and IRAK4 inducing the activation of IRF7 (Kawai et al., 
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2004). In a proof-of-concept study, we will use HT1080 cells to investigate if LASV cell entry via 
Axl evades innate detection by endosomal TLRs. In case HT1080 cells lack endogenous TLR3 and 
TLR7, they will be expressed as recombinant proteins using retroviral gene delivery vectors. In a 
first step, we will examine activation of the downstream transcription factors IRF3/7 and NF-κB 
upon infection of cells with rLCMV-LASVGP, using Sendai virus (SeV) as a positive control. 
Activation of IRF3/7 could be detected by its nuclear translocation, which is indispensable for the 
activation of the INF-β promoter (Martinez-Sobrido et al., 2007; Martinez-Sobrido et al., 2006). 
The nuclear translocation of IRF3/7 critically depends on its phosphorylation, which could be 
assessed by Western-blot using an antibody that specifically recognizes the phosphorylated form as 
described (Pythoud et al., 2012). Activation of NF-κB could be monitored using NF-κB luciferase 
reporter constructs and nuclear translocation assessed by cell fractionation (Rodrigo et al., 2012). 
Consequent up-regulation of IFN-β could be monitored by RT-PCR. In case Axl-mediated cell 
entry of rLCMV-LASVGP induces IRF3/7 and/or NF-κB, we will confirm the roles of TLR7/8 and 
TLR3. For this purpose, we will employ specific siRNAs that target and efficiently silence TLR 
genes. 
As mentioned above, when rLCMV-LASVGP uses DG as receptor, it enters and infects 
cells via an unusual pathway that seems to bypass the early endosome, which may allow the virus to 
escape from detection by endosomal PRRs like TLRs. It will be interesting to compare the innate 
immune response between HT1080 cells expressing functional DG and cells expressing only Axl. 
For this purpose, we would compare the induction of IFN-β upon cell entry of rLCMV-LASVGP 
into either wild-type HT1080 cells expressing TLRs or the same cells in which functional DG has 
been rescued by over-expression of LARGE using an adenoviral vector (LARGE-AdV). If the 
rescue of functional DG prevents induction of INF-β in response to infection, the results would 
indicate that high affinity binding of LASV to DG “sequesters” the virus away from the TAM 
receptors and allows it to bypass recognition by endosomal TLRs. This may suggest that selection 
of DG as a high affinity receptor by arenaviruses may have allowed them to escape from the innate 
detection by endosomal PRRs in cells co-expressing DG and TAM receptors. 
Can LASV suppress the function of antigen presenting cells via Axl? 
Autoimmunity phenotypes have been observed in TAM-knockout mice, revealing the 
importance of the TAM family in the regulation of the host’s immune response (Lu and Lemke, 
2001). A proposed mechanism is the negative regulation of pro-inflammatory signaling by Axl in 
innate immune cells (Fig. 2). Specifically, it has been demonstrated that the activation of the 
Gas6/Axl pathway leads to inhibition of TLR and cytokine receptor signaling in antigen presenting 
cells (APC). Mechanistically, Gas6/Axl co-activates the INFAR (IFNα/β receptor)/STAT1 (signal 
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transducer and activator of transcription 1) pathway, which increases the expression of pro-
inflammatory signal suppressors, such as Twist 1, SOCS1 and SOCS3 (Fig. 2) (Rothlin et al., 2007; 
Sharif et al., 2006). 
Human DCs, like for example monocyte-derived DCs (MDDC) are highly susceptible to 
LASV infection, but fail to be activated and do not produce type I IFNs or cytokines in response to 
infection (Baize et al., 2004; Mahanty et al., 2003). Recent studies in our laboratory and by others 
showed that MDDC lack functional DG and Axl. However, Axl, but not DG were induced upon 
exposure of MDDCs to type I IFNs (Scutera et al., 2009). This scenario is of interest regarding 
human LASV infection in vivo, since experimental studies in primates revealed early infection of 
plasmacytoid DCs (pDCs) resulting in production of high levels of type I IFNs. Type I IFN released 
from pDCs early in infection could act upon classical DCs, resulting in the up-regulation of Axl. 
We speculate that the interaction of LASV with Axl on DCs may induce inhibitory signals and may 
contribute to the down-modulation of the DC’s cytokine production. We are currently testing this 
hypothesis in the laboratory. 
 
Figure 2. Overview of TAM signaling. (A) Phagocytic removal of apoptotic cells. Phagocytic cells use TAM receptors 
(red) to identify and engulf apoptotic cells and membranes. TAM ligands, such as Gas6 and protein S (green), bind to 
phosphatidylserine (PtdSer; light blue) that is expressed on the surface of apoptotic cells. The carboxy-terminal domains 
of these ligands then interact with and activate TAM receptors on the phagocyte. This induces a signal transduction 
cascade that results in mobilization of the actin cytoskeleton, and the phagocytosis of the apoptotic cell. (B) Regulation of 
the inflammatory response. This same scheme of engagement, when it occurs in the context of the joint expression of 
TAM and type I IFN receptors (IFNARs; dark blue) in macrophages and DCs, also inhibits the inflammatory response of 
the innate immune system. Induced-expression of SOCS proteins inhibit the signaling downstream of both IFNARs and 
Toll-like receptors (TLRs, violet) (Rothlin and Lemke, 2010). 
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Summary
The extracellular matrix (ECM) receptor dystrogly-
can (DG) serves as a cellular receptor for the highly
pathogenic arenavirus Lassa virus (LASV) that
causes a haemorrhagic fever with high mortality in
human. In the host cell, DG provides a molecular
link between the ECM and the actin cytoskeleton via
the adapter proteins utrophin or dystrophin. Here
we investigated post-translational modiﬁcations of
DG in the context of LASV cell entry. Using the
tyrosine kinase inhibitor genistein, we found that
tyrosine kinases are required for efficient internali-
zation of virus particles, but not virus–receptor
binding. Engagement of cellular DG by LASV enve-
lope glycoprotein (LASV GP) in human epithelial
cells induced tyrosine phosphorylation of the cyto-
plasmic domain of DG. LASV GP binding to DG
further resulted in dissociation of the adapter
protein utrophin from virus-bound DG. This virus-
induced dissociation of utrophin was affected by
genistein treatment, suggesting a role of receptor
tyrosine phosphorylation in the process.
Introduction
The Old World arenavirus Lassa virus (LASV) is the
causative agent of a severe viral haemorrhagic fever in
humans with several hundred thousand infections per
year in Africa and thousands of deaths annually (McCor-
mick and Fisher-Hoch, 2002). Fatal LASV infection is
characterized by rapid viral replication and spread, result-
ing in uncontrolled viral infection with progressive signs
and symptoms of haemorrhagic disease and shock (Geis-
bert and Jahrling, 2004). The death toll of LASV infection
among hospitalized patients can reach 15–30%. There is
no licensed vaccine against LASV and current therapeutic
options are limited, making LASV arguably one of the
most neglected tropical pathogens.
Arenaviruses are enveloped negative-strand RNA
viruses with a bisegmented genome, whose replication
takes place in the cytoplasm (Buchmeier et al., 2007; de la
Torre, 2009). The two viral RNAsegments, L and S, include
each two open reading frames. The S segment encodes
the envelope glycoprotein precursor (GPC) and the
nucleoprotein (NP) and the L segment codes for the matrix
protein (Z) and the viral polymerase (L). LASV GPC is
synthesized as a single polypeptide and undergoes
processing by the host cell protease subtilisin kexin
isozyme-1 (SKI-1)/site-1 protease (S1P) (Lenz et al.,
2001; Beyer et al., 2003; Rojek et al., 2008b), yielding the
N-terminal GP1 and the transmembrane GP2. LASV GP1
is involved in binding to cellular receptors (Borrow and
Oldstone, 1992), whereas the GP2 part mediates fusion
and resembles the membrane-proximal regions of other
viral fusion proteins (Eschli et al., 2006; Igonet et al., 2011).
Binding of a virus to its cellular receptor(s) and subse-
quent entry into target cells are the ﬁrst steps of virus
infection and a fundamental aspect of the virus–host cell
interaction. These initial steps of infection are also prom-
ising targets to block the pathogen before it can take
control over the host cell. Therapeutic intervention at the
level of cell entry is of particular interest for highly patho-
genic viruses like LASV. The ﬁrst cellular receptor discov-
ered for LASV and the prototypic Old World arenavirus
lymphocytic choriomeningitis virus (LCMV) is dystroglycan
(DG), a ubiquitous receptor for extracellular matrix (ECM)
proteins (Cao et al., 1998; Oldstone and Campbell, 2011).
More recently, additional candidate receptors for LASV
have been reported, including the C-type lectins DC-SIGN,
LSECtin, and the Tyro3/Axl/Mer (TAM) receptor tyrosine
kinases Axl and Tyro3 (Shimojima et al., 2012). However,
in DG-expressing cells, DG appears to be the preferred
receptor for LASV (Shimojima et al., 2012).
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Dystroglycan is a highly conserved protein initially
translated as a single polypeptide chain that is cleaved
into the extracellular a-DG, and transmembrane b-DG
(Barresi and Campbell, 2006). DG is expressed in most
developing and adult tissues in cells that adjoin basement
membranes (Durbeej et al., 1998) and is crucial for
normal cell–matrix interactions (Henry and Campbell,
1998; Henry et al., 2001). Alpha-DG has a central, highly
glycosylated mucin-type domain that connects the globu-
lar N- and C-terminal domains. At the extracellular site,
a-DG undergoes high-affinity interactions with the ECM
proteins laminin, agrin, perlecan and neurexins (Barresi
and Campbell, 2006). Alpha-DG is non-covalently associ-
ated with b-DG, which binds intracellularly to the adaptor
proteins dystrophin or utrophin that link DG to the actin
cytoskeleton. DG is also associated with a number of
signalling molecules, including the adaptor molecule grb2
(Yang et al., 1995), the canonical MAP kinases MEK and
ERK (Spence et al., 2004) and the focal adhesion kinase
(Cavaldesi et al., 1999). Upon receptor binding, LASV
and LCMV are internalized via an endocytotic pathway
that is independent of clathrin, caveolin and dynamin and
bypasses classical Rab5-dependent incoming routes of
vesicular trafficking (Quirin et al., 2008; Rojek et al.,
2008c). During cell entry, LASV and LCMV pass through
the multivesicular endosome, where the virus–receptor
complex undergoes sorting by the endosomal sorting
complex required for transport (ESCRT) delivering the
viruses to late endosomes, where low pH-induced fusion
occurs after 20–30 min (Quirin et al., 2008; Rojek et al.,
2008c; Pasqual et al., 2011).
In the host cell, DG appears as a structural component
of cell–matrix contacts, which suggests a rather static
role. Considering the receptor dynamics expected in the
context of LASV cell entry, we hypothesized that virus
binding may alter DG trafficking, e.g. by inducing post-
translational modiﬁcations that target the DG complex
towards rapid endocytosis. Studies in prototypic primate
and human cells had demonstrated that cell adhesion to
ECM proteins can induce phosphorylation of tyrosine
Y892 located within a PPxY motif present at the
C-terminus of the cytoplasmic domain of b-DG by non-
receptor tyrosine kinases of the src family (James et al.,
2000; Sotgia et al., 2001; 2003). This tyrosine phosphor-
ylation of Y892 prevented the association of b-DG with the
cytoskeletal adaptor protein utrophin (James et al., 2000)
and resulted in a redistribution of the DG complex from
the plasma membrane to intracellular compartments
(Sotgia et al., 2003), linking tyrosine phosphorylation of
b-DG to receptor internalization. More recent studies con-
ﬁrmed a role of tyrosine phosphorylation of b-DG at Y892
for the endocytosis of DG in myoblasts and provided
evidence for a role of tyrosine phosphorylation of DG in
the development of muscle pathophysiology in an animal
model for muscular dystrophy (Miller et al., 2012). In the
present study we investigated the role of receptor tyrosine
phosphorylation for cell entry of LASV.
Results
Tyrosine kinases are involved in endocytosis of
rLCMV–LASVGP
Recent studies using the broadly speciﬁc tyrosine kinase
inhibitor genistein revealed a role for tyrosine kinases in
cell entry of LASV (Kolokoltsov et al., 2012). However, the
speciﬁc step(s) of the viral entry process that depend on
tyrosine kinases had not yet been deﬁned. In a ﬁrst step,
we sought to conﬁrm and extend these earlier studies
and tried to distinguish effects of genistein on virus–cell
attachment from endocytosis. Since LASV is a BSL4
pathogen, work with live virus is restricted to laboratories
with high security containment. To circumvent these
biosafety restrictions, we used a recombinant form of the
prototypic LCMV expressing the envelope GP of LASV
(rLCMV–LASVGP) (Rojek et al., 2008c). The chimera
rLCMV–LASVGP does not show signiﬁcant attenuation in
vitro when compared to the parental LCMV strain and
grows to robust titres. Since receptor binding and host cell
entry of arenaviruses are mediated exclusively by the viral
GP, rLCMV–LASVGP adopts the receptor binding charac-
teristics of LASV (Rojek et al., 2008c) and represents a
suitable BSL2 surrogate for our studies on LASV–
receptor interaction and cell entry. As a cell culture model,
we chose the human lung epithelial cell line WI-26 VA4,
which had previously been utilized for studies on DG
signalling (Ferletta et al., 2003) and the interaction of
LASV with its receptor DG (Rojek et al., 2012).
First, we veriﬁed that cell attachment and entry of LASV
into WI-26 VA4 cells were mediated by DG. Cells were
pretreated with increasing concentration of the mono-
clonal antibody (mAb) IIH6 that recognizes a functional
glycan epitope on a-DG (Kanagawa et al., 2004) and
competes with virus binding (Kunz et al., 2005b). Cells
were then infected with rLCMV–LASVGP and infected
cells detected after 16 h by immunoﬂuorescence (IF)
staining of the viral nucleoprotein. Pretreatment with mAb
IIH6, but not an IgM isotype control, signiﬁcantly blocked
infection with rLCMV–LASVGP in a dose-dependent
manner, conﬁrming DG as a major receptor for LASV in
these cells (Fig. 1A), as shown previously (Rojek et al.,
2012).
To exclude unspeciﬁc cytotoxicity caused by genistein,
WI-26 VA4 cells were treated with increasing concentra-
tions of the drug for 4 h, followed by a wash out and
incubation for a total of 16 h. Cell viability was assessed
by Cell Titer Glo® assay, which measures intracellular
levels of ATP. WI-26 VA4 cells tolerated genistein up to a
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concentration of 100 mM with only mild loss of cell viability
(Fig. 1B). To test the effect of genistein on early infection
with LCMV–LASVGP, WI-26 VA4 cells were pretreated
with increasing concentrations of genistein for 1 h and
infected with rLCMV–LASVGP at multiplicity of 1. At 4 h
post infection, the drug was removed by wash out. To
prevent further infection, the lysosomotropic agent ammo-
nium chloride was added to the fresh medium. When
added to cells ammonium chloride raises the endosomal
pH rapidly and blocks low pH-dependent membrane
fusion without causing overall cytotoxicity (Ohkuma and
Poole, 1978; 1981). After 12 h in presence of ammonium
chloride, cells were ﬁxed and infection detected by IF
staining for LCMV NP. As shown in Fig. 1C, genistein
blocked infection with rLCMV–LASVGP in a dose-
dependent manner.
Using expression of LCMV NP in infected cells as
readout for infection did not allow discriminating between
effects of genistein on LASVGP-mediated cell entry and
post-entry steps of early viral infection. To speciﬁcally
validate the effects of genistein on LASV cell entry in our
system, we used recombinant vesicular stomatitis virus
(VSV) pseudotyped with the envelope GPs of LASV
(rVSV–LASVGP) and VSV (rVSV–VSVG). These pseudo-
types are replications-deﬁcient and contain a green ﬂuo-
rescent protein (GFP) reporter in their genome. Previous
studies demonstrated that rVSV–LASVGP closely mimics
the receptor binding and entry characteristics of LASV
(Kunz et al., 2005a; Pasqual et al., 2011). Increasing
concentrations of genistein blocked infection of rVSV–
LASVGP more efficiently than rVSV–VSVG (Fig. 1D),
consistent with previous reports (Kolokoltsov et al., 2012).
Notably, the dose–response characteristic of rVSV–
LASVGP closely matched the one of rLCMV–LASVGP
(Fig. 1C and D), indicating that at least some of the inhibi-
tory effect of genistein on early infection with rLCMV–
LASVGP was due to perturbation of LASVGP-mediated
cell entry.
To differentiate between effects of genistein on
LASVGP-mediated cell attachment from perturbation of
endocytosis, we used a well-established assay previously
used to study virus internalization (Pelkmans et al., 2002;
Rojek et al., 2008a), schematically shown in Fig. 1E.
Brieﬂy, rLCMV–LASVGP was puriﬁed over a renograﬁn
gradient and puriﬁed virus labelled with the reagent NHS-
SS-biotin, resulting in a biotin label that is cleavable by
reducing agents. As long as the virus stays bound to the
cell surface, the biotin label can be cleaved efficiently
with the potent, membrane-impermeable reducing agent
Tris(2-carboxyethyl)phosphine (TCEP) (Fig. 1E). Once
Fig. 1. Genistein inhibits internalization of rLCMV–LASVGP.
A. LASV infection in WI-26 VA4 cells is mediated by DG. Monolayers of WI-26 VA4 cells in M96 plates were blocked with mAb IIH6 or an
unrelated mouse IgM (control IgM) at the indicated concentrations for 2 h at 4°C. Next, 200 pfu of rLCMV–LASVGP was added for 45 min.
Infection was assessed after 16 h by immunoﬂuorescence (IF) staining for LCMV NP. Infected foci were counted in each well (means  SD,
n = 3).
B. Cytotoxicity of genistein. WI-26 VA4 cells were treated with the indicated concentrations of the drug for 4 h, followed by a wash out and
incubation for a total of 16 h. Cell viability was assessed by Cell Titer Glo® assay. Data are triplicates  SD.
C. Inhibition of rLCMV–LASVGP infection with genistein. WI-26 VA4 cells were treated with the indicated concentrations of genistein for 1 h,
followed by infection with rLCMV–LASVGP at multiplicity of 1, followed by wash out of the drug at 4 h. After 12 h of culture in presence of
20 mM ammonium chloride, cells were ﬁxed and infection detected by IF for LCMV NP. Data are triplicates  SD.
D. Inhibition of infection of VSV pseudotypes with genistein. WI-26 VA4 cells were treated with the indicated concentrations of genistein for
1 h, followed by infection with rVSV–LASVGP and rVSV–VSVG (200 pfu per well). After 24 h, infection was assessed by detection of
GFP-positive cells in direct ﬂuorescence microscopy (n = 3  SD).
E. Schematic of the virus internalization assay (for details, please see text).
F. Genistein treatment prevents internalization of rLCMV–LASVGP. WI-26 VA4 cells were pretreated with 50 mM genistein or vehicle control
(DMSO). After 1 h, cells were chilled on ice and incubated with biotin-S-S-labelled rLCMV–LASVGP (100 particles per cell) for 1 h in the cold.
Unbound virus was removed, cells shifted to 37°C in presence or absence of genistein. After the indicated time points, cells were chilled on
ice and treated with TCEP (+TCEP) or reaction buffer only (-TCEP). After quenching of residual TCEP, cells were lysed, viral GP isolated by
IP with mAb 83.6 to GP2. Biotinylated GP2 was detected with streptavidin-HRP in Western blot under non-reducing conditions using
enhanced chemiluminescence (ECL). The upper blot (+TCEP) was exposed for 10 min; the lower blot (-TCEP) was exposed for 1 min.
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internalized via endocytosis, the biotin-labelled virus is
protected from TCEP and retains its biotin moiety after
exposure of cells to TCEP. To assess possible effects of
genistein on virus cell attachment and internalization,
WI-26 VA4 cells were pretreated with 50 mM genistein or
vehicle control. After 1 h, cells were cooled on ice and
incubated with biotin-labelled rLCMV–LASVGP (100 par-
ticles per cell) for 1 h in the cold. Unbound virus was
removed and cells shifted to 37°C in presence of genis-
tein. After the indicated time points, cells were rapidly
chilled on ice and immediately treated with cold TCEP or
reaction buffer only. After quenching of residual TCEP
with iodacetamide, cells were lysed and the viral GP iso-
lated by immunoprecipitation (IP) with mAb 83.6 to GP2.
Proteins were separated by SDS-PAGE and biotinylation
of GP2 detected by Western blot under non-reducing con-
ditions. In specimens treated with reaction buffer only,
similar amounts of cell-associated biotinylated virus were
detected in presence and absence of genistein (Fig. 1F),
indicating that genistein treatment did not affect virus
attachment to the receptor. In control samples treated with
TCEP, biotinylated virus became detectable after circa
5 min, with an increase over the next 20 min. In cells
treated with genistein and TCEP, the signals for bioti-
nylated GP2 were markedly reduced, indicating a block in
an early step of virus internalization in presence of the
inhibitor. In sum, our studies revealed that genistein does
not affect virus–cell attachment, but inhibits the subse-
quent early steps of virus internalization.
Binding of rLCMV–LASVGP to cellular DG induces
tyrosine phosphorylation of b-DG
Since the binding of LASV to DG is of high affinity and
virtually irreversible under neutral pH (Kunz et al., 2005a),
we speculated that virus-bound DG may be internalized
during endocytosis of the virus. The apparent block of
virus internalization in presence of genistein at an early
time point (5–20 min) (Fig. 1E) opened therefore the pos-
sibility that uptake of the virus–receptor complex could
involve tyrosine phosphorylation of the receptor and/or
receptor-associated cellular factors. Since phosphoryla-
tion of b-DG at residue Y892 had previously been linked to
internalization of the DG complex (Sotgia et al., 2003;
Miller et al., 2012), we monitored phosphorylation of DG
at Y892 during LASV cell entry. For this purpose, we
applied mAb cl14a that speciﬁcally recognizes b-DG
phosphorylated at Y892 (Sotgia et al., 2003). In a ﬁrst
step, we conﬁrmed the speciﬁcity of mAb cl14a in our
system. To this end, we coexpressed recombinant full-
length DG containing a C-terminal HA tag (DGHA,
Fig. 2A) with recombinant c-src in HEK293 cells. Previous
studies demonstrated that C-terminal tagging of b-DG had
no inﬂuence on the biosynthesis, transport and function of
DG (Rojek et al., 2007b). Cells were either treated with
the speciﬁc src tyrosine kinase family inhibitor PP2
(20 mM) or mock treated. After 48 h, DGHA was isolated
by IP with HA matrix and phosphorylation of Y892
detected with mAb cl14a in Western blot. As expected,
DGHA isolated from cells overexpressing c-src was spe-
ciﬁcally recognized by mAb cl14a, whereas treatment with
PP2 markedly reduced the signal, conﬁrming the speciﬁ-
city of the assay (Fig. 2B).
To examine the effect of LASV binding on tyrosine
phosphorylation of DG at Y892, monolayers of WI-26 VA4
cells were incubated with rLCMV–LASVGP (100 particles
per cell). Virus attachment was performed in the cold to
allow virus binding but prevent lateral movement of recep-
tor molecules in the membrane. As a control, we used the
New World arenavirus Pichinde (PICV) that does not bind
to a-DG (Spiropoulou et al., 2002). After removal of
unbound virus, cells were rapidly shifted to 37°C to
restore membrane ﬂuidity. At the indicated time points,
cells were lysed in presence of the phosphatase inhibitor
sodium orthovanadate. Cleared cell lysates were sub-
jected to lectin puriﬁcation with wheat germ agglutinin
(WGA). Precipitated proteins were separated by SDS-
PAGE and probed with mAb cl14a anti-b-DGPY892 and
mAb 8D5 to b-DG that binds independently of phosphor-
ylation. Binding of rLCMV–LASVGP, but not PICV,
resulted in transient phosphorylation of b-DG at Y892
(Fig. 2C) with maximal signals observed after 5–10 min.
To conﬁrm the role of src family kinases in the apparent
virus-induced receptor phosphorylation at Y892, we
treated cells with the src kinase inhibitor PP2 for 30 min
prior to addition of virus. As shown in Fig. 2D, pretreat-
ment with PP2 markedly reduced virus-induced tyrosine
phosphorylation of b-DG at Y892, indicating a direct or
indirect involvement of src kinases. In some experiments,
we observed an apparent decrease in total b-DG at later
time points (Fig. 2C and D). However, this was not
observed consistently.
To address a possible role of the observed virus-
induced receptor phosphorylation at Y892 for viral entry,
we monitored the entry kinetics of LASV in presence
of PP2. Upon receptor binding, LASV is taken up by
clathrin- and caveolin-independent endocytosis and
rapidly delivered to late endosomes, where low pH-
dependent membrane fusion occurs (Borrow and Old-
stone, 1994; Quirin et al., 2008; Rojek et al., 2008a,c). To
assess how fast receptor-bound rLCMV–LASVGP traf-
ﬁcked to late endosomes in presence and absence of
PP2, we determined the time required for the virus to
become resistant to ammonium chloride. Brieﬂy, WI-26
VA4 cells were either pretreated with PP2 for 1 h, or mock
treated with vehicle (DMSO) only. Cells were then incu-
bated with rLCMV–LASVGP in the cold, allowing virus
attachment without internalization. Unbound virus was
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removed and cells quickly shifted to 37°C to allow virus
internalization in presence or absence of PP2. After dif-
ferent time points, 20 mM ammonium chloride was added
to cells and kept throughout the experiment. At 16 h post
infection, cells were ﬁxed and infection assessed by IF
detection of NP. As shown in Fig. 2E, pretreatment of cells
with PP2 had no signiﬁcant effect on the entry kinetics of
rLCMV–LASVGP, suggesting that tyrosine phosphoryla-
tion of b-DG at Y892 was dispensable for virus cell entry.
To complement these inhibitor studies, we examined the
entry kinetics of rLCMV–LASVGP in murine embryonic
ﬁbroblasts (MEFs) derived from mice deﬁcient for the src
family kinases src, fyn and yes (Newsome et al., 2006).
When compared to wild-type MEFs, src/fyn/yes-deﬁcient
cells were infected with similar kinetics (data not shown),
in line with our src kinase inhibitor studies (Fig. 2E).
Despite the marked inhibition of rLCMV–LASVGP
internalization by genistein (Fig. 1F), treatment of cells
with the src inhibitor PP2 did not affect LASV cell entry,
which was rather unexpected. Examination of the
sequence of the cytoplasmic tail of b-DG revealed the
presence of four putative sites of tyrosine phosphoryla-
tion, in addition to Y892 (Fig. 3A). To assess tyrosine
phosphorylation of b-DG in response to LASV binding at
sites other than Y892, WI-26 VA4 cells were pretreated
with PP2 or vehicle, followed by exposure to rLCMV–
LASVGP as described above. After the indicated time
points, b-DG was isolated by IP using mAb 8D5 that
does not discriminate between phosphorylated and
unphosphorylated b-DG. Immunocomplexes were sepa-
rated by SDS-PAGE and probed in Western blot using
mAb cl14a to b-DGPY892 and mAb 4G10 to tyrosine
phosphate. Total b-DG was detected with polyclonal anti-
body AP83. As expected, treatment with PP2 prevented
virus-induced phosphorylation at Y892 (Fig. 3B). How-
ever, immunoblotting with the broadly speciﬁc anti-
phosphotyrosine mAb 4G10 revealed signiﬁcant tyrosine
phosphorylation of b-DG in response to virus binding that
was not affected by PP2 (Fig. 3B). This suggested that
binding of rLCMV–LASVGP to cellular DG induced tyro-
sine phosphorylation of b-DG at sites other than Y892,
possibly implicating non-src family tyrosine kinases. Pre-
Fig. 2. Binding of LASV to cellular DG induces tyrosine phosphorylation of b-DG by src family kinases.
A. Schematic representation of C-terminally tagged DG (DGHA). The N-terminal domain (white), the mucin-type domain (black) and the
C-terminal domain (gray) of a-DG, b-DG and the C-terminal HA tag are indicated.
B. Detection of tyrosine phosphorylation at residue Y892 with mAb cl14a. DGHA was transiently expressed either alone or in combination with
c-src. Parallel specimens were pretreated with 20 mM PP2 or mock treated with vehicle (DMSO). After 48 h, DGHA was isolated by pull-down
with HA matrix. Proteins were separated and probed in Western blot with an antibody to HA (anti-HA) or mAb cl14a to b-DG phosphorylated
at tyrosine 892 (anti-b-DG PY892). Apparent molecular masses and the positions of b-DG are indicated.
C. Attachment of rLCMV–LASVGP to cells induces tyrosine phosphorylation of b-DG. Monolayers of WI-26 VA4 cells were incubated with
rLCMV–LASVGP or PICV (100 particles per cell) for 1 h in the cold. Unbound virus was removed and cells shifted to 37°C. At the indicated
time points, cells were lysed and DG enriched by WGA affinity puriﬁcation. WGA-bound glycoproteins were probed in Western blot with mAb
cl14a (anti-b-DG PY892) and antibody 8D5 to b-DG. The positions of b-DG and b-DG PY892 are indicated.
D. Virus-induced tyrosine phosphorylation of b-DG is blocked by PP2. Monolayers of WI-26 VA4 cells were pretreated with 20 mM PP2 or
DMSO (control) for 1 h prior to exposure to rLCMV–LASVGP. Virus-induced phosphorylation of b-DG at Y892 was assessed as in C.
E. The phosphorylation of b-DG at PY892 is not required for LASV cell entry. Monolayers of WI-26 VA4 cells were pretreated with 20 mM PP2
or DMSO (control) for 1 h as in D, followed by incubation with rLCMV–LASVGP (MOI = 1) in the cold in presence of the drug. After 1 h,
unbound virus was removed and prewarmed (37°C) medium containing the drug added. At the indicated time points, 20 mM ammonium
chloride was added and left throughout the experiment. At 16 h post infection, cells were ﬁxed and infection detected by intracellular staining
for LCMV NP (means  SD, n = 3). The apparent differences in infection at 60 min were not statistically signiﬁcant.
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treatment of cells with genistein (50 mM) for 30 min
reduced virus-induced tyrosine phosphorylation of b-DG
altogether (Fig. 3C).
Engagement of DG by LASV GP detaches the DG
complex from the adaptor utrophin
In the host cell, DG provides a molecular link between the
ECM and the actin cytoskeleton by anchorage of the
cytoplasmic domain of b-DG to the cytoskeletal adapter
proteins dystrophin or utrophin. Cell entry of LASV occurs
independently of the dynamics and stability of the actin
cytoskeleton (Rojek et al., 2008c). We hypothesized that
virus binding, possibly involving receptor clustering and
signalling, may somehow detach DG from the cytoskeletal
adaptors, allowing subsequent actin-independent endo-
cytosis. A major challenge to test this hypothesis was to
assess speciﬁc changes in utrophin binding to the rela-
tively small fraction of virus-bound DG as compared to
total cellular DG. To overcome this problem, we used
recombinant retroviruses bearing the recombinant GP of
LASV. Retroviral pseudotypes containing the GP of the
New World virus Amapari (AMPV), which does not use
DG as a receptor (Spiropoulou et al., 2002), served as a
negative control. These arenavirus pseudotypes, which
have been previously generated and extensively charac-
terized in our laboratory, adopt the receptor binding char-
acteristics and cellular tropism of the viruses from which
the GPs are derived (Rojek et al., 2007a). Importantly, the
use of retroviral pseudotypes allowed the insertion of a
C-terminal FLAG tag into LASV GP and AMPV GP
(Fig. 4A) allowing co-IP of the viral GP with associated
cellular receptor proteins. The C-terminal FLAG tag had
no adverse effect on the function of the viral GPs in host
cell attachment and entry (Rojek et al., 2008b). Retroviral
pseudotypes containing FLAG-tagged LASV GP and
AMPV GP were produced and puriﬁed as described
(Rojek et al., 2007a,b) and detection of GP in puriﬁed
pseudotypes by ELISA revealed more efficient incorpora-
tion of LASV GP when compared to AMPV GP (Fig. 4B).
As previously shown, infection of cells with LASV pseu-
dotypes, but not AMPV pseudotypes or pseudotypes of
VSV, depended on DG (Fig. 4C), conﬁrming their receptor
speciﬁcity.
To assess the impact of LASV GP binding on the asso-
ciation of cellular DG with utrophin, we incubated LASV or
AMPV pseudotypes with monolayers of WI-26 VA4 cells.
A parallel set of cells was incubated with medium only.
This step was carried out in the cold to allow receptor
binding without clustering or internalization. Cells were
either kept on ice or shifted to 37°C for 10 min, followed by
cell lysis in the cold. Lysates prepared from cells incu-
Fig. 3. Binding of LASV to cellular DG induces tyrosine phosphorylation of b-DG by non-src tyrosine kinases.
A. Sequence of the cytoplasic domain of human b-DG. The putative transmembrane domain is underlined in black and tyrosine residues
indicated with gray arrows. Putative phosphorylation sites for src family kinases are underlined and Y residues marked (arrows). The PPxY
motif including Y892 is double underlined.
B. Detection of virus-induced tyrosine phosphorylation b-DG in presence of PP2. WI-26 VA4 cells were pretreated with 20 mM PP2 or vehicle,
followed by exposure to rLCMV–LASVGP as in Fig. 2D. After the indicated time points, b-DG was isolated by IP using mAb 8D5 against b-DG
covalently coupled to sepharose 4B. Immunocomplexes were eluted under non-reducing conditions, separated by SDS-PAGE and probed in
Western blot using mAb cl14a to b-DGPY892 and mAb 4G10 to tyrosine phosphate (pY). For detection of bound mouse IgG a TrueBlot®
detection system was used to avoid cross reaction with the murine IgG heavy and light chains. Total b-DG was detected with rabbit polyclonal
antibody AP83.
C. Genistein blocks virus-induced tyrosine phosphorylation of b-DG. Cells were pretreated with 50 mM genistein or vehicle (DMSO) only. After
30 min, rLCMV–LASVGP was added (100 particles per cell) for the indicated time points and tyrosine phosphorylation of b-DG was assessed
as in B.
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bated with pseudotypes were subjected to IP with FLAG
matrix. Lysates of untreated control cells were incubated
with mAb 16G4 to a-DG, combined with protein G sepha-
rose. Immunocomplexes and total cell lysates were
probed for b-DG and utrophin in Western blot. As shown in
Fig. 5A, IP anti-FLAG in specimens incubated with LASV,
but not AMPV, pseudotypes resulted in the detection of
b-DG and co-IP of utrophin, suggesting speciﬁc pull-down
of LASV GP-associated DG complex. As expected, IP of
a-DG resulted in robust co-IP of utrophin under all condi-
tions. To quantify possible changes in the ratio of utrophin/
b-DG upon exposure of cells to LASV pseudotypes, we
performed densitometric analysis of the signals for both
conditions and normalized to the utrophin/b-DG detected
in the IP of a-DG (Fig. 5B). In cells kept at 4°C, we
consistently observed a signiﬁcantly lower utrophin/b-DG
ratio in the LASV GP-associated receptor fraction when
compared to the DG–utrophin complexes isolated by IP
with anti-a-DG antibody. This suggested that the LASV
pseudotypes associate preferentially with cellular DG that
shows a weaker or more transient association with
utrophin. As shown in Fig. 5B, the temperature shift to
37°C, which allows clustering of the receptor and signal-
ling to occur, resulted in a reduction of the utrophin/b-DG
ratio in LASV GP-associated DG when compared to cells
kept in the cold. This suggests that virus-induced receptor
clustering and/or signalling promote(s) the dissociation of
the DG complex from utrophin.
To address the role of tyrosine phosphorylation in the
observed virus-induced dissociation of utrophin from
DG, we tested the effect of genistein and PP2. To this
end, cells were pretreated with genistein and PP2 for
1 h, followed by exposure to LASV pseudotypes. After
removal of unbound virus, cells were shifted to 37°C in
presence of the drugs. Virus-associated DG was isolated
by IP with FLAG matrix and the ratio of utrophin/b-DG
assessed as described above. Treatment with genistein
signiﬁcantly reduced virus-induced dissociation of
utrophin from DG, whereas PP2 had only a weak effect
(Fig. 5C and D). This suggested that the phosphorylation
of b-DG at Y892 was dispensable for the virus-induced
dissociation of utrophin from the DG complex.
To complement our inhibitor studies, we examined
LASV cell entry into murine ES cells expressing a DG
variant lacking the last 15 C-terminal amino acids of b-DG
(DGDC), including the PPxY motif containing Y892.
Brieﬂy, ES cells expressing either wild-type DG or DGDC
were infected with rLCMV–LASVGP at low multiplicity.
To exclude differences at the level of post-entry steps
in LCMV replication, a recombinant LCMV expressing
VSVG was used as a control. At 4 h of infection, 20 mM
ammonium chloride was added to prevent secondary
infection. After 16 h, cells were ﬁxed and infection
detected by IF for LCMV NP. As shown in Fig. 5E, ES cells
expressing DGDC were as permissive as wild-type cells,
suggesting that the last 15 amino acids of b-DG are dis-
pensable for LASV cell entry.
Discussion
In the present study we investigated the role of tyrosine
phosphorylation for cell entry of LASV. We show that
tyrosine kinases are required for endocytosis of the virus–
receptor complex, but dispensable for virus–receptor
binding. Binding of LASV to cellular dystroglycan (DG)
induced phosphorylation of DG at Y892 by src family
kinases and other tyrosine residues of b-DG by non-src
kinases. Virus-induced receptor phosphorylation was
accompanied by dissociation of DG from the cytoskeletal
adaptor protein utrophin, which might facilitate virus
endocytosis.
Fig. 4. Retroviral pseudotypes.
A. Schematic representation of Flag-tagged LASV GP. The
receptor binding GP1 and transmembrane GP2 parts are indicated.
The transmembrane domain of GP2 is represented as a grey box
and the C-terminal FLAG tag indicated.
B. Detection of GP in retroviral pseudotypes. Retroviral
pseudotypes were generated by cotransfection of packaging cell
line GP2293 expressing retroviral Gag/Pol with a GP expression
plasmid and an expression plasmid for a packable retroviral
genome bearing a luciferase and a GFP reporter gene.
Pseudotypes were puriﬁed by ultracentrifugation through a sucrose
cushion and resuspended in HBSS. Puriﬁed pseudotypes of LASV
(LAS), AMPV (AMP) and VSV, as well as pseudotypes lacking GP
(C), were immobilized in microtitre plates and the viral GP detected
with mAb 83.6, combined with an HRP-conjugated secondary
antibody in a colour reaction (means  SD, n = 3).
C. Infection of cells with LASV pseudotypes depends on DG. DG
(-/-) murine embryonic stem (ES) cells and parental DG (+/-) ES
cells were infected with pseudotypes of LASV (LAS), AMPV (AMP)
and VSV, as well as pseudotypes lacking GP (C). After 48 h,
infection was detected by luciferase assay (means  SD, n = 3).
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In the host cell, DG provides a molecular link between
the ECM and the actin-based cytoskeleton and has a slow
turnover. However, engagement of DG by LASV results in
rapid internalization of the virus and delivery to the late
endosome (Quirin et al., 2008; Rojek et al., 2008c),
suggesting marked changes in trafficking dynamics of
DG induced by virus binding. In our study, we investigated
if attachment of LASV affects post-translational modiﬁca-
tions of DG, altering receptor trafficking in the membrane.
Extending previous studies (Vela et al., 2008; Kolokoltsov
et al., 2012), we found that treatment of cells with
the broadly speciﬁc tyrosine kinase inhibitor genistein
prevented LASV cell entry at an early step of virus inter-
nalization without affecting virus–receptor binding, provid-
ing a ﬁrst link between tyrosine phosphorylation and viral
endocytosis. Since tyrosine phosphorylation of b-DG at
Y892 by src family kinases has previously been impli-
cated in internalization of DG (Sotgia et al., 2003; Miller
et al., 2012), we tested the effect of LASV binding on
phosphorylation of the receptor at Y892. Engagement of
Fig. 5. Effect of LASV pseudotype binding on the association of DG with utrophin.
A. Monolayers of WI-26 VA4 cells were chilled on ice and incubated with either LASV or AMPV pseudotypes (LASV-PS, AMPV-PS) at a
multiplicity of infection (MOI) of 50 transforming units (TU) per cell. Parallel specimens were incubated with mAb 16G4 to a-DG (anti-DG).
After 1 h, unbound viruses or mAb were removed by washing. Cells were either kept on ice (virus binding 4°C) or shifted to 37°C for 10 min
(temperature shift 37°C). Cells were quickly chilled on ice, lysed and subjected to IP using FLAG matrix or protein G-conjugated sepharose.
Immunocomplexes were separated by SDS-PAGE using 100% of the IP anti-FLAG and 5% of the IP anti-DG. Beta-DG and utrophin were
detected on Western blot using monoclonal antibodies 8D5 and combined with HRP-conjugated secondary antibodies in a TrueBlot® detection
system to avoid cross reaction with the IgG heavy chain. For the detection of total protein in cell lysates, 1/20 of the lysates were separated
by SDS-PAGE and subjected to Western blot detection.
B. Quantiﬁcation of the signals in A. Blots were scanned in a densitometer and the ratios of the signals for utrophin normalized to b-DG
(utrophin/b-DG) for the IP anti-FLAG (LASV pseudotypes only) and the IP anti-DG. For each series, the utrophin/b-DG ratio detected in the IP
anti-DG was deﬁned as 1.0.
C. Pretreatment with genistein, but not PP2, reduced virus-induced dissociation of utrophin from DG. Monolayers of WI-26 VA4 cells were
pretreated with DMSO only (control), 20 mM PP2 and 50 mM genistein for 1 h. Cells were then chilled on ice and incubated with LASV
pseudotypes (LASV-PS) for 1 h in the cold in presence of drugs. Cells were then quickly shifted to 37°C, lysed and subjected to IP with FLAG
matrix as in A. Precipitated b-DG and utrophin were detected in Western blot and the ratios utrophin/b-DG determined as in B.
D. Quantiﬁcation of the data in C.
E. The 15 C-terminal amino acids of b-DG are dispensable for LASV cell entry. Murine ES cells expressing either wild-type DG (DG wt) or DG
lacking the C-terminal 15 amino acids of b-DG (DGDC) were infected with rLCMV–LASVGP or rLCMV–VSVG at a multiplicity of 0.1. Infection
of the cells expressing wild-type DG was set at 100% (means  SD, n = 3).
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cellular DG by rLCMV–LASVGP rapidly induced phospho-
rylation of b-DG at Y892 that was blocked by the src
kinase inhibitor PP2. The observed kinetics of Y892 phos-
phorylation was compatible with a role in viral endocyto-
sis. However, rather unexpected, treatment of cells with
PP2 had no effect on the entry kinetics of the virus. Since
the cytoplasmic tail of b-DG contains four additional puta-
tive sites of tyrosine phosphorylation, in addition to Y892,
we examined virus-induced phosphorylation at tyrosines.
We found that LASV binding induced tyrosine phosphor-
ylation of b-DG at sites other than Y892 with similar kinet-
ics. These tyrosine phosphorylation events were not
sensitive to PP2 and likely involved non-src tyrosine
kinases. Virus-induced tyrosine phosphorylation of b-DG
was entirely abrogated by genistein.
Using a pseudotype platform, we assessed the compo-
sition of DG complexes associated with LASV GP upon
virion attachment. We found that LASV pseudotypes
associated with a fraction of cellular DG that showed less
association with utrophin. The reasons for this are cur-
rently unclear, but may be related to different accessibility
of DG as a function of its association with utrophin and the
actin cytoskeleton. In cells, DG associated with cell–
substrate adhesion structures at the lower plasma mem-
brane tends to colocalize with utrophin (Belkin and
Smalheiser, 1996). Due to the close association with the
substratum at the basal face of the cell, DG located in
such substrate adhesion complexes may be less acces-
sible to the virus.
Our analysis further revealed that engagement of DG
by LASV GP results in dissociation of utrophin from b-DG.
This virus-induced dissociation of utrophin could be
perturbed by genistein, but not PP2, suggesting that
phosphorylation of b-DG at Y892 by src kinases was
dispensable. The efficient virus-induced dissociation of
utrophin from DG in presence of PP2 is in line with the
inability of the inhibitor to perturb viral entry. However, our
ﬁndings are different from reports supporting a role for
phosphorylation of b-DG at Y892 by src kinases in the
regulation of utrophin binding and endocytosis of DG in
prototypic primate cells (James et al., 2000; Sotgia et al.,
2003) and myoblasts (Miller et al., 2012) in response to
endogenous substrates. The reasons for this discrepancy
are currently unclear. One possibility is that, contrary to
our initial assumption, DG may not stay associated with
the virus during the entry process. In this scenario, DG
would serve as an attachment factor rather than a true
entry receptor. One would have to postulate the existence
of another, yet unknown receptor molecule that would
mediate viral endocytosis. The recently discovered alter-
native LASV receptors Axl and Dtk (Shimojima et al.,
2012) appear as interesting candidates in this context.
Alternatively, binding of the multivalent virion particle to
cellular DG may induce extensive clustering and activate
signalling pathways that are not triggered by DG’s ECM
ligands, allowing the virus to ‘bypass’ a block in Y892
phosphorylation. To address these possibilities, studies
aiming at tracking the virus–DG complex in live cells are
currently launched in our laboratory.
Since virus-induced phosphorylation of b-DG is blocked
by genistein, which inhibits internalization of the virus, it is
tempting to speculate that virus-induced phosphorylation
of b-DG is necessary for virus entry. However, in the host
cell, DG is found associated with a number of cellular
proteins that are required for the correct assembly and
stability of the DG complex in the membrane, as well as its
anchorage to the actin cytoskeleton (Barresi and Camp-
bell, 2006). Such ‘preformed’ DG complexes represent
the functional units of virus attachment. Our data have
shown that virus binding to DG results in receptor signal-
ling. Such virus-induced signalling may affect the compo-
sition of the virus–receptor complex by recruiting new
proteins into the virus–DG complex and/or excluding
others. During the entry process, the ‘interactome’ of the
virus–DG complex may therefore change in a dynamic
manner resulting in sorting at the plasma membrane
required for subsequent cell entry. Candidate cellular pro-
teins that interact with the virus–DG complex during the
entry process and are part of this ‘interactome’ would
represent potential substrates for tyrosine phosphoryla-
tion. We cannot exclude the possibility that tyrosine phos-
phorylation of such receptor-associated proteins, and not
b-DG itself, is the actual target of genistein in the viral
entry process.
In sum, the data at hand suggest that attachment of
LASVGP to cellular DG induces tyrosine phosphorylation
of b-DG at Y892 and other tyrosine residues accompanied
by the dissociation of DG from utrophin. The consequent
detachment of virus-bound DG from the actin-based
cytoskeleton may facilitate subsequent endocytosis of the
virus–receptor complex, providing a possible link between
virus-induced post-translational modiﬁcation of DG and
virus entry.
Experimental procedures
Cell lines and viruses
WI-26 VA4 cells (ATCC CCL-95.1) were cultured in DMEM, 10%
(vol/vol) FBS, supplemented with glutamine, and penicillin/
streptomycin. Embryonic stem (ES) cells DG (+/-), DG (-/-) have
been described (Henry and Campbell, 1998). Transgenic ES
cells expressing DG lacking the last 15 amino acids (DGDC) were
generated through introduction of a triple premature stop codon
affecting all possible reading frames via targeted homologous
recombination (gift from Kevin P. Campbell).
The recombinant virus rLCMV–LASVGP has been described
elsewhere (Rojek et al., 2008c) and was produced and the titres
determined as previously described (Dutko and Oldstone, 1983).
Recombinant LASV GP and AMPV GP containing a C-terminal
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FLAG tag have been described (Rojek et al., 2008b). Retroviral
pseudotypes expressing GFP and luciferase reporters were pro-
duced and concentrated, and titres determined as described
(Rojek et al., 2006). Concentrated pseudotypes were diluted in
HBSS at 107 transforming units (TU) ml-1. For detection of viral
GP in ELISA, puriﬁed pseudotypes were immobilized in microtitre
plates at 106 TU ml-1 and the viral GP detected as described
(Rojek et al., 2008a). Recombinant VSV pseudotyped with LASV
GP (rVSVDG–LASVGP) and VSV GP (rVSVDG–VSVG) were
generated as reported previously (Kunz et al., 2005a). Virus titres
were determined by the infection of Vero E6 cell monolayers and
detection of GFP-positive cells by ﬂuorescence microscopy.
Antibodies and reagents
Monoclonal antibodies (mAbs) 113 (anti-LCMVNP) and 83.6
(anti-LCMVGP) have been described (Buchmeier et al., 1981;
Weber and Buchmeier, 1988), as has mAb IIH6 anti-a-DG
(Ervasti and Campbell, 1991). Other mAbs included mouse IgG
8D5 anti-b-DG (Novocastra) and mouse IgG 16C4 to a-DG (pro-
vided by Kevin P. Campbell), mouse IgG anti-utrophin from St
Cruz Biotechnology (St Cruz, CA, USA), mAb cl14a to phospho-
b-DG PY982 (BD Bioscience) and mAb 4G10 to phosphotyrosine
(St Cruz, CA, USA). Rabbit anti-inﬂuenza HA (Y11) was from St
Cruz Biotechnology (St Cruz, CA, USA). Polyclonal rabbit anti-
mouse secondary antibodies conjugated to HRP were from Dako
(Glostrup, Denmark) and goat anti-mouse antibodies conjugated
with Rhodamin Red X were from Jackson Immuno Research
Laboratories. Genistein and PP2 were purchased from Calbio-
chem. The Bright-Glo® luciferase assay and Cell Titer Glo®
assay systems were obtained from Promega (Madison, WI,
USA).
Immunoblotting
Proteins were separated by gel electrophoresis using 12% poly-
acrylamide gels and transferred to nitrocellulose. After blocking in
5% (wt/vol) skim milk in PBS, membranes were incubated with
Abs used at following concentrations: mAb 8D5, mAb cl14a, mAb
4G10 and polyclonal Abs AP83, and Y11 (10 mg ml-1) in 2%
(wt/vol) skim milk, PBS for 12 h at 6°C. Secondary Abs coupled
to HRP were applied 1:5000 in PBS, 0.1% (wt/vol) Tween for 1 h
at room temperature. Blots were developed by enhanced chemi-
luminescence (ECL) using Super Signal West Pico ECL Sub-
strate or TrueBlot® detection system (Pierce), where indicated.
Infection of cells with retroviral pseudotypes
Cells were plated in 96-well plates in a density of 104 cells per
well. After 24 h, retroviral pseudotypes were added at the indi-
cated MOI and incubated for 1 h at 37°C. The viral particles were
removed, cells washed twice with DMEM and fresh medium
added. Infection was quantiﬁed by Bright Glo® luciferase assay.
Luminescence was calculated as fold increase over background
signals obtained from uninfected cells.
Infection of cells with rLCMV–LASVGP
Cells were plated in 96-well plates in a density of 104 cells per
well. After 24 h, cells were pretreated with genistein or PP2 as
indicated, followed by infection with rLCMV–LASVGP at the indi-
cated MOI for 1 h at 37°C. Unbound virus were removed, cells
washed twice with DMEM and fresh medium added. Infection
was quantiﬁed by detection of LCMV NP in IF as described (Kunz
et al., 2004). Cell entry kinetics of rLCMV–LASV in presence and
absence of PP2 were performed as described (Rojek et al.,
2008c). Blocking of infection with mAb IIH6 was carried out as
reported (Kunz et al., 2005b).
Virus internalization assay
Puriﬁcation of rLCMV–LASVGP was performed by ultracentrifu-
gation on a renograﬁn gradient. Puriﬁed LCMV was labelled with
the thiol-cleavable reagent NHS-SS-biotin (Pierce). The cleavage
of the biotin label was veriﬁed by reaction with the membrane-
impermeable reducing agent Tris(2-carboxyethyl)phosphine
(TCEP) (10 mM) (Pierce) for 30 min, which resulted in a loss of
> 95% of the biotin label. Internalization assay was performed as
described previously (Rojek et al., 2008a). Brieﬂy, cells were
cultured in 10 cm dishes to obtain closed monolayers. Medium
was removed, and cells were washed twice with cold HBSS and
chilled on ice for 5 min. Cold solution containing NHS-SS-
biotinylated rLCMV–LASVGP (107 pfu ml-1) in HBSS was added.
After incubation for 1 h on ice, unbound virus was removed and
cells were washed with cold HBSS. For internalization, cells were
shifted to 37°C. After the indicated incubation times, medium was
removed and cells chilled on ice. TCEP (15 mM) in 50 mM
Hepes, pH 7.5, 150 mM NaCl, 1 mM CaCl2 and 1 mM MgCl2 was
added (5 ml per dish) and applied twice for 30 min on ice. Cells
were washed three times with cold HBSS, and the remaining
TCEP was quenched with 100 mM iodoacetamide for 10 min,
and cells were lysed immediately. LCMV GP2 was isolated by IP
as described (Rojek et al., 2008a). Immunocomplexes were
separated by non-reducing SDS-PAGE. Biotinylated LCMV GP2
was detected by Western blotting with HRP-conjugated strepta-
vidin as described above.
Detection of DG–utrophin complexes associated with
LASV GP
Triplicate cultures of WI-26 VA4 cells were cultured in 10 cm
plates over night to obtain closed monolayers. Retroviral pseu-
dotypes of LASV and AMPV (107 TU ml-1 in HBSS) were added
at 50 TU per cell. Parallel specimens were incubated with
10 mg ml-1 mAb 16C4 to a-DG in HBSS. After incubation for 1 h
in the cold, cells were washed three times with cold HBSS. One
series of cultures was kept on ice whereas the other was quickly
shifted to 37°C in a water bath. After 10 min, cells were chilled on
ice. Cells were lysed for 30 min in 1% (wt/vol) b-octylglucoside,
1 mM CaCl2, 1 mM MgCl2, 150 mM NaCl, 50 mM Hepes pH 7.5,
10% (wt/vol) glycerin supplemented with protease inhibitor
cocktail Complete® (Roche) and 1 mM PMSF. Cleared lysates
were subjected to IP with FLAG matrix (Sigma) or protein
G-conjugated sepharose 4B (Sigma) for 2 h at 6°C. After three
short washes in lysis buffer, the matrix was eluted with non-
reducing SDS-PAGE sample buffer to minimize elution of IgG
from the FLAG matrix. After addition of 100 mM DTT (ﬁnal con-
centration) and boiling for another 5 min Western blot was per-
formed as described above. For quantiﬁcation, X-ray ﬁlms were
scanned with a Storm densitometer, and acquired data were
processed using Image Quant software.
10 M.-L. Moraz et al.
© 2012 Blackwell Publishing Ltd, Cellular Microbiology
Acknowledgements
The authors thank Jillian M. Rojek, Alexandra von Siebenthal and
Zoe Enderlin for their contributions to the experiments. This
research was supported by Swiss National Science Foundation
Grant FN 310030_132844 (S. K.), the Prix Leenaards 2009 pour
la promotion de la recherche scientiﬁque (2009) (S. K.) and the
Marie Curie International Reintegration Grant No. 224780 of
the European Community (S. K.). K. P. C. is an investigator of the
Howard Hughes Medical Institute. The retroviral construct
pLZRs–Luc–gfp was kindly provided by Dr Gary Nabel.
References
Barresi, R., and Campbell, K.P. (2006) Dystroglycan: from
biosynthesis to pathogenesis of human disease. J Cell Sci
119: 199–207.
Belkin, A.M., and Smalheiser, N.R. (1996) Localization of
cranin (dystroglycan) at sites of cell-matrix and cell-cell
contact: recruitment to focal adhesions is dependent upon
extracellular ligands. Cell Adhes Commun 4: 281–296.
Beyer, W.R., Popplau, D., Garten, W., von Laer, D., and
Lenz, O. (2003) Endoproteolytic processing of the lym-
phocytic choriomeningitis virus glycoprotein by the subti-
lase SKI-1/S1P. J Virol 77: 2866–2872.
Borrow, P., and Oldstone, M.B. (1992) Characterization of
lymphocytic choriomeningitis virus-binding protein(s): a
candidate cellular receptor for the virus. J Virol 66: 7270–
7281.
Borrow, P., and Oldstone, M.B. (1994) Mechanism of lym-
phocytic choriomeningitis virus entry into cells. Virology
198: 1–9.
Buchmeier, M.J., Lewicki, H.A., Tomori, O., and Oldstone,
M.B. (1981) Monoclonal antibodies to lymphocytic chori-
omeningitis and pichinde viruses: generation, characteriza-
tion, and cross-reactivity with other arenaviruses. Virology
113: 73–85.
Buchmeier, M.J., de la Torre, J.C., and Peters, C.J. (2007)
Arenaviridae: the viruses and their replication. In Fields
Virology. Knipe, D.L., and Howley, P.M. (eds). Philadelphia,
PA: Lippincott-Raven, pp. 1791–1828.
Cao, W., Henry, M.D., Borrow, P., Yamada, H., Elder, J.H.,
Ravkov, E.V., et al. (1998) Identiﬁcation of alpha-
dystroglycan as a receptor for lymphocytic choriomeningi-
tis virus and Lassa fever virus [see comments]. Science
282: 2079–2081.
Cavaldesi, M., Macchia, G., Barca, S., Deﬁlippi, P., Tarone,
G., and Petrucci, T.C. (1999) Association of the dystrogly-
can complex isolated from bovine brain synaptosomes with
proteins involved in signal transduction. J Neurochem 72:
1648–1655.
Durbeej, M., Henry, M.D., Ferletta, M., Campbell, K.P., and
Ekblom, P. (1998) Distribution of dystroglycan in normal
adult mouse tissues. J Histochem Cytochem 46: 449–
457.
Dutko, F.J., and Oldstone, M.B. (1983) Genomic and biologi-
cal variation among commonly used lymphocytic chori-
omeningitis virus strains. J Gen Virol 64: 1689–1698.
Ervasti, J.M., and Campbell, K.P. (1991) Membrane organi-
zation of the dystrophin–glycoprotein complex. Cell 66:
1121–1131.
Eschli, B., Quirin, K., Wepf, A., Weber, J., Zinkernagel, R.,
and Hengartner, H. (2006) Identiﬁcation of an N-terminal
trimeric coiled-coil core within arenavirus glycoprotein 2
permits assignment to class I viral fusion proteins. J Virol
80: 5897–5907.
Ferletta, M., Kikkawa, Y., Yu, H., Talts, J.F., Durbeej, M.,
Sonnenberg, A., et al. (2003) Opposing roles of integrin
alpha6Abeta1 and dystroglycan in laminin-mediated extra-
cellular signal-regulated kinase activation. Mol Biol Cell 14:
2088–2103.
Geisbert, T.W., and Jahrling, P.B. (2004) Exotic emerging
viral diseases: progress and challenges. Nat Med 10:
S110–S121.
Henry, M.D., and Campbell, K.P. (1998) A role for dystro-
glycan in basement membrane assembly. Cell 95:
859–870.
Henry, M.D., Satz, J.S., Brakebusch, C., Costell, M., Gustafs-
son, E., Fassler, R., and Campbell, K.P. (2001) Distinct
roles for dystroglycan, beta1 integrin and perlecan in
cell surface laminin organization. J Cell Sci 114: 1137–
1144.
Igonet, S., Vaney, M.C., Vonhrein, C., Bricogne, G., Stura,
E.A., Hengartner, H., et al. (2011) X-ray structure of the
arenavirus glycoprotein GP2 in its postfusion hairpin con-
formation. Proc Natl Acad Sci USA 108: 19967–19972.
James, M., Nuttall, A., Ilsley, J.L., Ottersbach, K., Tinsley,
J.M., Sudol, M., and Winder, S.J. (2000) Adhesion-
dependent tyrosine phosphorylation of (beta)-dystroglycan
regulates its interaction with utrophin. J Cell Sci 113: 1717–
1726.
Kanagawa, M., Saito, F., Kunz, S., Yoshida-Moriguchi, T.,
Barresi, R., Kobayashi, Y.M., et al. (2004) Molecular rec-
ognition by LARGE is essential for expression of functional
dystroglycan. Cell 117: 953–964.
Kolokoltsov, A.A., Adhikary, S., Garver, J., Johnson, L.,
Davey, R.A., and Vela, E.M. (2012) Inhibition of Lassa virus
and Ebola virus infection in host cells treated with the
kinase inhibitors genistein and tyrphostin. Arch Virol 157:
121–127.
Kunz, S., Sevilla, N., Rojek, J.M., and Oldstone, M.B. (2004)
Use of alternative receptors different than alpha-
dystroglycan by selected isolates of lymphocytic chori-
omeningitis virus. Virology 325: 432–445.
Kunz, S., Rojek, J.M., Perez, M., Spiropoulou, C.F., and
Oldstone, M.B. (2005a) Characterization of the interaction
of Lassa fever virus with its cellular receptor alpha-
dystroglycan. J Virol 79: 5979–5987.
Kunz, S., Rojek, J.M., Kanagawa, M., Spiropoulou, C.F.,
Barresi, R., Campbell, K.P., and Oldstone, M.B. (2005b)
Posttranslational modiﬁcation of alpha-dystroglycan, the
cellular receptor for arenaviruses, by the glycosyltrans-
ferase LARGE is critical for virus binding. J Virol 79:
14282–14296.
Lenz, O., ter Meulen, J., Klenk, H.D., Seidah, N.G., and
Garten, W. (2001) The Lassa virus glycoprotein precursor
GP-C is proteolytically processed by subtilase SKI-1/S1P.
Proc Natl Acad Sci USA 98: 12701–12705.
McCormick, J.B., and Fisher-Hoch, S.P. (2002) Lassa fever.
Curr Top Microbiol Immunol 262: 75–109.
Miller, G., Moore, C.J., Terry, R., La Riviere, T., Mitchell, A.,
Piggott, R., et al. (2012) Preventing phosphorylation of
Lassa virus receptor phosphorylation 11
© 2012 Blackwell Publishing Ltd, Cellular Microbiology
dystroglycan ameliorates the dystrophic phenotype in mdx
mouse. Hum Mol Genet 21: 4508–4520.
Newsome, T.P., Weisswange, I., Frischknecht, F., and Way,
M. (2006) Abl collaborates with Src family kinases to stimu-
late actin-based motility of vaccinia virus. Cell Microbiol 8:
233–241.
Ohkuma, S., and Poole, B. (1978) Fluorescence probe meas-
urement of the intralysosomal pH in living cells and the
perturbation of pH by various agents. Proc Natl Acad Sci
USA 75: 3327–3331.
Ohkuma, S., and Poole, B. (1981) Cytoplasmic vacuolation
of mouse peritoneal macrophages and the uptake into
lysosomes of weakly basic substances. J Cell Biol 90:
656–664.
Oldstone, M.B., and Campbell, K.P. (2011) Decoding arena-
virus pathogenesis: essential roles for alpha-dystroglycan–
virus interactions and the immune response. Virology 411:
170–179.
Pasqual, G., Rojek, J.M., Masin, M., Chatton, J.Y., and Kunz,
S. (2011) Old World arenaviruses enter the host cell via the
multivesicular body and depend on the endosomal sorting
complex required for transport. PLoS Pathog 7: e1002232.
Pelkmans, L., Puntener, D., and Helenius, A. (2002) Local
actin polymerization and dynamin recruitment in SV40-
induced internalization of caveolae. Science 296: 535–
539.
Quirin, K., Eschli, B., Scheu, I., Poort, L., Kartenbeck, J., and
Helenius, A. (2008) Lymphocytic choriomeningitis virus
uses a novel endocytic pathway for infectious entry via late
endosomes. Virology 378: 21–33.
Rojek, J.M., Spiropoulou, C.F., and Kunz, S. (2006) Charac-
terization of the cellular receptors for the South American
hemorrhagic fever viruses Junin, Guanarito, and Machupo.
Virology 349: 476–491.
Rojek, J.M., Spiropoulou, C.F., Campbell, K.P., and Kunz, S.
(2007a) Old World and clade C New World arenaviruses
mimic the molecular mechanism of receptor recognition
used by {alpha}-dystroglycan’s host-derived ligands. J Virol
81: 5685–5695.
Rojek, J.M., Campbell, K.P., Oldstone, M.B., and Kunz, S.
(2007b) Old World arenavirus infection interferes with the
expression of functional {alpha}-dystroglycan in the host
cell. Mol Biol Cell 18: 4493–4507.
Rojek, J.M., Perez, M., and Kunz, S. (2008a) Cellular entry of
lymphocytic choriomeningitis virus. J Virol 82: 1505–1517.
Rojek, J.M., Lee, A.M., Nguyen, N., Spiropoulou, C.F., and
Kunz, S. (2008b) Site 1 protease is required for proteolytic
processing of the glycoproteins of the South American
hemorrhagic fever viruses Junin, Machupo, and Guanarito.
J Virol 82: 6045–6051.
Rojek, J.M., Sanchez, A.B., Nguyen, N.T., Torre, J.C., and
Kunz, S. (2008c) Different mechanisms of cell entry by
human-pathogenic Old World and New World arenavi-
ruses. J Virol 82: 7677–7687.
Rojek, J.M., Moraz, M.L., Pythoud, C., Rothenberger, S., Van
der Goot, F.G., Campbell, K.P., and Kunz, S. (2012)
Binding of Lassa virus perturbs extracellular matrix-
induced signal transduction via dystroglycan. Cell Microbiol
14: 1122–1134.
Shimojima, M., Stroher, U., Ebihara, H., Feldmann, H., and
Kawaoka, Y. (2012) Identiﬁcation of cell surface molecules
involved in dystroglycan-independent Lassa virus cell
entry. J Virol 86: 2067–2078.
Sotgia, F., Lee, H., Bedford, M.T., Petrucci, T., Sudol, M., and
Lisanti, M.P. (2001) Tyrosine phosphorylation of beta-
dystroglycan at its WW domain binding motif, PPxY,
recruits SH2 domain containing proteins. Biochemistry 40:
14585–14592.
Sotgia, F., Bonuccelli, G., Bedford, M., Brancaccio, A., Mayer,
U., Wilson, M.T., et al. (2003) Localization of phospho-
beta-dystroglycan (pY892) to an intracellular vesicular
compartment in cultured cells and skeletal muscle ﬁbers in
vivo. Biochemistry 42: 7110–7123.
Spence, H.J., Dhillon, A.S., James, M., and Winder, S.J.
(2004) Dystroglycan, a scaffold for the ERK-MAP kinase
cascade. EMBO Rep 5: 484–489.
Spiropoulou, C.F., Kunz, S., Rollin, P.E., Campbell, K.P., and
Oldstone, M.B. (2002) New world arenavirus clade C, but
not clade A and B viruses, utilizes alpha-dystroglycan as its
major receptor. J Virol 76: 5140–5146.
de la Torre, J.C. (2009) Molecular and cell biology of the
prototypic arenavirus LCMV: implications for understand-
ing and combating hemorrhagic fever arenaviruses. Ann N
Y Acad Sci 1171 (Suppl. 1): E57–E64.
Vela, E.M., Bowick, G.C., Herzog, N.K., and Aronson, J.F.
(2008) Genistein treatment of cells inhibits arenavirus
infection. Antiviral Res 77: 153–156.
Weber, E.L., and Buchmeier, M.J. (1988) Fine mapping of a
peptide sequence containing an antigenic site conserved
among arenaviruses. Virology 164: 30–38.
Yang, B., Jung, D., Motto, D., Meyer, J., Koretzky, G., and
Campbell, K.P. (1995) SH3 domain-mediated interaction
of dystroglycan and Grb2. J Biol Chem 270: 11711–
11714.
12 M.-L. Moraz et al.
© 2012 Blackwell Publishing Ltd, Cellular Microbiology
APPENDIX  117
   
 
 
    
 
Original article 
“Binding of Lassa virus perturbs extracellular matrix-induced signal transduction via 
dystroglycan” 
Jillian M. Rojek4, Marie-Laurence Moraz1, Christelle Pythoud1, Sylvia Rothenberger1, F. Gisou Van 
der Goot2, Kevin P. Campbell3 and Stefan Kunz1* 
1 Institute of Microbiology, University Hospital Center and University of Lausanne, Lausanne, 
 Switzerland 
2 Global Health Institute, Ecole Polytechnique Fédérale de Lausanne, Faculty of Life Sciences, 
 Lausanne, Switzerland 
3 Howard Hughes Medical Institute, Senator Paul D. Wellstone Muscular Dystrophy Cooperative 
 Research Center, Department of Molecular Physiology and Biophysics, Department of Neurology, 
 and Department of Internal Medicine, Roy J and Lucille A. Carver College of Medicine, The 
 University of Iowa, Iowa City, IA 52242, USA. 
4 Department of Immunology and Microbial Science, The Scripps Research Institute La Jolla, CA 
 92037, USA 
* Corresponding author. Mailing address: Institute of Microbiology, University Hospital Center and 
University of Lausanne, Lausanne CH-1011, Switzerland. Phone: +41-21 314 7743, Fax: +41-21 314 
4060, E-mail Stefan.Kunz@chuv.ch 
Cellular Microbiology (2012) 14(7), 1122–1134 
  
Binding of Lassa virus perturbs extracellular
matrix-induced signal transduction via dystroglycan
Jillian M. Rojek,4† Marie-Laurence Moraz,1
Christelle Pythoud,1 Sylvia Rothenberger,1
F. Gisou Van der Goot,2 Kevin P. Campbell3 and
Stefan Kunz1*
1Institute of Microbiology, University Hospital Center and
University of Lausanne, Lausanne, Switzerland.
2Global Health Institute, Ecole Polytechnique Fédérale
de Lausanne, Faculty of Life Sciences, Lausanne,
Switzerland.
3Howard Hughes Medical Institute, Senator Paul D.
Wellstone Muscular Dystrophy Cooperative Research
Center, Department of Molecular Physiology and
Biophysics, Department of Neurology, and Department
of Internal Medicine, Roy J and Lucille A. Carver
College of Medicine, The University of Iowa, Iowa City,
IA 52242, USA.
4Department of Immunology and Microbial Science, The
Scripps Research Institute La Jolla, CA 92037, USA.
Summary
The arenavirus Lassa virus (LASV) causes a
severe haemorrhagic fever with high mortality in
man. The cellular receptor for LASV is dystrogly-
can (DG). DG is a ubiquitous receptor for extracel-
lular matrix (ECM) proteins, which cooperates with
b1 integrins to control cell–matrix interactions.
Here, we investigated whether LASV binding to DG
triggers signal transduction, mimicking the natural
ligands. Engagement of DG by LASV resulted in
the recruitment of the adaptor protein Grb2 and the
protein kinase MEK1 by the cytoplasmic domain of
DG without activating the MEK/ERK pathway, indi-
cating assembly of an inactive signalling complex.
LASV binding to cells however affected the activa-
tion of the MEK/ERK pathway via a6b1 integrins.
The virus-induced perturbation of a6b1 integrin
signalling critically depended on high-affinity
LASV binding to DG and DG’s cytoplasmic domain,
indicating that LASV–receptor binding perturbed
signalling cross-talk between DG and b1 integrins.
Introduction
Lassa virus (LASV) is the causative agent of a severe
haemorrhagic fever with high mortality in humans that is
endemic to West Africa and infects several hundred thou-
sand individuals per year with thousands of deaths (Gei-
sbert and Jahrling, 2004). There is neither a licensed
vaccine nor an efficacious treatment for this disease,
resulting in 15–30% mortality in hospitalized patients
(McCormick and Fisher-Hoch, 2002). Despite the wide-
spread viral replication in fatal Lassa fever cases, histo-
logical analysis revealed only modest inﬁltration of
inﬂammatory cells (Walker et al., 1982). The terminal
shock syndrome associated with fatal Lassa fever occurs
without evidence of massive cellular necrosis, vascular
damage or bleeding, suggesting that direct perturbation of
host cell function by LASV contributes to disease (McCor-
mick and Fisher-Hoch, 2002; Kunz, 2009; Moraz and
Kunz, 2011). The analysis of the virus–host cell interaction
and the consequences for host cell function are therefore
important to understand the viral pathogenesis underlying
fatal Lassa fever.
LASV belongs to the family Arenaviridae, enveloped
negative strand RNA viruses with a non-lytic life cycle
conﬁned to the cytoplasm (Buchmeier et al., 2007). The
bisegmented genome of LASV codes for only four pro-
teins, an RNA-dependent RNA polymerase (L), the viral
nucleoprotein (NP), the matrix protein (Z) and the precur-
sor of the viral envelope glycoprotein (GPC) (Buchmeier
et al., 2007). The GPC precursor is processed by the
cellular protease subtilisin kexin isozyme-1(SKI-I)/site-1
protease (S1P) yielding the mature envelope proteins
GP1 and GP2. (Lenz et al., 2001; Beyer et al., 2003;
Rojek et al., 2008c). The GP1 part is implicated in binding
to cellular receptor(s), whereas GP2 resembles fusion-
active portions of other viral GPs (Eschli et al., 2006;
Igonet et al., 2011).
The ﬁrst cellular receptor discovered for LASV and
other Old World arenaviruses is a-dystroglycan (a-DG),
the peripheral subunit of DG, a ubiquitously expressed
versatile receptor for extracellular matrix (ECM) proteins
Received 9 January, 2012; revised 21 February, 2012; accepted 5
March, 2012. *For correspondence. E-mail Stefan.Kunz@chuv.ch;
Tel. (+41) 21 314 7743; Fax (+41) 21 314 4060.
†Present address: Genomics Institute of the Novartis Research Foun-
dation, La Jolla, CA 92037, USA.
Cellular Microbiology (2012) 14(7), 1122–1134 doi:10.1111/j.1462-5822.2012.01784.x
First published online 4 April 2012
© 2012 Blackwell Publishing Ltd
cellular microbiology
(Cao et al., 1998; Oldstone and Campbell, 2011). Very
recently, additional candidate receptors for LASV have
been reported: the C-type lectins DC-SIGN, LSECtin, as
well as the Tyro3/Axl/Mer (TAM) receptor tyrosine kinases
Axl and Tyro3 (Shimojima et al., 2012). While the C-type
lectins have expression patterns limited to speciﬁc cell
types, the TAM receptors Tyro3 and in particular Axl are
widely expressed, including cell types positive for DG.
Notably, in cells coexpressing DG and Axl, DG seems to
be the preferred receptor for LASV (Shimojima et al.,
2012), suggesting a role for TAM receptor kinases as
LASV receptors primarily in cells lacking functional DG.
Dystroglycan is expressed in most developing and adult
tissues, typically in cell types that adjoin basement mem-
branes (Durbeej et al., 1998) and is crucial for normal
cell–matrix adhesion (Henry and Campbell, 1998; Henry
et al., 2001). Mutations affecting DG in humans result in
severe congenital diseases (Barresi and Campbell,
2006). Encoded as a single protein, DG is proteolytically
processed into a-DG, which is extracellular, and b-DG
which is membrane anchored (Barresi and Campbell,
2006). DG provides a molecular link between the ECM
and the actin-based cytoskeleton. Alpha-DG binds with
high affinity to the ECM proteins laminin, agrin, perlecan
and neurexins and is non-covalently associated with b-DG
that interacts with the cytoskeletal adaptor proteins dys-
trophin and utrophin, which anchor the DG complex to the
actin-based cytoskeleton (Ervasti and Campbell, 1991;
1993). The cytoplasmic domain of b-DG was found to
interact with the signalling adaptor molecule Grb2 (Yang
et al., 1995), the protein kinases MEK, ERK and focal
adhesion kinase (FAK) (Yang et al., 1995; Cavaldesi
et al., 1999; Spence et al., 2004), suggesting a role of DG
in cellular signal transduction.
Several lines of evidence support a functional interac-
tion between DG and b1 integrins in the assembly of
laminin-based ECM structures (Henry et al., 2001). Lami-
nins recognize a-DG and b1 integrins via distinct LG
modules located in the C-terminal G domain of their
a-chain, LG4 and LG1–3 respectively (Hohenester et al.,
1999). Interestingly, DG and a6b1 integrins seem to have
opposing roles in the regulation of the canonical MEK/
ERK MAP kinase pathway in response to laminin (Ferletta
et al., 2003). Binding of laminin LG1–3 to a6b1 integrins
activates MEK/ERK signalling, whereas attachment of
LG4 to a-DG resulted in a dose-dependent reduction of
MEK/ERK activation (Ferletta et al., 2003). Simultaneous
binding of laminin to the two receptors likely results in a
deﬁned equilibrium of MEK/ERK signalling critical for
normal cell–matrix adhesion.
In mammals, a-DG undergoes complex post-
translational modiﬁcations that are crucial for its function
as an ECM receptor (Barresi and Campbell, 2006; Kana-
gawa and Toda, 2006). Of particular importance are
speciﬁc O-glycan modiﬁcations of a-DG’s mucin-type
domain, which involve protein O-mannosylation and
modiﬁcations by the glycosyltransferases LARGE and
LARGE2 (Barresi et al., 2004). We and others have
shown that protein O-mannosylation and LARGE-
dependent modiﬁcations are also crucial for a-DG’s func-
tion as a high-affinity receptor for arenaviruses (Kunz
et al., 2005b) and that the viruses closely mimic the
molecular mechanisms of receptor recognition by ECM
proteins (Rojek et al., 2007a). As a consequence LASV
competes with ECM proteins for receptor binding, result-
ing in displacement of DG-bound ECM (Kunz et al.,
2005a), likely affecting DG’s function in the host cell. In
the present study, we investigated the impact of LASV
binding to a-DG on DG-mediated signal transduction. We
found that engagement of LASV affected the interaction of
DG with signalling molecules and perturbed the signalling
cross-talk with b1 integrins.
Results
Binding of inactivated LASV to cellular DG triggers
recruitment of Grb2 and MEK1 without activating MEK1
Considering the high binding affinity of LASV for a-DG
and the multivalent nature of the virus particles, we
hypothesized that virus attachment may result in
extensive receptor clustering with possible effects on
DG-mediated signal transduction. Since LASV is a BSL4
pathogen, work with live virus is restricted to laboratories
with high security containment. To circumvent this
problem, we used either inactivated virus or recombinant
retroviruses bearing the envelope glycoprotein of LASV
(Reignier et al., 2006; Rojek et al., 2006). Since receptor
binding and host cell entry of arenaviruses are mediated
exclusively by the viral GP, recombinant retroviruses dis-
playing LASV GP adopt the receptor binding characteris-
tics of LASV (Reignier et al., 2006). They represent a
suitable BSL2 surrogate for LASV and have been widely
used to study LASV–receptor interactions (Kunz et al.,
2005a,b; Reignier et al., 2006; Rojek et al., 2007a). As a
cell culture model, we chose the human lung epithelial cell
line WI-26 VA4, which had previously been utilized for
studies on DG signalling (Ferletta et al., 2003). Alpha-DG
isolated from WI-26 VA4 cells by lectin affinity puriﬁcation
bound inactivated LASV with high affinity, as assessed by
virus overlay protein binding assay (Fig. 1A). In a next
step, we veriﬁed if cell attachment and entry of LASV into
WI-26 VA4 cells was indeed mediated by a-DG. For this
purpose, cells were pre-treated with increasing concen-
tration of the monoclonal antibody (mAb) IIH6 that recog-
nizes a functional glycan epitope on a-DG (Kanagawa
et al., 2004) and competes with virus binding (Kunz et al.,
2005b). Cells were then infected with LASV pseudotypes
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containing a green ﬂuorescent protein (GFP) reporter in
their genome at a multiplicity of infection (moi) of 0.01
infectious virus particle per cell. Infected cells were
detected after 24 h by immunoﬂuorescence (IF) detection
of the GFP reporter. Pre-treatment with mAb IIH6, but not
an IgM isotype control signiﬁcantly blocked infection with
LASV pseudotypes in a dose-dependent manner, con-
ﬁrming DG as a major receptor for LASV in these cells
(Fig. 1B). The only partial inhibition of LASV pseudotype
infection in presence of 200 mg ml-1 mAb IIH6 is consis-
tent with earlier studies (Kunz et al., 2005b) and is likely
due to the high binding affinity of LASV GP to a-DG.
The cytoplasmic tail of b-DG can associate with sig-
nalling molecules, including Grb2, MEK, ERK and FAK,
suggesting a role in cellular signal transduction (Yang
et al., 1995; Cavaldesi et al., 1999; Spence et al., 2004).
We next assessed the impact of LASV binding to cellular
a-DG on the association of b-DG with these signalling
molecules. Since available anti-b-DG antibodies recog-
nize the cytoplasmic domain, interference with the
binding of signalling molecules was a concern. To cir-
cumvent this problem, we made use of a recombinant
full-length DG containing a C-terminal spacer sequence
of four amino acids (GGGS), followed by an HA-tag
(DGHA) (Fig. 2A). Previous studies demonstrated that
this C-terminal tagging of b-DG had no inﬂuence on the
biosynthesis, transport and function of DG (Rojek et al.,
2007b). Considering the biosafety restrictions of work
with live LASV and to avoid any possible effect due to
virus replication, we used inactivated LASV to study the
effect of virus binding on DG signalling. For this purpose,
LASV (strain Josiah) was grown in a BSL4 facility of the
Centers for Disease Control and inactivated by gamma
irradiation as described (Spiropoulou et al., 2002). As a
control, we used inactivated Amapari virus (AMPV), a
New World arenavirus that does not use DG as a recep-
tor (Spiropoulou et al., 2002). Previous studies had
shown that our inactivation protocol abrogated virus rep-
lication, but did not affect receptor binding (Spiropoulou
et al., 2002). In a ﬁrst step, we determined binding of
LASV and AMPV to WI-26 VA4 cells. Brieﬂy, monolayers
of WI-26 VA4 cells were cultured in microtitre plates,
chilled on ice and incubated with increasing concentra-
tions of inactivated virus. After removing unbound virus,
cells were ﬁxed. Bound virus was detected with mAb
83.6 that recognizes a highly conserved epitope in LASV
and AMPV GP2 (Weber and Buchmeier, 1988), com-
bined with a HRP-labelled secondary antibody in a
colour reaction. Both LASV and MAPV bound WI-26 VA4
cells to a similar extent in a dose-dependent manner
(Fig. 2B). Next, WI-26 VA4 cells were transfected with
DGHA, using un-tagged DG as a control. After 48 h, cells
were incubated with inactivated LASV and AMPV (100
particles per cell) in the cold, allowing virus attachment
without receptor clustering. After removal of unbound
virus, the temperature was shifted to 37°C for 10 min.
Cells were rapidly chilled, cold detergent extracts pre-
pared and cleared lysates subjected to immunoprecipita-
tion (IP) with anti-HA matrix. Immunocomplexes were
probed for the presence of DGHA, Grb2, Sos, FAK,
MEK1/2 and ERK1/2 in Western blot. Similar amounts of
DGHA were detected in IPs from cells incubated with
LASV, AMPV and mock-treated cells (Fig. 2C), excluding
receptor downregulation and/or degradation as a conse-
quence of virus binding. In line with published data (Yang
et al., 1995; Spence et al., 2004), we detected an asso-
ciation of b-DG with Grb2 and MEK1/2, whereas neither
FAK, Sos nor ERK was detected in anti-HA immunocom-
plexes in this cell type under our experimental conditions
(Fig. 2D and E). Binding of LASV, but not AMPV resulted
in a signiﬁcant increase in the amounts of b-DG-
associated Grb2 (Fig. 2D and F) and MEK1 (Fig. 2E and
F), indicating recruitment of Grb2 and MEK1 upon virus
binding. In a next step, we investigated if the observed
LASV-induced recruitment of Grb2 and MEK1 resulted in
activation of MEK1. For this purpose, we exposed cells
to LASV and AMPV, isolated HA-tagged b-DG at different
time points as described above. Immunocomplexes were
probed with a mAb speciﬁc for phosphorylated (acti-
vated) MEK1 in Western blot and signals normalized to
total MEK1. At no time point did we observe signiﬁcant
phosphorylation of MEK1 (data not shown), suggesting
that the observed virus-induced recruitment of Grb2 and
MEK1 results in assembly of an inactive signalling
complex associated with b-DG.
Fig. 1. Cell entry of LASV pseudotypes in WI-26 VA4 human lung
epithelial cells is mediated by DG.
A. WI-26 VA4 cells express DG that is functional as LASV receptor.
WI-26 VA4 cells were lysed and glycoproteins enriched by affinity
puriﬁcation with the lectin wheat germ agglutinin. Functional a-DG
was detected by laminin overlay assay (Ln) and virus overlay
protein binding assay using inactivated virus (LASV).
B. Blocking of infection with mAb IIH6. Monolayers of WI-26 VA4
cells were blocked with mAb IIH6 or an unrelated mouse IgM
(Control IgM) at the indicated concentrations for 2 h at 4°C. Next,
LASV pseudotypes (200 PFU) were added for 45 min. Infection
was assessed after 24 h by immunoﬂuorescence staining for GFP.
Infected foci were counted in each well (means  SD, n = 3).
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Infection with LASV pseudotypes depends on DG, but
not b1 integrins
Several lines of evidence indicate that DG functionally
interacts with b1 integrins in the host cell (Henry et al.,
2001; Ferletta et al., 2003). While the role of DG in host
cell attachment and entry of LASV has been well estab-
lished, a possible function of b1 integrins in LASV cell
entry had not yet been addressed. To address this issue,
we exploited the fact that LASV efficiently infects wild-
type murine embryonic stem (ES) cells (Spiropoulou
et al., 2002). To deﬁne a possible role of b1 integrins in
LASV cell entry, we employed a murine ES cell line deﬁ-
cient in b1 integrin (-/-) and the parental hemizygous
(+/-) line (Fassler and Meyer, 1995; Fassler et al.,
1995). To separate virus entry mediated by the envelope
GP of LASV from subsequent steps of virus replication,
we employed recombinant retroviruses pseudotyped
with LASVGP that contained a luciferase reporter in their
genome (Rojek et al., 2007a). As a control, we used ret-
roviral pseudotypes containing the GP of AMPV, which is
independent of DG. Murine ES cell with the genotypes
DG (+/-), DG (-/-), b1 integrin (+/-) and b1 integrin (-/-)
were infected with retroviral pseudotypes bearing the
GPs of LASV and AMPV. Since murine retroviruses
show relatively low levels of reporter gene expression in
murine ES cells (Reignier et al., 2006), pseudotype
infection was performed at high moi (10). Infection was
assessed after 48 h by luciferase assay. In line with pre-
vious reports, cells deﬁcient in DG showed markedly
reduced susceptibility to LASV pseudotypes, whereas
AMPV pseudotype infection was not affected (Fig. 3). In
contrast, cells deﬁcient in b1 integrins showed similar
susceptibility to both pseudotypes (Fig. 3) indicating that
b1 integrins are dispensable for LASVGP-mediated cell
attachment and entry.
Attachment of inactivated LASV and LASV pseudotypes
to cells perturbs activation of MEK/ERK signalling
by laminin
Previous studies demonstrated that cell adhesion to
laminin results in activation of the MEK/ERK pathway via
b1 integrins, which is counterbalanced by DG (Ferletta
et al., 2003). To validate our experimental system, we
monitored the activation of the MEK/ERK pathway in
WI-26 VA4 cells in response to cell adhesion to laminin
employing a cell adhesion assay described previously
(Ferletta et al., 2003). Brieﬂy, WI-26 VA4 cells were cul-
tured for 16 h under serum starvation, detached and
single-cell suspension prepared. Cells were then added
to culture dishes coated with puriﬁed mouse laminin-1 or
left in suspension. At different time points, cells were
lysed, total protein extracted and the phosphorylation of
MEK and ERK detected by speciﬁc antibodies to the
phosphorylated forms of the kinases in Western blot. For
normalization, total MEK/ERK was detected with anti-
bodies that are insensitive to the phosphorylation state.
Adhesion of WI-26 VA4 cells to laminin-1 resulted in the
induction of phosphorylation of MEK and ERK with
maximal activation after 40–60 min, a kinetic proﬁle con-
sistent with published work (Ferletta et al., 2003)
(Fig. 4A). Addition of the speciﬁc MEK inhibitor PD98059
abrogated phosphorylation of ERK, conﬁrming that the
enhanced phosphorylation of ERK was mediated by
MEK (Fig. 4B).
Next, we addressed the impact of LASV binding to
cellular a-DG on laminin-induced signalling. For this
purpose, single-cell suspensions of WI-26 VA4 cells were
mixed with inactivated LASV or AMPV (10 particles per
cell) immediately before adding to plates coated with
laminin-1. The presence of the viruses did not affect the
number of adherent cells (data not shown), excluding
simple blocking of cell adhesion by the virus. After 40 min,
cells were lysed and the phosphorylation of MEK and
ERK detected. As shown in Fig. 4C, cell adhesion to
laminin-1 in presence of LASV, but not AMPV resulted in
signiﬁcantly reduced activation of MEK and ERK phos-
phorylation (Fig. 4C and D).
The MEK/ERK kinase pathway is inﬂuenced by many
cellular signalling cascades including cellular responses
to stress. To exclude artefacts due to unknown contami-
nations that may be present in our inactivated virus prepa-
rations, we performed analogous experiments with
retroviral pseudotypes for LASV and AMPV. As shown in
Fig. 4E and F, adhesion of WI-26 VA4 cells to laminin in
Fig. 3. Infection of LASV pseudotypes is independent on b1
integrins. DG (-/-) and DG (+/-), b1 integrin (-/-) and b1 integrin
(+/-) mouse ES cells cultured in 96-well plates were infected with
the retroviral pseudotypes bearing the GPs of LASV or AMPV
(moi = 10). Infection was assessed after 48 h by luciferase assay
(n = 3, SD).
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presence of pseudotypes gave similar results than
obtained with inactivated viruses. Only the presence of
pseudotypes bearing the GP of LASV, but not AMPV
signiﬁcantly reduced the induction of MEK/ERK phospho-
rylation in response to cell adhesion to laminin. Together,
the data suggest that LASV attachment to cells somehow
perturbs laminin-induced activation of the MEK/ERK
pathway.
Activity of the MEK/ERK pathway is dispensable for cell
entry of LASV pseudotypes
The ability of LASV to modulate cellular MEK/ERK signal-
ling raised the possibility that this pathway may be
involved in cell entry of the virus. To test this possibility,
we pre-treated cells with the MEK inhibitor PD98059
at concentrations that abrogated ERK phosphorylation
(Fig. 4B), followed by infection with LASV and AMPV
pseudotypes. When assessed after 48 h, pre-treatment
with the MEK inhibitor did not signiﬁcantly affect LASV
pseudotype infection, indicating that MEK/ERK signalling
is dispensable for LASVGP-mediated cell attachment and
entry (Fig. 5A). Since these ﬁrst experiments detected
infection at 48 h post infection, i.e. at a late time point, we
next examined the cell entry kinetics of LASV in presence
of the MEK inhibitor PD98059. Upon receptor binding,
LASV is taken up by clathrin- and caveolin-independent
endocytosis and rapidly delivered to late endosomes,
where low pH-dependent membrane fusion occurs
(Borrow and Oldstone, 1994; Quirin et al., 2008; Rojek
et al., 2008a,b). To assess how fast receptor-bound LASV
pseudotypes trafficked to late endosomes, we determined
the time required for the virus to become resistant to the
lysosomotropic agent ammonium chloride. When added
to cells, ammonium chloride raises the endosomal pH
rapidly and blocks low pH-dependent membrane fusion
without causing overall cytotoxicity (Ohkuma and Poole,
1978; 1981). WI-26 VA4 cells were either pre-treated with
Fig. 4. Binding of inactivated LASV to cells perturbs laminin-induced activation of the ERK-MAP kinase pathway.
A. Phosphorylation of MEK and ERK in WI-26 VA4 cells in response to cell adhesion to laminin-1. Serum-starved cells were detached and
seeded onto wells coated with laminin-1 or kept in suspension. At the indicated time points, total-cell lysates were prepared and subsequently
analysed for the presence of MEK1/2 and ERK1/2 as well as the phosphorylated forms of the kinases using speciﬁc antibodies.
B. ERK is phosphorylated via MEK: suspensions of serum-starved cells were incubated with the MEK-speciﬁc inhibitor PD98059 (50 mM) or
solvent control for 30 min and then plated onto wells coated with laminin-1 for 40 min. The phosphorylated forms of MEK1/2 and ERK1/2,
MEK2 and ERK2 were detected in total-cell lysates.
C. Binding of inactivated LASV to cells reduces laminin-induced activation of MEK and ERK: serum-starved WI-26 VA4 cells were detached,
mixed with inactivated LASV or AMPV (10 particles per cell), or no virus, and plated onto wells coated with laminin-1. After 40 min of cell
adhesion, total-cell lysates were prepared and analysed for the presence of phosphorylated MEK and ERK as in (A).
D. Quantiﬁcation of (C): the signal for phosphorylated MEK1/2 and ERK1/2 in the control samples set as 100% (n = 3, SD).
E and F. Binding of LASV pseudotypes reduces laminin-induced activation of MEK and ERK: experiment was performed as in (C) and (D)
using retroviral pseudotypes of LASV and AMPV (10 PFU per cell) and pseudotypes without GP (no GP).
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PD980592 for 1 h or mock treated with vehicle (DMSO)
only. Cells were then incubated with LASV pseudotypes in
the cold, to allow virus attachment without internalization.
Unbound virus was removed and cells quickly shifted to
37°C to allow virus internalization in presence or absence
of PD980592. After different time points, 20 mM ammo-
nium chloride was added to cells and kept throughout the
experiment. After 24 h, cells were ﬁxed and infection
assessed by detection of the luciferase reporter activity.
As shown in Fig. 5B, pre-treatment of cells with PD98059
had no signiﬁcant effects on the cell entry kinetics of
LASV pseudotypes, suggesting that activity of the MEK/
ERK pathway is dispensable for virus cell entry.
Binding of LASV pseudotypes to cells perturbs
activation of MEK and ERK via the integrin a6b1
The major laminin-binding integrins in WI-26 VA4 cells
are the integrins a6b1 and a3b1, whereas a6b4 integrin
is present only at low levels (Ferletta et al., 2003). Since
mouse laminin-1 binds only to human a6b1 but not
a3b1 integrins (Delwel et al., 1994), laminin-1-induced
activation of MEK and ERK in WI-26 VA4 cells is thought
to be mediated by a6b1 integrins (Ferletta et al., 2003).
To validate the role of a6b1 integrins in laminin-1-
induced MEK/ERK signalling in our system, serum-
starved WI-26 VA4 cells were added to tissue culture
plates coated with the signalling inducing anti-integrin a6
mAb GoH3, as well as mAb P1B5 anti-a3. Consistent
with published reports, only adhesion to the mAb anti-
integrin a6, but not anti-integrin a3 resulted in signiﬁcant
activation of MEK and ERK (Fig. 6A), conﬁrming the
role of a6b1 integrins in laminin-mediated MEK/ERK
activation.
To speciﬁcally address the effect of LASV binding to
cells on the activation of MEK/ERK via a6b1 integrin-
mediated signalling, we performed cell adhesion to mAb
anti-a6 in presence of LASV and MAPV pseudotypes.
Fig. 5. MEK1 activity is dispensable for cell entry of LASV
pseudotypes.
A. Infection of LASV pseudotypes is not affected by the MEK
inhibitor PD98059. Monolayers of WI-26 VA4 cells were pre-treated
with PD98059 (50 mM) or solvent control (DMSO) for 30 min,
followed by infection with LASV and AMPV pseudotypes
(moi = 0.1). Infection was detected by luciferase assay and fold
increase of luminescence above background is given
(means  SD, n = 3).
B. The MEK inhibitor PD98059 does not affect LASV cell entry
kinetics. Monolayers of WI-26 VA4 cells were pre-treated with
PD98059 as in (A), followed by incubation with LASV pseudotypes
(moi = 0.1) in the cold in presence of the drug. After 1 h, unbound
virus was removed and pre-warmed (37°C) medium containing the
drug added. At the indicated time points, 20 mM ammonium
chloride was added and left throughout the experiment. At 24 h
post infection was detected by luciferase assay as in (A)
(means  SD, n = 3). Please note that the apparent differences in
infection at 60 min were not statistically signiﬁcant.
Fig. 6. Binding of LASV pseudotypes to cells blocks a6b1 integrin-mediated activation of MEK and ERK.
A. Induction of MEK and ERK phosphorylation by anti-a6 integrin antibody. Serum-starved WI-26 VA4 cells were detached and plated onto
wells coated with antibodies to a6 and a3 integrin or an isotype control antibody for 40 min. Activation of MEK and ERK was determined by
Western blot.
B. Binding of LASV pseudotypes reduces MEK and ERK phosphorylation induced by anti-a6 integrin antibody: serum-starved WI-26 VA4 cell
suspensions were mixed with pseudotypes of LASV and AMPV at 10 particles per cell or control pseudotypes containing no GP (no GP) and
plated onto wells coated with antibodies to a6. After 40 min of cell adhesion total-cell lysate were prepared and phosphorylation of MEK and
ERK analysed by Western blot.
C. Quantiﬁcation of (B), setting the signal for phosphorylated MEK1/2 and ERK1/2 in the control sample (no GP) as 100% (n = 3, SD).
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Single-cell suspensions of serum-starved WI-26 VA4 cells
were mixed with LASV and MAPV pseudotypes at 10
particles per cell and immediately added to cell culture
plates coated with mAb GoH3 anti-a6 integrin At 40 min,
cells were lysed and phosphorylation of MEK and ERK
detected by Western blot. Pseudotypes of LASV, but not
AMPV speciﬁcally perturbed the activation of MEK and
ERK induced by mAb anti-a6 (Fig. 6B and C), suggesting
that LASVGP binding to cells perturbs activation of MEK
and ERK via the integrin a6b1.
LASV pseudotype-induced perturbation of a6b1
integrin-mediated signalling depends on functional DG
To address the involvement of DG in the LASV-induced
perturbation of a6b1 integrin signalling, we utilized two
well-characterized DG mutants (Fig. 7A). DGE contains
the LASV binding site but lacks the N-terminal domain
and does not undergo the post-translational modiﬁcations
required for LASV binding (Kanagawa et al., 2004).
DGDCyt lacks the cytoplasmic tail of b-DG, but shows
normal cell surface expression and virus binding (Kunz
et al., 2003). First, we veriﬁed virus-binding phenotypes of
DGE and DGDCyt. For this purpose, the DG mutants and
wild-type DG were expressed in DG (-/-) ES cells using
adenoviral (AdV) vectors (Kunz et al., 2001). After 48 h,
total-cell lysates were prepared and glycoproteins iso-
lated by wheat germ agglutinin (WGA) affinity puriﬁcation
(Michele et al., 2002). Glycoprotein fractions were sepa-
rated by SDS-PAGE and virus overlay assay performed
with inactivated LASV (Cao et al., 1998). As expected, the
a-DG part of DGE lacked detectable virus binding,
Fig. 7. Functional a-DG and the cytoplasmic domain of b-DG are involved in LASV pseudotype-induced inhibition of a6 integrin-mediated
MEK/ERK activation.
A. Schematic representation of the DG mutants.
B. Detection of the a-DG parts of the DG variants. DGE, DGDCyt, wild-type DG and GFP were expressed in DG (-/-) ES cells using AdV
vectors. After 48 h, total membrane extracts were prepared and probed with an antibody to HA and in virus overlay protein binding assay
(VOPBA).
C. Overexpression of DG DN mutants releases LASV pseudotype-induced inhibition of a6 integrin mediated MEK/ERK activation. WI-26 VA4
cells were infected with AdV expressing the DG variants. After 48 h, cells were serum-starved and detached. Single-cell suspensions were
mixed with LASV and AMPV pseudotypes and plated onto wells coated with antibody to a6. Activation of ERK was determined by Western
blot.
D. Quantiﬁcation of (B), setting the signal for phosphorylated MEK1/2 and ERK1/2 in the control sample (no GP) as 100% (n = 3, SD).
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whereas a-DG from DGDCyt and wild-type DG bound
LASV with high affinity (Fig. 7B).
To test the effect of the DG mutants on LASV-induced
modulation of a6b1 integrin signalling, WI-26 VA4 cells
were infected with AdV vectors expressing DGE, DGDCyt
and wild-type DG. After 48 h, cells were serum-starved for
16 h, detached, and added to plates pre-coated with mAb
anti-a6 integrin in presence of LASV and AMPV pseudot-
ypes. Cells were lysed and phosphorylation of ERK
assessed by Western blot. In cells overexpressing DGE
and DGDCyt the inhibition of anti-a6 integrin-induced ERK
phosphorylation by LASV pseudotypes was signiﬁcantly
released (Fig. 7C and D). As expected, no effect was
observed in cells exposed to AMPV pseudotypes (Fig. 7C
and D). The ability of the DG mutants to partially release
the LASV-induced blocking of a6b1 integrin-mediated
MEK/ERK activation suggest that LASV-pseudotype
induced perturbation of a6b1 integrin-mediated signalling
involves functional DG.
Discussion
Viruses have evolved to use a plethora of different cell
surface molecules with very different biochemical charac-
teristics and functions for host cell attachment and entry
(Smith and Helenius, 2004; Marsh and Helenius, 2006). In
some cases, the pathogens evolved to mimic the nature
of the natural ligands of their cellular receptors, like, e.g.
the integrin binding sites found in some picornaviruses
(Baranowski et al., 2003). Old World arenaviruses, includ-
ing LASV provide a striking example for this phenomenon
(Rojek et al., 2007a; Oldstone and Campbell, 2011).
Similar to DG’s ECM ligands, high-affinity binding of
arenaviruses critically depends on functional glycans
present on a-DG. A comparative study between ECM
proteins and arenaviruses revealed that the viruses mimic
the molecular mechanism of receptor binding of a-DG’s
ECM ligands in a striking manner as both recognizing
a highly conserved glycan epitope derived from the
glycosyltransferase LARGE (Rojek et al., 2007a). In the
present study we investigated the consequences of this
‘mimicry’ on the normal function of DG in the host cell, in
particular DG-mediated signal transduction.
Several lines of evidence indicate that in the host cell,
DG can associate with signalling molecules, including
components of the MEK/ERK signalling pathway, Grb2,
MEK and ERK (Yang et al., 1995; Spence et al., 2004;
Moore and Winder, 2010). However the roles of these
interactions for the cellular function of DG are currently
unclear. Engagement of cellular a-DG by LASVGP, dis-
played on either inactivated LASV virions or retroviral
pseudotypes, resulted in signiﬁcant recruitment of Grb2
and MEK1 by the DG complex. Interestingly, we were
unable to detect recruitment of the GTP exchange factor
Sos, required by Grb2 for the activation of the canonical
Ras/Raf/MEK/ERK pathway and found no evidence for
activation of MEK/ERK signalling upon virus binding at
any point, suggesting recruitment of Grb2 and MEK1 into
an inactive signalling complex. An important role for such
an inactive signalling complex for viral entry seemed
rather unlikely. We therefore investigated the effect of
these virus-induced changes on DG’s association with
Grb2 and MEK1 on the known cross-talk between DG and
b1 integrins.
Previous work by us and others showed that attach-
ment and cell entry of LASV critically depends on the
high-affinity interaction between LASVGP and cellular
a-DG (Cao et al., 1998; Kunz et al., 2005a; Reignier et al.,
2006). Our present study revealed that b1 integrins are
dispensable for attachment and cell entry of LASV
pseudotypes. However, binding of inactivated LASV and
LASV pseudotypes to cells markedly reduced the phos-
phorylation of MEK and ERK in response to laminin-1 and
signalling activating antibodies to a6b1 integrins. Using
mutants of DG, which either were deﬁcient in virus binding
or lacked the cytoplasmic tail of b-DG, we found that the
effect of LASV cell attachment on a6b1 integrin signalling
involves functional DG. Together, our data provide evi-
dence that high-affinity LASV binding to cellular a-DG
perturbs the signalling cross-talk between DG and
a6b1 integrins, shifting the normal signalling equilibrium
towards inhibition of the MEK/ERK pathway.
It is currently unclear how LASV binding to a-DG modu-
lates MEK/ERK signalling through a6b1 integrins. To acti-
vate ERK, integrins can use two distinct pathways, one,
involving FAK, and the other, the adaptor protein Shc
(Giancotti and Ruoslahti, 1999). In both pathways,
tyrosine phosphorylation of the adaptor proteins gener-
ates binding sites for the SH2 domain of Grb2, which in
turn recruits Sos leading to activation of the Ras/Raf/MEK/
ERK cascade. In contrast, binding of Grb2 to b-DG occurs
in an SH3-dependent manner (Yang et al., 1995). Here we
show that virus binding affects the association of DG with
Grb2. However, an association of DG with Grb2 and MEK1
is already detected in uninfected cells and the extent of
recruitment upon virus binding seems modest (Fig. 2F). It
seems therefore rather unlikely that virus–receptor binding
can sufficiently sequester signalling molecules like Grb2
and MEK1 to affect a6b1 integrin signalling. One might
speculate that LASV binding to DG induces a negative
regulatory signal of unknown nature that may affect a6b1
integrin-induced MEK/ERK signalling (Fig. 8).
Intrigued by the observation that binding of LASV to
cells can modulate cellular MEK/ERK signalling, we
investigated the role of this pathway for LASV cell entry.
Inhibition of MEK, which is the only kinase that can phos-
phorylate ERK, did not affect infection of cells with LASV
pseudotypes, making a role of this pathway in LASVGP-
1130 J. M. Rojek et al.
© 2012 Blackwell Publishing Ltd, Cellular Microbiology, 14, 1122–1134
mediated cell entry rather unlikely. Due to biosafety
restrictions associated with work with live LASV, a pos-
sible role of MEK/ERK signalling in post-entry steps of
LASV replication have not yet been addressed, but will be
pursued in future studies.
Since DG and a6b1 integrins are coexpressed on
a wide variety of human cell types involved in LASV
pathogenesis like epithelial cells, endothelial cells and
macrophages (Wei et al., 1998; ffrench-Constant and
Colognato, 2004) the impact of LASV binding on
DG-mediated signalling may affect normal cell function in
LASV infected individuals. A possible concern with our in
vitro studies is the relatively high particle/cell ratios used.
However, in late stages of fatal human Lassa fever, virus
loads often exceed 109 infectious particles per ml of
blood and similar virus loads are found in many tissues
(Walker et al., 1982; McCormick and Fisher-Hoch, 2002;
Moraz and Kunz, 2011). In this situation, extensive
binding of virus particles to cellular a-DG may result in
signiﬁcant perturbation of DG-mediated signalling that
may contribute to cellular dysfunctions that are associ-
ated with the Lassa shock syndrome.
In fatal Lassa fever there is surprisingly little inﬂamma-
tion and tissue destruction, vascular damage is mild and
disseminated intravascular coagulation (DIC) is rare
(Walker et al., 1982; McCormick and Fisher-Hoch, 2002).
The absence of classical hallmarks of immunopathology
in fatal disease suggests that the direct interaction of the
virus with host cells may contribute to some aspects
of pathogenesis, such as vascular leakage and oedema
formation. Among other mechanisms, the virus-induced
perturbation of ECM-induced cell signalling shown in this
study, may contribute to the functional alterations of epi-
thelial and vascular endothelial cells that precede shock
and death (Fisher-Hoch et al., 1987). This type of LASV-
induced receptor signalling reported here is likely due to
the extensive mimicry of endogenous ligand binding by
the pathogen. The consequent perturbation of cell signal-
ling appears as a ‘collateral damage’ inﬂicted on the cell
that may contribute to viral pathogenesis.
Fig. 8. Working model: binding of LASV to DG perturbs signalling cross-talk with b1 integrins.
A. Binding of laminin to cellular DG modulates MEK/ERK signalling through a6b1 integrins: laminin engages cellular DG via the LG domains 4
and 5 of the a1 chain (Hohenester et al., 1999) and binding critically depends on a-DG-linked O-glycans, in particular sugar polymers
attached by LARGE (Kanagawa et al., 2004). Binding of laminin to a6b1 integrins involves the LG domains 1–3 of a1 (Hohenester et al.,
1999) and results in activation of MEK/ERK signalling (Ferletta et al., 2003). Simultaneous binding of laminin to DG via LG4/5 inhibits
activation of MEK/ERK via a6b1 integrins (Ferletta et al., 2003).
B. High-affinity binding of LASV to cellular a-DG perturbs the signalling cross-talk between DG and a6b1 integrins (this study): binding of
inactivated LASV and LASV pseudotypes to cellular DG inhibits activation of a6b1 integrins via laminin or a signalling-inducing antibody to a6.
The effect of LASV on a6b1 integrin signalling depends on the functional O-glycosylation of a-DG and the cytoplasmic domain of b-DG. The
nature of the inhibitory signal induced by binding of laminin LG4/5 and LASV is currently unknown.
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Experimental procedures
Proteins and antibodies
Mouse laminin-1 was from Gibco-BRL (Gaithersburg, MD).
Monoclonal antibody (mAb) IIH6 anti-a-DG has been described
(Ervasti and Campbell, 1991). Polyclonal rabbit anti-laminin-1
was from Sigma (St. Louis, MO) and rabbit anti-inﬂuenza HA
(Y11) and mouse anti-HA (F7) from St. Cruz Biotechnology (St.
Cruz, CA). HRP-conjugated secondary Abs and Streptavidin-
HRP were from Pierce. MAbs to human integrins P1B5 anti-a3
and GoH3 anti-a6 were from Chemicon (Temecula, CA) and BD
Biosciences (San Jose, CA) respectively. Mouse mAbs speciﬁc
for MEK1, MEK2, ERK1 and ERK2 were from Transduction
Laboratories (Lexington, KY), rabbit polyclonal Abs against
phospho-MEK1/2 (S217/221) and phospho-ERK1/2 (T202/Y204)
were from New England Biolabs (Beverly, MA). Polyclonal rabbit
anti-Sos-1 Abs were from Upstate (Lake Placid, NY), mouse mAb
anti-Grb2 from Chemicon, and rabbit polyclonal Ab to p125FAK
from St. Cruz. The Steady Glo® and Bright-Glo® luciferase
assay systems were obtained from Promega (Madison, WI). The
MEK-speciﬁc inhibitor PD98059 was obtained from Calbiochem.
Cell lines
WI-26 VA4 cells (ATCC CCL-95.1) were cultured in DMEM,
10% (v/v) FBS, supplemented with glutamine, and penicillin/
streptomycin. Embryonic stem (ES) cells DG (+/-), DG (-/-) have
been described (Henry and Campbell, 1998). Mouse ES cells b1
integrin (+/-) and b1 integrin (-/-) (Fassler and Meyer, 1995;
Fassler et al., 1995) were kindly provided by Dr R. Fassler. All ES
cell lines were cultured as described (Henry and Campbell,
1998).
Virus strains, puriﬁcation and quantiﬁcation
Recombinant AdV DGDH30-A316 (DGE) and DGDCyt and wt DG
have been described (Kunz et al., 2001; 2003). Lassa virus
(LASV) strain Josiah and Amapari (AMPV) virus were obtained
from the collection at the Special Pathogens Branch, Center for
Disease Control and Prevention in Atlanta GA and inactivated
viruses produced as reported (Spiropoulou et al., 2002). Retro-
viral pseudotypes expressing GFP and luciferase reporters were
produced as described (Rojek et al., 2006) and, where indicated,
inactivated by UV irradiation for 5 min. Inactivation was veriﬁed
by luciferase assay.
Immunoblotting and VOPBA
Proteins were separated by gel electrophoresis and transferred
to nitrocellulose. After blocking in 5% (w/v) skim milk in PBS,
membranes were incubated with Abs used at following concen-
trations: mAb IIH6, mAb F7, mAb 8D5 and polyclonal Abs FTP,
AP83 and Y11 (10 mg ml-1) in 2% (w/v) skim milk, PBS for 12 h at
6°C. Abs to MEK1/2, ERK1/2, Sos-1, Grb-2, p125FAK, phospho-
MEK1/2 and phospho-ERK1 at 1:1000 in 2% (w/v) skim milk,
TBS for 12 h at 6°C. Secondary Abs coupled to HRP were
applied 1:5000 in PBS, 0.1% (w/v) Tween for 1 h at room tem-
perature. Blots were developed by enhanced chemilumines-
cence (ECL) using Super Signal West Pico ECL Substrate
(Pierce). Laminin overlay assay (LOA) and VOPBA with
g-inactivated LASV, and AMPV were performed as described
(Kunz et al., 2005b).
Virus cell binding assay
Monolayers of WI-26 VA4 cells were cultured in 96-well microti-
tre plates. For virus binding, medium was removed, cells
washed twice with PBS, chilled on ice and blocked for 1 h in 1%
(w/v) FBS/PBS containing 0.1% (w/v) of sodium azide. Cells
were incubated with the indicated concentrations of inactivated
LASV and AMPV in 1% (w/v) FBS/PBS/0.1% (w/v) sodium
azide. After 1 h on ice, cells were washed three times with cold
PBS and ﬁxed with 4% (w/v) paraformaldehyde supplemented
with 0.1% (w/v) glutaraldehyde for 20 min in ice. For detection of
bound virus, cells were incubated with mAb 83.6 (20 mg ml-1
puriﬁed IgG) overnight in the cold. After three washes in PBS,
primary antibody was detected with goat anti-mouse IgG conju-
gated to HRP for 45 min in the cold. After three wash-steps in
PBS, HRP-conjugated secondary antibody was detected in a
colour reaction using ABTS [2,2′azino-bis(3-ethylbenzthiazoline-
6-sulfonic acid)] substrate and OD405 detected in an ELISA
reader.
Infection of cells with retroviral pseudotypes
Cells were plated in 96-well plates in a density of 104 cells per
well. After 24 h, retroviral pseudotypes were added at the indi-
cated moi and incubated for 1 h at 37°C. The viral particles were
removed, cells washed twice with DMEM and fresh medium
added. Luciferase activity was determined by Steady-Glo®
luciferase assay except in murine ES cells. AdV-mediated gene
transfer of wild-type DG and the DG DN mutants DGE (DH30-
A316) and DGDCyt was performed as described (Kunz et al.,
2005b). After 48 h, the indicated infectious units (iu) of pseudot-
ypes were added to AdV transfected DG (-/-) ES cells, as well as
untreated control cells and incubated for 1 h at 37°C. The viral
particles were removed, cells washed twice with DMEM and fresh
medium added. Infection was quantiﬁed by Bright Glo® luciferase
assay. Luminescence was calculated as fold increase over back-
ground signals obtained from uninfected cells. Cell entry kinetics
of LASV pseudotypes were performed as described (Rojek et al.,
2008b). Blocking of infection with mAb IIH6 was done as reported
(Kunz et al., 2005b).
Co-immunoprecipitation
For virus binding and co-IP of b-DG with signalling molecules,
WI-26 VA4 cells were transfected with DGHA and DGwt with
Superfect® (QIAGen). After 48 h, cells were exposed to puriﬁed,
inactivated LASV, AMPV, or LASV- and AMPV pseudotypes at
a particle to cell ratio of 1:100 for the indicated time periods. To
detect changes in the association of signalling molecules with
b-DG, co-IP was performed as described (Rojek et al., 2007b)
using either mAb F7 or Y11 immobilized on Sepharose 4B for
IP of DHHA and the abovementioned Abs for detection of sig-
nalling molecules in Western blot. IP with mouse mAb F7 were
analysed with polyclonal rabbit Abs and IP with pAb Y11 with
mouse mAbs.
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Detection of MEK/ERK activation by cell adhesion to
laminin and anti-a6 integrin Abs
Cell adhesion assays were performed according to Ferletta et al.,
2003. MEK/ERK activation was detected from WI-26 VA4 cells that
had been seeded to conﬂuence, serum starved for 16–24 h,
detached and plated on laminin-1 or wells pre-coated with mAbs to
a3 and a6 integrins in presence or absence of puriﬁed inactivated
LASV, AMPV, or LASV- and AMPV pseudotypes at a particle to
cell ratio of 1:10 for the indicated time periods. Phosphorylated and
total MEK and ERK were determined by Western blot as described
above and the degree of phosphorylation determined as
described (Ferletta et al., 2003) using densitometry (Kunz et al.,
2004). For overexpression of the DN DG mutants DGE and
DGDCyt and wt DG in WI-26 VA4 cells we used AdV vectors
(moi = 100) for gene transfer as described (Kunz et al., 2005b).
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Prevalence
a  b  s t r a  c t
Lymphocytic  choriomeningitis virus  (LCMV) is a rare  cause  of central nervous  system disease in humans.
Screening  by  real-time RT-PCR  assay  is of interest  in the  case  of aseptic meningitis  of unknown etiology.
A  speciﬁc  LCMV  real-time RT-PCR  assay, based  on the  detection of genomic  sequences  of the  viral
nucleoprotein  (NP),  was developed  to assess the  presence  of LCMV  in cerebrospinal  ﬂuids (CSF)  sent for
viral  screening to  a Swiss  university  hospital  laboratory.
A  10-fold  dilution  series  assay  using a plasmid  containing  the  cDNA of the  viral  NP of  the  LCMV  isolate
Armstrong  (Arm)  53b demonstrated  the  high  sensitivity  of the  assay  with  a lowest  detection  limit  of
≤50 copies per reaction.  High sensitivity  was  conﬁrmed  by  dilution  series  assays in a pool  of  human  CSF
using four  different LCMV  isolates  (Arm53b,  WE54,  Traub  and E350) with  observed  detection limits of
≤10 PFU/ml  (Arm53b  and WE54)  and 1 PFU/ml (Traub  and  E350).
Analysis  of 130 CSF showed  no  cases  of acute  infection.  The absence  of positive  cases  was  conﬁrmed
by a published  PCR assay  detecting  all Old  World  arenaviruses.
This  study  validates a  speciﬁc and  sensitive  real-time  RT-PCR  assay  for  the  diagnosis  of LCMV  infections.
Results  showed  that  LCMV  infections  are extremely  rare in hospitalized patients  western in Switzerland.
© 2011 Elsevier B.V. All rights reserved.
Lymphocytic choriomeningitis virus (LCMV), the prototypic
member of the Arenaviridae family, was isolated from a  fatal case
of aseptic meningitis during the St. Louis encephalitis epidemic in
1933 (Armstrong and Lillie, 1934).
In nature, LCMV is maintained by congenital transmission
within infected populations of the mouse species Mus  domesticus
and Mus  musculus. LCMV infects readily other rodents, including
hamsters and guinea pigs. The LCMV carrier state is  characterized
by persistent infection with high virus loads in  serum and sev-
eral organs in  the absence of a  virus-speciﬁc immune response and
overt pathology. Humans are accidental hosts and the main route
of transmission is  by contact with infected rodents that shed large
∗ Corresponding author at: Laboratory of Virology, Division of Infectious Dis-
eases, University of Geneva Hospitals, 4  Rue Gabrielle-Perret-Gentil, 1211 Geneva
14, Switzerland. Tel.: +41 22 3724079; fax: +41 22  3724097.
E-mail address: samuel.cordey@hcuge.ch (S. Cordey).
1 These authors contributed equally to this work.
quantities of virus in nasal secretions, saliva, milk, semen, urine,
and feces.
Although human LCMV cases are observed throughout the year,
disease incidence increases in winter, due probably to the move-
ment of infected rodents indoors, thus increasing the risk of  human
exposure (Barton et al., 1993). In immunocompetent adult indi-
viduals, LCMV infection is  either asymptomatic or results in  a
self-limiting febrile illness associated rarely with fatalities. Signs
and symptoms are largely non-speciﬁc, including fever, myalgia,
and malaise. Central nervous system involvement manifests as
headache and photophobia, associated with nausea or vomiting.
In most cases, infected individuals recover completely, but this
may require several months. Severe aseptic meningitis or menin-
goencephalitis is observed only in  a  minority of  cases (Barton
et al., 1993). Human-to-human transmission has been documented
through organ donation associated with severe disease in  the
immunocompromised recipient (Fischer et al., 2006), and congeni-
tal infections leading to severe and irreversible brain (Barton et al.,
1993; Barton and Mets, 2001; Bonthius et al., 2007; Wright et al.,
0166-0934/$ – see front matter ©  2011 Elsevier B.V. All rights reserved.
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1997) and retinal (Bonthius et al., 2007; Mets et al., 2000) injury
have been described.
Acute human LCMV infections are diagnosed generally by virus
isolation from CSF and the use of serological testing or  classical PCR
assays (Park et al., 1997; Emonet et al., 2007) offer the possibility
to detect pre- and postnatal LCMV infections. More recently, SYBR
Green-based quantitative PCR assays were developed to  quantify
LCMV in  infected mice (McCausland and Crotty, 2008; Emonet et al.,
2007). Due to their higher sensitivity and speciﬁcity compared to
both viral culture and immunoﬂuorescence-based detection meth-
ods, RT-PCR viral assays are favored for the diagnosis of viral
infection in  most routine laboratories.
A real-time RT-PCR assay with speciﬁc primers and probes
adapted to published LCMV sequences available was developed to
screen acute LCMV infections in CSF. The use of a  speciﬁc probe has
the main advantage to  increase the LCMV-speciﬁcity compared to
SYBR Green PCR methods. Over a  period of two years, all hospital-
ized pediatric cases and adults less than 25-years-old for whom a
screening for viral meningoencephalitis was required by  the physi-
cian at the University of Geneva Hospitals were screened for LCMV
infections using this real-time RT-PCR.
To identify primers and probes, conserved regions speciﬁc to
LCMV were screened based on an extensive alignment of all LCMV
and Old  World arenavirus’s sequences available in  Genbank in
August 2010, including all recently discovered arenaviruses (Briese
et al., 2009; Gunther et al., 2009; Palacios et al., 2008). This align-
ment allowed to  pinpoint a conserved region within the viral
nucleoprotein (NP) gene. Primer pairs were designed to corre-
spond to the least number of combinations matching perfectly
each distinct LCMV sequence. Therefore, the primers used in the
PCR are constituted of a mix  of 9 and 8 selected forward and
reverse primers, respectively (Fig. 1). Primers and probe (Eurogen-
tech, Seraing, Belgium) were screened by  NCBI nucleotide BLAST
(Altschul et al., 1990) to exclude any cross-reactions with human
cellular sequences and distantly related viruses. The probe was
labelled at the 5′ end with the 6-carboxyﬂuorescein (FAM) and at
the 3′ end with the BHQ1 black hole quencher. In brief, the viral
genome was extracted individually from 400 l  of samples using
the NucliSENS easyMAG (bioMérieux, Geneva, Switzerland) nucleic
acid kit, according to  the manufacturer’s instructions. In addi-
tion, 20 l  of standardized canine distemper virus (CDV) of known
concentration was added to  each sample before extraction to  con-
trol for intra- and inter-assay variability as previously described
(Cordey et al., 2010). To remove a maximum of DNA contami-
nant in eluates, a  DNAse treatment was done using the DNA-free
kit (Ambion, Rotkreuz, Switzerland), according to the manufac-
turer’s instructions. This step was necessary for optimal sensitivity
in the presence of more than 5 ng/ml of human DNA in the sam-
ple. The synthesis of cDNA was performed with random hexamers
(Roche, Rotkreuz, Switzerland) at 42 ◦C using the Superscript II
Reverse Transcriptase (Invitrogen, Basel, Switzerland), according
to the manufacturer’s instructions. cDNA was ampliﬁed using a
TaqMan® 7500 (Applied Biosystems, Rotkreuz, Switzerland) ther-
mocycler under the following cycling conditions: 95 ◦C for 9 min; 50
cycles of 15 s at 95 ◦C and 1 min  at 58 ◦C. After assessment of optimal
primers/probe concentrations, the reaction was performed in  20 l
containing 1× TaqMan® Universal PCR Master Mix  (Applied Biosys-
tems), 0.2 M of each individual LCMV forward primer, 0.2 M of
each individual LCMV reverse primer, 0.2 M of LCMV probe per
reaction, and 5 l  of cDNA. Results were analyzed using the SDS 1.4
program (Applied Biosystems).
The analytical sensitivity of the LCMV real-time RT-PCR was
determined using the mammalian expression plasmid pcAGGS
containing the cDNA of the NP derived from the LCMV isolate
Armstrong (Arm) 53b in 10-fold serial dilutions. The experiment
showed a linear range between 50 and 5 × 104 copies of input
with the lowest limit of detection being ≤50  copies per reac-
tion (Fig. 2). Of note, 5 plasmid copies were detected only in
one of the triplicate wells. Sensitivity was assessed further using
crude stocks of the LCMV isolates LCMV-Arm53b, LCMV-WE54,
LCMV-Traub, and LCMV-E350 grown in BHK21 cells (Table 1)
which were diluted serially in  a  pool of human CSF negative for
LCMV. The four LCMV isolates showed low limits of detection in
plaque-forming units (PFU) determined by immunofocus assay
(≤10 PFU/ml for Arm53b, ≤10 PFU/ml for WE54, ≤1 PFU/ml for
Traub, and ≤1 PFU/ml for E350). Similarly, dilution series assays
performed in phosphate buffered saline showed a  reproducible
detection limit of ≤1 PFU/ml for each LCMV isolate, thus suggest-
ing the presence of defective interfering particles, a  well-known
phenomenon with LCMV (Martinez Peralta and Lehmann-Grube,
1983; Francis and Southern, 1988; Meyer and Southern, 1997).
In addition, the recently identiﬁed LCMV-Marseille strain super-
natant (Emonet et al., 2007) has also been tested positive. To assess
the potential speciﬁcity of this real-time RT-PCR, the genetically
more distant New World arenaviruses, Junin virus and Pichinde
virus isolates, as well as individual pcAGGS plasmids containing
the cDNA of the NP derived from Lassa virus, Machupo virus,
Tacaribe virus, Latino virus, and Whitewater Arroyo virus were
examined also (Table 1). Consistent with their phylogenetic dis-
tance from LCMV, none of these arenaviruses was detected by
the assay, except Lassa virus for which a weak cross-reaction was
observed at a  very high concentration, although a  minimum of
1 and 4 mismatches are present in the forward and the reverse
primer sets, respectively. This cross-reaction can be explained by
the extremely high sequence homology between Lassa and LCMV.
Therefore, cross-reaction events should be  considered for samples
with CT (threshold value) values close to the limit of  positivity
determined at 40 CT.  Finally, a  large panel of unrelated virus isolates,
including herpes simplex virus, varicella zoster virus, Epstein–Barr
virus, JC virus, measles virus, enterovirus and parechovirus, belong-
ing to other virus families known to  lead potentially to  meningitis
or meningoencephalitis complications, remained undetected with
the LCMV real-time RT-PCR.
All hospitalized pediatric cases and adults less than 25  years old
who  underwent a CSF screening with negative results for selected
viral infections (enterovirus, parechovirus, herpes simplex virus,
varicella zoster virus, Epstein–Barr virus, JC virus, and/or measles
virus) between October 2008 and September 2010 were assessed
for LCMV with the newly developed real-time RT-PCR assay.
Of a  total of 130 CSF samples (56 female [43%]; 74 male [57%];
median age, 2 years old), 51 (39%) were collected in infants less
than 1-year-old. The clinical syndromes ranged from meningitis,
encephalitis, convulsions, and other central nervous system dis-
eases. The analysis covers two  winter seasons known to represent
the peak window period of infection.
None of the 130 CSF samples was found positive for LCMV. Since
the design of the speciﬁc LCMV primers and probe was based on the
available sequence information in Genbank at that time, the pres-
ence of yet unknown strains of LCMV circulating in rodents and
transmitted to humans cannot be ruled out. To address this issue,
a  previously published pan-arenavirus RT-PCR (Vieth et al., 2007)
capable of detecting all currently known Old World arenavirus
species, including LCMV, Lassa virus, and Mobala virus, was used.
When applied to  the 130 CSF samples, none was positive for LCMV,
similar to the results obtained with the speciﬁc LCMV real-time
RT-PCR assay described above.
This report describes the analytical validation of a LCMV real-
time RT-PCR assay allowing rapid detection of LCMV strains that
have been shown to infect humans.
Despite important efforts to contact most investigators with
documented cases of human LCMV infections over the last few
years, it was not possible to obtain such rare clinical samples due
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Fig. 1. Primers and probe for LCMV real-time RT-PCR assay. (a)  Nineteen LCMV NP  reference sequences indicated by their Genbank accession numbers (EU480452, EU480450,
DQ868487, DQ118959, M22138, DQ868485, DQ286931, AB261990, AB261991, FJ895883, FJ895884, FJ895882, AF325215, AF325214, DQ868483, DQ361065, AY847350,
M20869.1 and NC004294) were aligned with the MAFFT algorithm in the Geneious software package. Consensus was  established with 100% identical residue at each
position. Conserved residues are indicated by  dots and polymorphic residues by  their actual IUPAC code. The most conserved area, shown here as double stranded cDNA, was
used  as the target for the real-time RT-PCR assay. The primer sequences are boxed in strand-speciﬁc arrows. The forward primers (F1–F9) are on  the coding (upper) strand
and  the reverse primers (R1–R8) are on the complementary (lower) strand. The probe is  shown in bold fonts in the upper strand of the consensus sequence; capital letters
indicate LNA residues used to increase its  melting temperature. LNA residues were positioned within this highly conserved area to  limit the risk of false negativity with
unknown LCMV sequences. Numbers on top  refer to the 5′ end of the primer/probe positions within the NP open reading frame using the Armstrong strains as reference.
LCMV phylogeny is depicted by the tree on  the left-hand side pointing to each individual reference sequence. Primer combination adapted to the ampliﬁcation of each
genotype is shown to the right of the accession number and refers to the primer names indicated in (b) (F, For; R, Rev).
to the very limited amount of CSF collected initially. Nevertheless,
serial dilutions of both Arm-derived plasmid and different LCMV
strains cultures in a  pool of CSF conﬁrmed the high analytical sen-
sitivity of the new assay with limits of detection reaching ≤50
copies per reaction and ≤10 or 1 PFU/ml, respectively, indicating
a potential high clinical sensitivity.
Irrespective of the PCR assay used (LCMV speciﬁc real-time
RT-PCR and classical broad range arenavirus PCR), LCMV was
not detected in any CSF samples over the study period. These
results show the extremely low incidence of LCMV infections
leading to hospital admission for acute meningoencephalitis in
western Switzerland and conﬁrm previous prospective surveil-
lance investigations conducted elsewhere. For instance, Park et al.
(1997) found no positive case for LCMV among a total of  813
CSF samples collected over a  one-year period at two  Birming-
ham (UK) hospitals. Only extensive serological studies at country
level may  reveal the prevalence of LCMV within the human
population.
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Table  1
Performance of the LCMV real-time RT-PCR for the detection of different LCMV and other arenavirus strains.
Strain L  CMV  real-time RT-PCR Limit of detection Slope R2
LCMV-ARM53b Positive ≤10 PFU/ml (in CSF) 3.62 1
LCMV-WE54 Positive ≤10  PFU/ml (in CSF) 3.91 0.99
LCMV-Traub Positive ≤1 PFU/ml (in CSF) 3.87 1
LCMV-E350 Positive ≤1 PFU/ml (in CSF) 3.65 1
LCMV-Marseille Positive ND ND ND
Lassa  Weak positive cross-reaction (CT > 39) Tested for 104 plasmid copies/PCR
Tacaribe Negative Tested for 104 plasmid copies/PCR
Machupo Negative Tested for 104 plasmid copies/PCR
Latino Negative Tested for 104 plasmid copies/PCR
Whitewater Arroyo Negative Tested for 104 plasmid copies/PCR
Junin Negative Tested for 105 copies/ml (in plasma)
Pichinde Negative Tested for 105 copies/ml (in plasma)
Fig. 2.  Analytical sensitivity of the LCMV real-time RT-PCR assay. 10-Fold serial
dilutions of Armstrong-derived plasmid (5 × 104–5 ×  101 copies per reaction) were
tested by real-time RT-PCR assay. The log of copy numbers is  plotted versus the
threshold cycle (CT). Each dot represents the average of three independent exper-
iments. Of note, a  dilution with 5  ×100 plasmid copies showed positive detection
in  only one single triplicate. It was not considered for slope calculation. Errors bars
indicate standard deviations.
The real-time RT-PCR assay described here provides a  sensitive
and adapted tool for specialized clinical laboratories.
Although the current study did not  reveal the presence of acute
LCMV infection in children and young adults over the past two
years in  western Switzerland, potential infections should not be
overlooked as clinical complications related to LCMV have been
observed in sporadic cases throughout the world (Asnis et al.,
2010; Ceianu et al., 2008; Emonet et al., 2007; Sosa et al., 2009).
In addition, this real-time RT-PCR assay could be used in  rodents,
particularly in pet shops, as they represent the principal LCMV
reservoir.
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Arenavirus hemorrhagic fevers are 
devastating emerging human diseases
Viral hemorrhagic fevers (VHFs) are severe 
human diseases that show different clinical 
courses and are associated with the cardinal 
symptoms of fever, hemorrhages and shock. A 
wide variety of viruses that belong to different 
virus families can cause VHFs, including the 
ﬁloviruses (Ebola and Marburg hemorrhagic 
fever [HF]), the arenaviruses (Lassa fever, 
Argentine HF [AHF], Bolivian HF, Venezuelan 
HF and Brazilian HF), bunyaviruses (Crimean 
Congo HF and Rift Valley fever) and ﬂavi-
viruses (Yellow fever and Dengue HF) [1]. The 
arenaviruses are a large and diverse family of 
enveloped RNA viruses that include several 
causative agents of severe VHFs, which belong 
to the most devastating emerging human dis-
eases and serious public health problems [1,2]. 
Arenavirus VHFs in humans are acute diseases 
characterized by fever and, in severe cases, dif-
ferent degrees of hemorrhages associated with 
a shock syndrome in the terminal stage. The 
most prevalent pathogen among the arenavi-
ruses is Lassa virus (LASV), the causative agent 
of Lassa fever that is endemic to West Africa 
from Senegal to Cameroon and causes several 
hundred thousand infections per year with thou-
sands of deaths [3]. The mortality of hospitalized 
Lassa fever patients is 15–30% and can reach 
more than 50% in some outbreaks. There is 
currently no vaccine available and therapeutic 
intervention is limited to intensive care and the 
use of ribavirin, which shows some efﬁcacy when 
given early in disease. On the South American 
continent, the arenaviruses Junin virus (JUNV), 
Machupo virus (MACV), Guanarito virus 
(GTOV) and Sabia virus (SABV) have emerged 
as etiological agents of severe VHF in Argentina, 
Venezuela, Bolivia and Brazil, respectively [2]. 
The prototypic arenavirus lymphocytic chorio-
meningitis virus (LCMV), which is distributed 
worldwide, is also a neglected human pathogen 
of clinical signiﬁcance, especially in pediatric 
medicine [4,5] and represents a threat to immu-
nocompromised individuals [6,7]. Considering 
the number of people affected and the unad-
dressed need for better therapeutics, arenaviruses 
arguably belong to the most neglected tropical 
pathogens. Apart from the severe humanitarian 
burden in endemic regions, arenavirus HF cases 
are regularly imported into metropolitan areas 
around the globe, placing local populations at 
risk [8]. This article will brieﬂy cover some gen-
eral aspects of the classiﬁcation, epidemiology 
and basic virology of arenaviruses, and will then 
provide a more detailed overview of the clini-
cal disease, and in particular the pathogenesis 
of arenavirus VHFs with an emphasis on recent 
developments in the ﬁeld. 
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Viral hemorrhagic fevers (VHFs) caused by arenaviruses belong to the most devastating emerging 
human diseases and represent serious public health problems. Arenavirus VHFs in humans are 
acute diseases characterized by fever and, in severe cases, different degrees of hemorrhages 
associated with a shock syndrome in the terminal stage. Over the past years, much has been 
learned about the pathogenesis of arenaviruses at the cellular level, in particular their ability to 
subvert the host cell’s innate antiviral defenses. Clinical studies and novel animal models have 
provided important new information about the interaction of hemorrhagic arenaviruses with 
the host’s adaptive immune system, in particular virus-induced immunosuppression, and have 
provided the ﬁrst hints towards an understanding of the terminal hemorrhagic shock syndrome. 
The scope of this article is to review our current knowledge on arenavirus VHF pathogenesis 
with an emphasis on recent developments.
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Classiﬁcation & epidemiology of arenaviruses
The Arenaviridae are currently subdivided into two major sub-
groups, the Old World arenaviruses and the New World arena-
viruses [9,10]. The Old World lineage contains the prototypic 
LCMV, the related Dandenong virus and the African viruses 
LASV, Mopeia, Mobala, Ippy and Morogoro virus. The New 
World arenaviruses are divided into three Clades, A, B and C. 
Clade A includes the South American viruses Pichinde virus, 
Parana virus, Pirital virus, Flexal virus and Allpahuayo virus. A 
North American Clade A/Rec comprises Whitewater Arroyo, 
Bear Canyon, and Tamiami, Catarina and Skinner Tank virus. 
The phylogenetic relationship of these viruses is poorly resolved, 
but there is evidence that a recombination event between Clade 
A and B viruses may be at the origin of this Clade as reviewed by 
Emonet et al. [9]. Whitewater Arroyo virus has been associated 
with three cases of fatal human disease [11,12]. However, a deﬁni-
tive causal relationship has not yet been established. Clade B con-
tains the hemorrhagic viruses JUNV, MACV, GTOV, SABV and 
the recently emerged Chapare virus, as well as the nonpathogenic 
viruses Tacaribe (TACV), Amapari and Cupixi. Clade C contains 
the viruses Oliveros, Latino and Pampa. 
In nature, each arenavirus species is carried by one or a limited 
number of related rodent species, which serve as their natural 
reservoirs. A possible exception is TACV, which has only been 
isolated from the fruit-eating bat species Artibeus. The present 
phylogenetic diversity of arenaviruses is the result of long-term 
co-evolution between viruses and their corresponding host spe-
cies, involving vertical and horizontal transfer of viruses within 
and between populations, respectively, and probably occasional 
genetic recombination events [9,10,13]. 
A particular concern is the continued emergence of novel 
arenaviruses that are associated with fatal human disease. New 
arenaviruses emerge on average every 3 years [9]. In December 
2003, a small cluster of fatal VHF cases was reported in a rural 
area near the Chapare River in Bolivia, Southern America. 
Examination of patient samples allowed the isolation and identi-
ﬁcation of Chapare virus, a novel species of arenavirus phyloge-
netically closely related to SABV [14]. More recently, in September 
2008, a nosocomial outbreak of unexplained VHF occurred in 
Zambia, Southern Africa. Five patients were involved and four 
of them died with suspected human-to-human transmission. A 
high-throughput sequencing approach based on unbiased pyro-
sequencing revealed the presence of an arenavirus-like genome 
identiﬁed as a new member of the Arenaviridae family called LuJo 
virus according to its geographic distribution: Lusaka, Zambia 
and Johannesburg, South Africa [15]. The high mortality of four 
out of ﬁve hospitalized individuals and the strong evidence for 
human-to-human transmission are of particular concern regard-
ing the epidemiological and disease potential of this new member 
of the arenavirus family. 
Human arenavirus infections occur principally by aerosol or close 
contact with rodent excreta, contamination of food and drink or via 
skin abrasions. AHF caused by JUNV has a marked seasonal inci-
dence, coinciding with the maize harvest between April and June 
when feral rodent populations reach their peak [16]. Agricultural 
workers and those in rural communities are thus at greatest 
risk. It is thought that transmission to humans results from the 
virus being carried on dust particles or by direct  ingestion of 
 contaminated foodstuffs. 
Molecular & cell biology of arenaviruses
The basic virology of arenaviruses has been covered by excellent 
recent reviews [2,17] and only a short summary will be given here. 
Arenaviruses are enveloped viruses with a bisegmented negative 
strand RNA genome and a nonlytic life cycle restricted to the cyto-
plasm (FIGURE 1A). Each genomic RNA segment, L (circa 7.3 kb) and 
S (circa 3.5 kb), uses an ambisense coding strategy to direct the 
synthesis of two polypeptides in opposite orientation, separated by 
a noncoding intergenic region with a predicted hairpin structure 
(FIGURE 1B). The S RNA encodes the viral glycoprotein (GP) pre-
cursor, which is synthesized as a single polypeptide chain (circa 
75 kDa) and post-translationally cleaved by the cellular proprotein 
convertase subtilisin kexin isozyme-1/site-1 protease to yield the 
mature virion GPs GP1 (40–46 kDa) and GP2 (35 kDa) [18–20], 
and the nucleoprotein (NP; circa 63 kDa). The L RNA encodes the 
viral RNA dependent RNA polymerase (RdRp or L polymerase; 
circa 200 kDa) and a small RING ﬁnger protein Z (circa 11 kDa). 
Attachment to the host cell is mediated by the arenavirus GP1, 
which is located at the top of the mature GP spike present in the 
viral envelope. The transmembrane GP2 resembles the fusion-
active membrane-proximal parts of other enveloped viruses. The 
cellular receptor for LASV, most other Old World arenaviruses 
and Clade C New World arenaviruses is D-dystroglycan (D-DG), 
a cell surface receptor for proteins of the extracellular matrix 
[21,22]. The hemorrhagic New World arenaviruses JUNV, MACV, 
GTOV and SABV can use human transferrin receptor 1 (TfR1) 
[23]. Upon attachment to the target cell, arenavirus particles are 
taken up by endocytosis and delivered to acidiﬁed endosomes 
where low pH induces membrane fusion [24]. New World are-
naviruses like JUNV that use human TfR1 enter the cell via 
clathrin-mediated endocytosis [25]. In contrast, the Old World 
arenaviruses LASV and LCMV, which depend on D-DG, use a 
distinct and unusual pathway for cell entry that is independent of 
clathrin, caveolin, dynamin and actin [26–28]. Upon penetration 
into the cytoplasm, the viral ribonucleoparticles serves as a tem-
plate for both transcription and replication that is mediated by the 
arenavirus RdRp L. The L and NP proteins are necessary and suf-
ﬁcient for these initial steps of viral transcription and replication 
[17]. Formation and release of arenavirus infectious progeny from 
infected cells occurs by budding during which ribonucleoparticles 
associate at the cell surface with membranes that are enriched in 
viral GPs. In arenaviruses, the Z protein functions as the main 
driving force for viral budding and resembles the matrix proteins 
of other enveloped RNA viruses [29,30]. 
Clinical disease & pathogenesis of Lassa fever
LASV was isolated in 1969 after a hospital outbreak in north-
ern Nigeria [31,32], with additional outbreaks in Nigeria, Liberia 
and Sierra Leone. In 1972, the reservoir of LASV was identi-
ﬁed as the rodent Mastomys natalensis [33]. Currently, LASV is 
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endemic from Senegal to Cameroon [3] with recent emergence in 
Mali [34]. Reliable epidemiological data are missing from most 
affected regions, however, available information on seroprevalence 
for Nigeria, Sierra Leone and Guinea reveal that in some areas, 
20–50% of the adult population have been infected with LASV 
[35], making LASV a major public health problem. Contact with 
urine or feces of persistently infected rodents invading human 
dwellings are the main routes of human transmission, and human-
to-human spread can occur by contact with contaminated blood 
or body ﬂuids [36,37]. The fatality rate of Lassa fever in hospitalized 
patients is between 15 and 20% [38], rising to more than 30% in 
pregnant women in the third trimester with fetal or neonatal loss 
of 88% [39]. The fatality ratio can be as high as 50% or greater in 
nosocomial outbreaks [37].
Acute Lassa fever presents with a wide spectrum of clinical 
manifestations from asymptomatic infection to fatal HF, and 
diagnosis based on early clinical symptoms is often difﬁcult [38]. 
After an incubation period of 7–18 days, patients develop fever, 
weakness and general malaise. A majority 
of patients develop cough, severe headache 
and sore throat. Gastrointestinal manifes-
tations such as nausea, diarrhea and vomit-
ing are frequent. Signs of increased vascular 
permeability such as facial edema and pleu-
ral effusions occur in a minority of patients 
and indicate a poor prognosis. With severe 
cases leading to death, deterioration is 
rapid, occurring between the sixth and 
tenth day of illness with progressive signs 
and symptoms of pulmonary edema, respi-
ratory distress, shock, signs of encephalopa-
thy accompanied with seizures and coma, 
and bleeding from mucosal surfaces. Those 
recovering, generally 2–3 weeks after dis-
ease onset, clear the virus from the blood. 
A complication late in the course of disease 
or in early convalescence is sensorineural 
deafness [40]. 
A highly predictive factor for the out-
come of LASV infection is the extent of 
viremia. Patients with fatal Lassa fever 
have higher viral loads at time of hospi-
talization and are unable to limit viral 
replication, whereas survivors have lower 
initial viral load and control the infection 
[41]. Despite the widespread infection and 
development of shock in terminal stages 
of the disease, histological examination of 
fatal Lassa fever cases showed surprisingly 
little cellular damage and only a mod-
est inﬁltration of inﬂammatory cells [42]. 
Hepatic lesions in the form of multifocal 
hepatocellular necrosis were a consistent 
pathological change [42,43]; however, the 
degree of hepatic tissue damage was insuf-
ﬁcient to cause hepatic failure and only minimal recruitment of 
inﬂammatory cells was observed. High viral titers were detected 
in the lung, spleen, kidney, heart and the adrenal gland [42]. Other 
histological alterations included interstitial pneumonia and acute 
myocarditis. In the spleen, necrosis occurred predominantly in the 
marginal zone of the splenic periarteriolar lymphocytic sheath.
A hallmark of fatal LASV infection in humans is the inability 
of the patient’s innate and adaptive immune system to contain 
the virus, resulting in uncontrolled fatal infection. Instead of 
being recognized and contained by the host cell’s innate defense 
system, pathogenic arenaviruses are able to subvert the normal 
mechanisms of innate pathogen recognition. The elucidation of 
the innate immune defense against arenaviruses and the mecha-
nisms of viral countermeasures have been a particularly active 
area of arenavirus research in the past 5 years. As is the case 
for other RNA viruses, the genomic RNA of arenaviruses can 
be recognized by the cytoplasmic RNA helicases of the reti-
noic acid-inducible gene I (RIG-I) family, which represent the 
Figure 1. Arenavirus particle and genome organization. (A) Schematic 
representation of an arenavirus particle. The viral RNA is packaged into 
ribonucleoparticles (RNPs) containing the viral NP. The RNA-dependent RNA polymerase 
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major innate sensors for viral RNA and induce the production 
of type I interferons (IFNs) [44,45]. However, cells infected with 
arenaviruses are unable to induce a type I IFN response owing 
to the ability of the viral NP to act as an IFN antagonist [46,47]. 
Mechanistically, the NPs of arenaviruses block the activation 
of the transcription factor IFN regulatory factor 3 (IRF3), a 
major downstream regulator of type I IFN induction via RIG-I 
helicases [46]. The ability of arenavirus NP to block type I IFN 
induction is conserved among arenaviruses, with the exception 
of TACV, whose NP is much less efﬁcient [48]. In contrast to Old 
World arenaviruses, where the NP appears to be the only IFN 
antagonist, the matrix protein Z derived from the New World 
HF viruses JUNV, MACV, GTOV and SABV is also able to 
perturb the activation of RIG-I [49]. The Z protein of New World 
HF viruses directly interacts with RIG-I and blocks the activa-
tion of downstream signaling involving IRF3 and NF-NB via the 
adaptor mitochondrial antiviral signaling protein. Interestingly, 
arenaviruses selectively prevent the induction of type I IFNs, but 
do not perturb signaling induced by the addition of exogenous 
type I IFNs [46]. The role of the type I IFN response in survivors 
of LASV infection is not clear. Recent studies in nonhuman 
primates revealed production of type I IFNs early in LASV infec-
tion of animals that survived [50], however, the source of IFN 
has not been clearly identiﬁed and it is at present not clear what 
role this IFN response plays in protection. 
Fatal Lassa fever is characterized by a marked suppression of 
both branches of the adaptive immune response, cellular and 
humoral immunity. Surviving Lassa fever patients control the 
infection primarily by cellular immunity, in particular the anti-
viral T-cell response [51,52]. By contrast, antibodies play a modest 
role in acute LASV infection as patients can recover in the absence 
of a neutralizing antibody response [41]. The marked virus-induced 
immunosuppression in fatal Lassa fever likely involves infection 
of antigen-presenting cells (APCs), in particular macrophages 
and dendritic cells (DCs), crucial populations of professional 
APCs required to induce the adaptive antiviral immune response 
(FIGURE 2) [3]. Infection of human monocyte-derived macrophages 
and DC with LASV in vitro fails to activate the cells and results 
in an impairment of their ability to present antigens to T cells 
[53,54]. LASV infection of macrophages and DCs is not associ-
ated with the release of proinﬂammatory cytokines [53,54] and 
fatal Lassa fever in humans and nonhuman primates seems not 
to be associated with massive inﬂammatory and T-cell-derived 
cytokine release [50,55]. 
Another hallmark of LASV infection in humans and non-
human primates is lymphopenia, which is most pronounced in 
fatal cases and associated with tissue damage in lymphoid organs 
[3]. Recent studies in nonhuman primates revealed that both CD4 
and CD8 cells, as well as B cells and NK cells, were affected 
[50]. Since human T and B cells lack a functional LASV receptor 
[56,57], they are not infected, suggesting an indirect effect that 
may involve virus-induced immunoregulatory factors. Possible 
candidates are type I IFNs implicated in lymphopenia observed 
in experimental infection of the mouse with the related arenavirus 
LCMV [58]. 
Although hemorrhages represent a cardinal symptom of arena-
virus VHFs, blood loss does normally not account for the fatal 
outcome of the disease. This is particularly true for Lassa fever, 
where bleeding is not a salient feature and does not signiﬁcantly 
contribute to the shock syndrome [3]. LASV infection in humans 
is normally associated with only weak thrombocytopenia and 
mild perturbation of platelet function [59,60]. The platelet function 
defect appears to be mediated by a plasma inhibitor that has not yet 
been characterized [60]. Only mild vascular lesions were observed 
in postmortem examination of fatal human Lassa fever cases [42]. 
In contrast to other VHFs, disseminated intravascular coagula-
tion involving activation of ﬁbrin deposition is virtually absent in 
arenavirus VHFs (TABLE 1). Virus-induced impairment of vascular 
function is likely central to fatal Lassa fever (FIGURE 2) and perturba-
tion of the function of endothelial cells precedes the onset of shock 
and death [59,61]. The mechanisms by which LASV infection affects 
endothelial cells are largely unknown and may include direct effects 
of the virus infection and indirect mechanisms, for example. virus-
induced release of soluble factors that impact on endothelial cell 
function. In other VHFs, in particular Ebola and Marburg HF, 
alterations of vascular function have been attributed mainly to the 
virus-induced host responses, in particular excessive production of 
TNF-D, IFN-J and nitric oxide, resembling some aspects of septic 
shock syndrome [62,63]. Initial in vitro studies infecting human 
monocytes/macrophages and human endothelial cells with LASV 
provided the ﬁrst evidence for important differences between the 
pathogenesis of LASV and ﬁloviruses. LASV infection was highly 
productive in these cell types without causing an overt cytopathic 
effect. In the absence of cell damage, LASV infection resulted in 
reduced levels of proinﬂammatory cytokines, including TNF-D 
and IL-8 [64]. Detection of proinﬂammatory cytokines in the sera 
of patients with fatal Lassa fever and experimental infection in non-
human primates have so far revealed little evidence for a ‘cytokine 
storm’ as observed in ﬁlovirus VHF [50,55]. Although a possible 
role of host-derived soluble factors in LASV-induced perturbation 
of endothelial cell function in vivo can at present not be ruled out, 
it is conceivable that more direct effects of the virus on vascular 
endothelial cells as a consequence of viral gene expression may 
underlie at least some of the vascular dysfunction observed in fatal 
Lassa fever. In summary, the mechanisms underlying the profound 
shock associated with the terminal stage of fatal Lassa fever in 
humans are still largely unknown. According to a working model 
presented in FIGURE 2, infection of several cell types in different tis-
sues, including the vascular endothelium, the liver and the adrenal 
cortex, may result in an overall impairment of the regulation of vas-
cular permeability in a direct or indirect way. The terminal shock 
syndrome may involve an imbalance of ﬂuid distribution between 
intravascular and interstitial spaces combined with coagulation 
abnormalities and perhaps dysregulation of blood pressure. 
Clinical disease & pathogenesis of South American 
hemorrhagic fevers
Among the South American HF viruses, JUNV, the causative 
agent of AHF, represents the most important public health prob-
lem, whereas MACV, GTOV and SABV cause only sporadic 
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outbreaks. JUNV was isolated from fatal VHF cases in the humid 
Pampas, the major agricultural area of Argentina, in the 1950s 
[65,66]. The rodent Calomys musculinus serves as the main natu-
ral reservoir of the virus. The virus is occasionally isolated from 
other rodents, possibly because of transmission from the natural 
host population. Former endemic hot spots are currently cool-
ing off, whereas the overall geographic regions affected by the 
disease increases progressively [67]. AHF is a severe illness with 
hemorrhagic and/or neurological manifestations and a fatality 
rate of 15–30% in untreated cases [16,67,68]. JUNV appears to 
be infectious as aerosols and deposits in the terminal respiratory 
bronchioles [69]. Upon early replication in the lung, the virus 
enters into the lymphoid system and spreads systemically. After an 
incubation period of 1–2 weeks, AHF starts with rather unspeciﬁc 
symptoms: fever, asthenia, muscular pain, dizziness, skin and 
mucosal rashes, and lymph node swelling. A total of 6–10 days 
after disease onset, symptoms worsen with cardiovascular, gastro-
intestinal, renal and neurological involvement, associated with 
hematologic and hemostatic alterations. Disease manifestations 
are mainly neurological and/or hemorrhagic. Those who recover 
from AHF develop an antiviral immune response including anti-
bodies in the second week of disease and clear the virus [70]. In 
convalescent plasma from AHF survivors, robust titers of neutral-
izing antiviral antibodies, mainly IgG, can be detected. In fatal 
cases, viremia is unchecked and patients succumb to a terminal 
hemorrhagic shock syndrome with a mortality of 15–30% in the 
absence of immune plasma therapy [16,68]. 
Pathological lesions in fatal AHF include generalized vaso-
congestion with multiple hemorrhages in the gastrointestinal 
mucosa, different organs, such as the liver, kidney and lungs, as 
well as subcutaneous tissue. In the kidneys, tubular and papil-
lar necrosis is observed and scattered necrotic hepatocytes are 
found in the liver. No overt CNS pathology is apparent, despite 
the frequent manifestation of neurological symptoms. Secondary 
bacterial infections such as pneumonia are common in AHF. 
The lesions consistently associated with fatal cases are present 
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of the liver results in enhanced levels of transaminases and hepatocellular necrosis. While the histopathology in the liver is too weak to 
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in the lymphatic tissue with widespread necrosis of the splenic 
white pulp and in the cortical and paracortical areas of the lymph 
nodes. The bone marrow shows global cell depletion. The highest 
virus titers are found in the spleen, lymph nodes and lungs, and 
high levels of viral antigen are found in cells of the monocyte/
macrophage lineage in peripheral blood [71], lymphatic tissue, lung 
and liver [72]. Patients with AHF have very high levels of IFNs, 
TNF-D, and other inﬂammatory mediators that correlate with 
the severity of disease [73–75]. However, at present it is unclear if 
the enhanced levels of cytokines reﬂect mainly enhanced levels 
of viral replication and more widespread infection or if they play 
a role in immune-mediated pathology similar to fatal ﬁlovirus 
VHFs [62,63]. 
Virus-induced immunosuppression is also a hallmark of fatal 
infection with the South American HF viruses. Similar to LASV, 
JUNV efﬁciently targets DC early in infection, likely contribut-
ing to immunosuppression (FIGURE 2). In contrast to Lassa fever, 
AHF manifests with more pronounced hemorrhages, although the 
extent of vascular damage and blood loss does not account for the 
fatal outcome [16]. The hemorrhagic syndrome in AHF is attrib-
uted to coagulation alterations and marked thrombocytopenia, 
possibly in combination with virus and cytokine-induced vascular 
damage and does, in contrast to other VHF, generally not involve 
disseminated intravascular coagulation (TABLE 1). 
Several lines of evidence implicate infection of vascular endothe-
lial cells in AHF pathogenesis. Infection of cultured endo thelial 
cells with JUNV did not cause overt cytopathic effects but altered 
expression of cell adhesion molecules ICAM-1 and VCAM-1 and 
reduced secretion of coagulation factors, such as the prothrombic 
von Willebrand factor (vWF) [76]. The lat-
ter ﬁnding seems to contradict clinical data 
showing increased vWF in sera of AHF 
patients [77] and the reason for this discrep-
ancy is likely another source of vWF in AHF 
in vivo, such as megakaryocytes/platelets. Of 
particular interest is the increased produc-
tion of the vaso active mediator NO and 
prostaglandin PGI
2
 in endothelial cells 
infected with a virulent strain of JUNV, but 
not an avirulent isolate [76], providing a ﬁrst 
possible link between viral infection and the 
increased vascular permeability observed in 
fatal AHF cases. 
A hallmark of fatal AHFs are coagulation 
abnormalities, including thrombo cytopenia 
and low levels of platelet activity [78]. As 
in the case of Lassa fever, evidence for an 
inhibitor of platelet aggregation in plasma 
of infected patients has been found [60]. 
However, the exact nature of this inhibi-
tor remains elusive. Recent studies shed 
light on the mechanism of virus-induced 
thrombocytopenia employing an in vitro 
model of human CD43+ cells stimulated 
with thrombopoietin [79]. JUNV infection 
of CD43+ precursor cells did not affect proliferation and cell 
viability but markedly perturbed the differentiation of mega-
karyocytes resulting in reduced thrombopoiesis at the levels of 
proplatelet formation and platelet release. Interestingly, perturba-
tion of thrombopoiesis was not dependent on direct infection of 
cells, but seems to be, at least in part, mediated by a bystander 
effect that involves type I IFNs. A remarkable aspect of AHF is 
the fact that some patients die in absence of hemorrhagic disease 
and manifest mainly with neurological symptoms [16]. The patho-
physiological basis for the neurological syndrome that is present to 
a variable degree in AHF patients is currently largely unknown. 
MACV is also a rodent-borne pathogen that caused serious 
outbreaks of HF in Bolivia in the 1960s [80], but the number of 
cases has declined since. Human-to-human transmission has 
been reported [81]. GTOV emerged as the cause of Venezuelan 
HF in the 1990s [82,83]. Based on their close phylogenetic relation-
ship to JUNV, infections with MACV [84,85] and GTOV [82,83,86] 
resemble AHF in their pathology, clinical manifestations and 
mortality. 
While no speciﬁc treatments or vaccines have been established 
for MACV and GTOV, a live-attenuated JUNV has been devel-
oped and is used in high-risk groups in endemic areas [87]. Current 
therapy of AHF infection involves the administration of immune 
plasma from convalescent patients [88], which is effective when 
started during the ﬁrst week of disease and critically depends 
on the titers of neutralizing antibodies. Immune plasma therapy 
reduces mortality from 15–30% to less than 1%. Circa 10% of 
patients develop a self-limiting late neurological syndrome, whose 
pathophysiology is unknown. 
Table 1. Comparison of Lassa fever with the South American 
arenavirus hemorrhagic fevers and Ebola hemorrhagic fever.
Parameter LASV JUNV MACV Ebola 
Fever Yes Yes Yes Yes
Hypotension Yes Yes Yes Yes
Hemorrhages Weak† Occasional Occasional Occasional
,YMPHOPENIA Yes Yes Yes Yes
Hepatic lesions Yes Yes Yes Yes
Vascular lesions No No No No
Thrombocytopenia Rare Yes Yes Yes
Platelet dysfunction Mild Yes Yes Yes
DIC No‡ Rare§ Rare§ Yes
Infection of MP Yes Yes Yes Yes
Infection of DC Yes Yes Yes Yes
Elevated interferons No¶ Yes Yes Yes
Elevated cytokines No¶ Yes Yes Yes
†(EMORRHAGES IN ,!36 ARE LIMITED TO MUCOSAL SURFACES AND BLOOD LOSS IS MILD 
‡Fibrin deposits have been reported in rare cases.
§In isolated cases, there is biochemical evidence for DIC and detection of ﬁbrin deposits.
¶.O EXCESSIVE LEVELS OF INTERFERONS AND CYTOKINES DETECTED IN ,ASSA FEVER PATIENT SERA
$# $ENDRITIC CELL $)# $ISSEMINATED INTRAVASCULAR COAGULATION *5.6 *UNIN VIRUS ,!36 ,ASSA VIRUS 
MACV: Machupo virus; MP: Macrophage.
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Insights into the pathogenesis of arenavirus 
hemorrhagic fevers from new animal models
The investigation of arenavirus pathogenesis critically depends on 
suitable animal models. Nonhuman primates are still considered 
the major relevant model for Lassa fever, in particular rhesus and 
cynomolgus monkeys (Macaca mulatta and Macaca fascicularis, 
respectively). Experimental studies in these nonhuman primates 
largely reproduce the pathology of human Lassa fever at the sys-
temic and histological level, including hepatocellular necrosis, inter-
stitial pneumonia, increased blood transaminase levels, and hemor-
rhagic signs and symptoms [50,51,89–94]. As in the human disease, 
the terminal shock syndrome includes hypovolemia, hypotension 
and acute respiratory distress. A recent study comparing antiviral 
immune responses between fatal and nonfatal LASV infection in 
cynomolgus monkeys revealed that fatal infection was associated 
with only weak activation of antiviral T cells and monocytes, a 
delayed and weak antibody response resulting in unchecked vire-
mia, shock and death. Nonfatal infection was characterized by a 
vigorous antiviral T-cell response, activation of monocytes and 
effective control of viral replication [50]. The similarities with clini-
cal ﬁndings in human Lassa fever underline the potential of this 
model for future studies. Marmosets have recently been described 
as an alternative nonhuman primate model for LASV infection 
[95]. Another powerful model for LASV infection in nonhuman 
primates uses the closely related LCMV, which is a BSL2/3 patho-
gen [96,97]. This model has recently been used for comprehensive 
transcriptome ana lysis in the blood and liver of rhesus monkeys 
infected with a lethal dose of LCMV that has provided an invalu-
able source for the search for candidate genes involved in arenavirus 
VHF pathogenesis and biomarkers for diagnostic purposes [98,99]. 
A major challenge in LASV research has been the lack of a 
mouse model for LASV that allows the application of useful 
mouse genetics for studies on LASV pathogenesis in vivo, mainly 
owing to the fact that normal laboratory mouse strains are resis-
tant to LASV infection. A recent study found that mice expressing 
humanized MHC class I failed to control LASV infection and 
developed fatal VHF [100]. Interestingly, in this model, depletion 
of T cells prevented disease, irrespective of viremia, indicating a 
role for T cells in VHF pathogenesis. It will be of great interest 
to compare the observations from this novel small animal model 
with established nonhuman primate models and human infec-
tion. Another important lesson learned from this novel model is 
to consider the possibility of T-cell-mediated pathology in the 
development of novel Lassa fever vaccine strategies.
Other important BSL2/3 models for arenavirus VHF are the 
infection of Pichinde virus in guinea pigs (reviewed in [101]) and 
the infection of Syrian golden hamsters with Pirital virus [102,103]. 
Several experimental animal models exist for JUNV pathogenesis, 
including mice [104–107], guinea pigs [108–110] and rats [111], as well 
as New and Old World primates [112–116]. A particularly interest-
ing small animal model for JUNV infection has recently been 
established using the JUNV Romero strain in guinea pigs and 
largely recapitulates the pathological ﬁndings in human AHF [117], 
holding great potential for basic research on JUNV pathogenesis 
and evaluation of novel drugs and vaccine candidates. 
Expert commentary & ﬁve-year view
The past years have seen an impressive progress in our under-
standing of the basic molecular and cellular biology of arena-
viruses. In particular, the advent of a powerful reverse genetic 
system for arenaviruses [118–120] paves the way for sophisticated 
structure–function studies and the molecular dissection of the 
mechanisms of virus–host interaction in vitro and also in vivo. 
Over the years, much has been learned about the pathogenesis 
of arenaviruses at the cellular level, in particular their ability 
to subvert the host cell’s innate antiviral defenses [45–49]. Key 
IFN antagonists of arenaviruses have been discovered and the 
mechanisms by which the viruses block innate antiviral signaling 
elucidated. Other in vitro studies have shed light on the impact 
of arenavirus infection on the differentiation and function of 
cells targeted by hemorrhagic arenaviruses in vivo, including 
APCs such as macrophages and DCs [53,54], endothelial cells [76], 
and megakaryocytes [79] involved in platelet formation. At the 
same time, novel animal models provided important new infor-
mation about the interaction of hemorrhagic arenaviruses with 
the host’s adaptive immune system, in particular virus-induced 
immunosuppression, and provided the ﬁrst hints towards an 
understanding of the terminal hemorrhagic shock syndrome 
[50,98–100,117]. However, many questions remain unanswered. In 
particular, the pathogenesis of Lassa fever appears to be rather 
atypical with little evidence for immunopathological mecha-
nisms and largely unknown mechanisms underlying the vascular 
dysfunction involved in the terminal shock syndrome. As more 
subtle, direct effects of virus replication and gene expression may 
be responsible for the perturbation of endothelial cell function, 
future research involving suitable cell culture models for human 
endothelium, which allow detailed ana lysis of virus-induced cell 
biological and biochemical alterations, will be of great impor-
tance. Advances in endothelial cell culture, combined with high 
resolution confocal microscopy and the ability to measure endo-
thelial cell functions such as transendothelial electrical resistance 
and hydraulic conductivity in live cells will allow monitoring 
of subtle, virus-induced functional changes as a consequence 
of arenavirus infection. The availability of a powerful reverse 
genetic system for arenaviruses [118–120] combined with suitable 
well-controlled in vitro experimental systems may allow the iden-
tiﬁcation of viral proteins and their cellular targets implicated in 
virus-induced changes in the major cell types targeted by LASV 
in vivo, including APCs such as DCs and vascular endothelial 
cells. The identiﬁcation of cellular proteins and signaling path-
ways affected by virus infection and the characterization of the 
molecular interactions involved over the next 5 years will open 
new avenues for the development of drugs that could prevent 
arenavirus-induced endothelial cell dysfunction associated with 
fatal arenavirus VHFs. In addition, recently developed novel 
diagnostic tools, including more sensitive molecular probes for 
viral nucleic acids and new antibodies against LASV proteins, 
will allow a better assessment of the extent of viral infection of 
the endothelium and consequent functional alterations in vivo. 
The recent development of novel and promising small animal 
models for human Lassa fever and AHF, as well as reﬁnements 
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of established nonhuman primate models for LASV will greatly 
facilitate the validation of mechanistic ﬁndings obtained in vitro 
in the systemic context and allow evaluation of novel therapeutic 
strategies in preclinical studies. 
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Key issues
s  Viral hemorrhagic fevers (VHFs) caused by arenaviruses are among the most devastating emerging human diseases and represent 
serious public health problems. There is no licensed vaccine against these pathogens and therapeutic options are limited.
s  A particular concern with arenaviruses is the continued emergence of new viruses that are associated with severe VHFs, as illustrated by 
THE EMERGENCE OF #HAPARE VIRUS IN  AND ,UJO VIRUS IN 
s  Arenavirus VHFs in humans are acute diseases characterized by fever and, in severe cases, different degrees of hemorrhages associated 
with a shock syndrome in the terminal stage. Blood loss in arenavirus VHF does not account for the fatal outcome, and the 
pathophysiology underlying the terminal shock syndrome is not yet fully understood.
s  "ASED ON ITS CLINICAL AND PATHOLOGICAL FEATURES ,ASSA FEVER PRESENTS AS A RATHER ATYPICAL 6(& 0OSTMORTEM EXAMINATION OF FATAL ,ASSA 
fever cases show surprisingly little tissue damage and only modest inﬂammation with absence of disseminated intravascular coagulation 
in the terminal stage. 
s  Fatal arenavirus VHFs are characterized by marked immunosuppression of the host, resulting in uncontrolled viral spread and replication 
associated with hemorrhagic shock. The immunosuppression associated with fatal disease is likely related to the fact that hemorrhagic 
arenaviruses efﬁciently target antigen-presenting cells such as macrophages and, in particular, dendritic cells, and perturb their function 
in antigen presentation.
s  Arenaviruses can efﬁciently block the host cell’s antiviral interferon response with the viral nucleoprotein and, in some species, also the 
Z protein, acting as interferon antagonists. Efﬁcient blocking of the host innate antiviral defense by arenaviruses may contribute to the 
inability of the host to contain virus infection in fatal arenavirus VHF.
s  A number of novel animal models for VHFs have been developed in past years and hold much promise for future studies on arenavirus 
pathology in vivo.
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